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Summary 
Individuals with schizophrenia have severe cognitive impairments that impact 
upon their ability to function within society. Better understanding the genetic 
mechanisms underlying schizophrenia and cognition provides an opportunity 
for targeted pharmacological intervention. 
  
This thesis investigates common and rare genetic variation in schizophrenia and 
their associations with cognitive ability in schizophrenia cases and healthy 
controls. 
  
Polygenic risk of schizophrenia and bipolar disorder predicted ability on tests of 
cognitive domains affected in schizophrenia, performance, verbal and full scale 
IQ in healthy controls. Increased polygenic risk of schizophrenia was robustly 
associated with lower performance IQ at different training thresholds in two 
independent cognition samples. There was no consistent association 
between bipolar polygenic risk and cognition. Common genetic differences 
between schizophrenia and bipolar disorder were associated with verbal and full 
scale IQ. 
  
I investigated the hypothesis that 155 gene-sets across six biological categories 
relating to cognition, brain function and structure were enriched for SNPs 
influencing general cognitive ability. Schizophrenia polygenic pathway scores for 
gene-sets were not associated with general cognitive ability in schizophrenia 
patients, or performance IQ in healthy individuals. Separately, neither gene-sets 
 vi 
nor general categories were enriched for common SNPs showing association 
with general cognitive ability in schizophrenia cases. 
  
Associations between rare CNVs and general cognitive ability were tested in 
schizophrenia cases. Cases with a known pathogenic CNV performed 
approximately one standard deviation below other schizophrenia cases on the 
MATRICS composite score. In addition, increases in the number of genes hit by 
large (>100kb) and rare (frequency <1%) CNVs were associated with lower 
general cognitive ability. However, the number of genes hit in gene-sets 
previously mentioned was not associated with the MATRICS composite score. 
  
These findings indicate genetic variation in schizophrenia is associated with 
cognitive ability in schizophrenia cases and healthy controls, providing direction 
for future research.  
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1 Chapter 1 - Introduction 
1.1 Impact of schizophrenia  
Schizophrenia is a common psychiatric disorder characterized by severe and 
heterogeneous symptomatology and deficits in cognitive ability. It has a lifetime 
risk of approximately 0.5-1% (Jablensky, 2000), affecting individuals across 
countries and cultures. Patients have a low quality of life characterized by low 
employment prospects (Rosenheck et al., 2006), low adherence to medication 
(Valenstein et al., 2004) and increased mortality (Saha et al., 2007). 
Furthermore, only 1/7 patients have satisfactory improvements regarding both 
clinical symptoms and functional outcome (Jaaskelainen et al., 2013). Life 
expectancy is 19 years below the population mean (Laursen, 2011), which may 
be attributable to increased rates of smoking and their secondary diseases 
(Lasser et al., 2000), neuroleptic medication (Joukamaa et al., 2006) and 
increased suicidality (Hor & Taylor, 2010). The societal burden is large, with 
direct (health/social care) and indirect (reduced productivity, social welfare, 
judicial) costs estimated at £6.7 billion in England alone in 2007 (Mangalore & 
Knapp, 2007). 
 
1.2 History of schizophrenia 
The first descriptions of schizophrenia were characterised by Emil Kraeplin 
under the term “dementia praecox”, meaning early dementia. Kraeplin 
differentiated between the psychotic symptoms of dementia praecox and “manic 
depressive psychosis”, now classified as bipolar disorder.  
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The term “schizophrenia”, meaning “splitting of the mind”, was first used by 
Bluer, who considered schizophrenia to be categorised by a number of smaller 
related subtypes. In the following decades a distinction was made between 
psychotic and non-psychotic symptoms of schizophrenia, with Crow defining the 
modern terms of positive (irrational beliefs/delusions/hallucinations/paranoia) 
and negative symptoms (alogia, blunted affect, anhedonia) (Crow, 1981).  
 
A third model incorporating disorganised symptoms is now more widely 
accepted (Arndt et al., 1991). However, other studies have shown between 5-10 
symptom dimensions can be identified (Cuesta & Peralta, 2001; McGrath et al., 
2004a). This number varies based on the type of analytic methodology used (for 
example factor analysis, latent class analysis or grade of membership), and the 
number of symptom variables entered into the model (Jablensky, 2006). 
 
1.3 Schizophrenia diagnosis 
The Diagnostic Statistical Manual of Mental Disorders (DSM) V diagnosis of 
schizophrenia requires individuals to present with delusions, hallucinations or 
disorganised speech. Furthermore, individuals must present at least two core 
symptoms of hallucinations, delusions, disorganised speech, 
catatonic/disorganised behaviour or the presence of negative symptoms.  Other 
diagnostic factors may include impairment through social or occupational 
dysfunction, signs of persistent disturbance over a minimum of 6 months period. 
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Furthermore, symptoms should not be attributable to recreational drugs or 
prescription medication (American Psychiatric Association, 2013). 
 
Nevertheless, the dimensional structure of schizophrenia remains poorly defined 
(Jablensky, 2006), and from a diagnostic perspective the criteria for diagnosing 
schizophrenia has remained largely unchanged across the DSM, and their 
numerous iterations. 
 
1.4 Schizophrenia environmental risk factors 
A number of environmental risk factors are associated with increased risk of 
schizophrenia (van Os et al., 2010). Living in urbanised areas increases the risk 
of schizophrenia by 2.4 times compared to rural areas (Vassos et al., 2012). 
Other factors include recreational drug use, for example frequent cannabis users 
have a near fourfold increase for developing schizophrenia compared to non-
users (Manrique-Garcia et al., 2012), and on average develop psychosis 
approximately 3 years earlier than non-cannabis users (Large et al., 2011). 
Environmental factors may contribute during gestation and include maternal 
smoking (Stathopoulou et al., 2013), dietary malnutrition (Brown & Susser, 
2008) and maternal infection (Canetta & Brown, 2012).  
 
1.5 Genetics of schizophrenia 
Significant progress has been made over the past decade with respect to 
identifying both common and rare genetic variation contributing to 
 4 
schizophrenia pathogenesis. This section will describe schizophrenia heritability 
estimates, linkage studies of schizophrenia, positional candidate genes, common 
variants identified through genome wide association studies (GWAS), rare 
variation from copy number variations (CNVs) and rare single nucleotide 
variations (SNVs).  
 
1.5.1 Familial schizophrenia risk  
Schizophrenia risk aggregates in families of affected individuals. Relative to an 
affected individual, monozygotic MZ twins have the highest lifetime risk at 
around 50%, dizygotic twins have a lower lifetime risk of 17%, with risk 
decreasing as the genetic distance of relatives increases (Gottesman, 
1991). Increased risk of developing schizophrenia is also found in adopted 
children whose biological parents have the disorder (Ingraham & Kety, 
2000), further supporting a genetic as opposed to environmental aetiology. 
 
1.5.2 Schizophrenia heritability  
1.5.2.1 Deriving heritability estimates 
An individual’s phenotype is the product of their genotype, environment 
and their respective interactions. The classic twin design is the most popular 
method for quantifying the variance of a trait attributable to genetic and 
environmental factors. MZ twins share approximately 100% of their genetic 
information, whereas DZ twins share on average 50%. For traits under strong 
genetic influence, their correlation should be higher for MZ twins than for DZ 
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twins. A basic model of heritability investigates the contribution of additive 
genetic effect (VA), common environmental effects (VC) and unique 
environmental effects (VE) upon the phenotypic variation for a trait (VP) 
(Visscher et al., 2008):  
  
Vp = VA + VC + VE  
  
Heritability refers to the proportion of phenotypic variance (Vp) attributable to 
genetic factors (VG). Narrow-sense heritability (h2) refers to the proportion of 
phenotypic variance explained by additive genetic factors (VA): h2 = VA / Vp. 
Finally, broad-sense heritability refers to the proportion of genetic variance 
explained by all genetic factors, which may include interactions between alleles 
at the same (dominance) or different (epistasis) loci: H2 = VG / Vp  
  
Other methods are available for calculating narrow-sense heritability in large 
number of unrelated individuals, for example genome-wide complex trait 
analysis (GCTA) (Yang et al., 2011). GCTA estimates the variation of a particular 
trait explained by common SNPs across the genome by comparing the genotypic 
and phenotypic similarity of each pair of individuals within the sample. 
Furthermore, GCTA does not rely on twin pairs, permitting the use of large 
samples that have already been genotyped.   
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1.5.2.2  Schizophrenia heritability from twin studies & GCTA  
Twin study heritability estimates show additive genetic contribution to 
schizophrenia is approximately 80% (Sullivan et al., 2003). GCTA estimates have 
shown approximately 25% of schizophrenia liability is explained by common 
SNPs (Lee et al, 2012). Whilst this is substantially less than twin estimates, this is 
likely attributable to low linkage disequilibrium (LD) between causal SNPs and 
those tagged by genotyping platforms.   
 
Whilst heritability estimates can stipulate the genetic contribution to a disease 
or trait, they cannot identify the location or effect size of genetic variants 
contributing to them.  
 
1.5.3 Linkage associations with schizophrenia  
Linkage analysis uses the principle that one or more markers/genes in the same 
region of a chromosome have a greater probability of being inherited together. 
Linkage can therefore be applied to identifying traits or diseases that segregate 
amongst members of a family. Linkage analysis is a useful method for identifying 
pathogenic genes in diseases following simple Mendelian rules of inheritance, 
typically monogenic disorders (Elston, 1998). Early linkage studies of 
schizophrenia identified several regions harbouring genes of possible 
pathogenicity (Riley & Kendler, 2006), with a later meta-analysis of 32 
schizophrenia linkage studies finding association on chromosome 1, 2q, 3q, 4q, 
5q, 8p, and 10q (Ng et al., 2009). However, no single bin reached genome wide-
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significance. A region at 8p showed the strongest association in European data 
(p=5x10-4), and across all samples at 5q (p= 0.004) (Ng et al., 2009).   
 
1.5.4 Positional candidate gene studies 
In response to findings implicating several regions through linkage, further 
studies tried to identify plausible susceptibility genes for schizophrenia.  
 
Catechol-O-methyltransferase (COMT)  
COMT is located within the 22q11.2 locus, and has a crucial role in the regulation 
of dopamine in the prefrontal cortex (Gogos et al., 1998). COMT has two main 
isoforms: soluble COMT (S-COMT) is commonly expressed in non-brain tissues, 
whereas membrane-bound COMT (MB-COMT) is primarily expressed in the 
brain, particularly in the prefrontal cortex (Lachman et al., 1996).   
 
The Val (G) /Met (A) polymorphism at rs4680 is posited as the functional SNP in 
COMT.  Changes in the amino acid from valine to methionine result in increased 
(val) or decreased (met) levels of both S-COMT and MB-COMT (Williams et al., 
2007). Whilst COMT has attractive biological functions potentially supporting 
the dopamine hypothesis of schizophrenia (Williams et al., 2007), a meta-
analysis (Munafo et al., 2005) and other large studies (Williams et al., 2005) have 
failed to support an association of common variants in COMT with schizophrenia. 
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Disrupted in Schizophrenia 1 (DISC1) 
DISC1 is located on the 1q42 locus and was identified through an inherited 
chromosomal translocation linkage in a Scottish pedigree (Stclair et al., 1990). 
DISC1, and is arguably the most polarising candidate gene for association with 
schizophrenia (Sullivan, 2013; Porteous et al., 2014). DISC1 has appealing 
neurobiological functions (Brandon & Sawa, 2011), specifically it localises at the 
post-synaptic density in glutamatergic synapses which are strongly implicated in 
schizophrenia pathogenesis. However, no robust common or rare genetic 
variants in DISC1 have been identified in large genetic studies over the past 
decade.  
  
Dysbindin (DTNBP1) 
DTNBP1 maps to a region on chromosome 6p, which was identified as a putative 
schizophrenia region through linkage analysis of 265 Irish pedigrees (Straub et 
al., 1995). DTNBP1 forms part of the dystrophin-associated protein complex 
(Benson et al., 2001) and is strongly expressed in axon bundles and mossy fiber 
synaptic terminals within the cerebellar and hippocampal structures (Benson et 
al., 2001). DTNBP1 is localised on the pre-synapse, and changes in expression 
result in increased or decreased glutamate synthesis and release via exocytosis 
(Numakawa et al., 2004). In addition, DTNBP1 also contributes to changes in 
synaptic transmutation and plasticity via   
α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in 
the hippocampus (Orozco et al., 2014).  
 
 9 
1.5.4.1 Common variants in schizophrenia candidate genes 
Subsequent studies have not identified significant associations with common 
SNPs and schizophrenia in 14 candidate genes (RGS4, DISC1, DTNBP1, STX7, 
TAAR6, PPP3CC, NRG1, DRD2, HTR2A, DAOA, AKT1, CHRNA7, COMT, and ARVCF) 
 (Sanders, 2008). Thus, whilst linkage studies may be useful where a disease is 
highly penetrant within families, or harbour rare variants, their use as a tool for 
gene discovery in highly polygenic disorders such as schizophrenia has proven 
to be limited. 
 
Technological advances now allow for the investigation of millions of single 
nucleotide variants (SNPs) and structural chromosomal changes including CNVs, 
single nucleotide variants (SNVs) and indels. These methods have revolutionised 
the approaches aimed at identifying genetic variants associated with 
schizophrenia.  
 
1.5.5 Schizophrenia genome-wide association studies 
1.5.5.1 Overview of GWAS 
Genome wide association studies (GWAS) are a hypothesis free method of testing 
the common variant, common disease hypothesis (Lander, 1996) by assessing 
variation across the genome using single nucleotide polymorphisms (SNPs). 
Each SNP is tested for association with a dichotomous or continuous phenotype. 
The ability to identify risk variants depends upon several factors including effect 
size, population frequency and sample size (Bergen & Petryshen, 2012). SNPs 
may have a direct causal relationship with the phenotype, or be in linkage 
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disequilibrium with the causal variant. SNP genotyping platforms have hundreds 
of thousands of individual markers, which can be supplemented by imputation 
procedures, which ascertain the probability of an ungenotyped marker having a 
specific allele based upon linkage disequilibrium with a tagged variant.  
 
1.5.5.2 Early schizophrenia GWAS findings 
Early schizophrenia GWAS failed to identify common genetic variants reaching 
genome wide significance (Lencz et al., 2007; O'Donovan et al., 2008a; Sullivan et 
al., 2008). However, with the inclusion of bipolar cases representing a broader 
psychosis phenotype, rs1344706, an intronic SNP in Zinc Finger Protein 804a 
(ZNF804A) reached this threshold (O'Donovan et al., 2008a); the first such 
observation in a psychiatric disorder.  
 
To identify whether rs1344706 was the true functional variant in ZNF804A, this 
region was extensively mapped using de-novo polymorphism and high-density 
LD mapping (Williams et al., 2011a). The strongest association remained at 
rs1344706, providing evidence this was the susceptibility variant in the region. 
Furthermore, a meta-analysis of multiple schizophrenia GWAS showed 
rs1344706 reached genome wide significance, becoming stronger with the 
inclusion of bipolar cases (Williams et al., 2011a).  
 
Functionally, the risk T allele at rs1344706 reduces ZNF804A expression during 
neurodevelopment in the second trimester (Hill & Bray, 2012). A ZNF804A 
knockdown study showed altered gene expression for A2M, C2ORF80, CRYAB, 
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FRZB and STMN3 (Hill et al., 2012). The strongest evidence was observed in 
C2ORF80 and STMN3. Whilst C2ORF80 remains uncharacterised, STMN3 
contributes to branching of dendrites and axons (Poulain & Sobel, 2007).  
 
1.5.5.3 International Schizophrenia Consortium GWAS (2009) 
In 2009, using combined data from three schizophrenia consortia consisting of 
12945 cases and 43591 controls (Stefansson et al., 2009), seven genome wide 
significant loci emerged from this analysis. Five variants were within the major 
histocompatibility complex (MHC) region; one was an intronic SNP in TCF4, 
while the other was proximal to NRGN (Stefansson et al., 2009).  
 
The MHC is on chromosome 6, and is strongly associated with immune 
functioning and autoimmunity (Fernando et al., 2008). However, identifying the 
true functional variants are challenging due to high linkage disequilibrium (LD). 
A degree of scepticism has previously surrounded the role of immune response 
in schizophrenia (DeLisi, 1996), in part attributable to inadequate study design 
in human studies and unclear mechanisms of action (Strous & Shoenfeld, 2006). 
However, evidence is accumulating that shows MHC class 1 proteins also have 
non-immune related functions, including synaptic pruning and roles in synaptic 
plasticity (Oliveira et al., 2004; Lee et al., 2014).   
 
TCF4 is part of the helix-loop-helix protein group, which has largely been studied 
in respect of its role in the development of B and T lymphocytes (Murre, 2005). A 
fine mapping study of TCF4 found no non-synonymous variants, or cis-regulated 
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variants altering mRNA expression (Williams et al., 2011b). However, 
knockdown of TCF4 in neuroblastoma cells has substantial effects upon genes in 
signalling pathways that regulate cell differentiation and survival (Forrest et al., 
2013). Furthermore, TCF4 also alters the expression of other mental retardation 
genes including UBE3A and ZEB2, which are associated with Angelman 
Sybdrome and Mowat-Wilson syndrome respectively (Forrest et al., 2013).  
 
TCF4 does not appear to influence brain structure. A large structural MRI study 
in 1300 healthy individuals found no evidence of association between common 
SNPs in TCF4 and total volume of the brain, or grey or white matter volumes 
(Cousijn et al., In Press).  
 
1.5.5.4 Psychiatric Genetics Consortium (2010-Present) 
By combining samples across groups, the increase in power to detect variants 
increases substantially. This principle was important for the formation of the 
Psychiatric Genetics Consortium (PGC) (Psychiatric GWAS Consortium Steering 
Committee, 2009; Sullivan, 2010).  In 2011, a GWAS found SNPs in TCF4, MIR137, 
TRIM26, CSMD1, CNNM2, NT5C2, and proximal to PGCEM1, MMP16, STT3A and 
CCDC68 reached genome wide significance for association with schizophrenia 
(Schizophrenia PGC, 2011). Furthermore, variants in CACNA1C, ANK3 and ITIH3-
ITIH4 surpassed genome wide significance when individuals with schizophrenia 
and bipolar disorder were combined, providing further evidence for their genetic 
relatedness.  
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The PGC recently reported the largest GWAS of any psychiatric disorder to date, 
using a discovery sample of 34241 schizophrenia cases and 45604 controls 
(Schizophrenia Working Group of the Psychiatric Genetics Consortium, 2014). 
They found 128 loci reaching genome wide significance representing 108 
independent genomic regions. SNPs reaching genome-wide significance were 
found in genes whose biological functions were previously implicated in 
schizophrenia aetiology including; calcium channel (CACNA1C, CACNB2 and 
CACNA1I), dopamine receptor (DRD2) and glutamatergic (GRM3, GRIN2A, SRR, 
GRIA1) genes.  
 
Calcium channel genes are implicated in several psychiatric disorders including 
schizophrenia, bipolar disorder, autism, major depressive disorder and attention 
deficit hyperactivity disorder (Smoller et al., 2013). Genes encoding for voltage-
gated calcium channels have important roles regarding the activation of 
intracellular signalling pathways, altering both neuronal development and 
functionality, as well as affecting gene expression (Dolmetsch, 2003). A de-novo 
missense mutation G406R in CACNA1C is the cause of Timothy Syndrome, a 
disorder characterised by an autistic phenotype with cognitive abnormalities, as 
well as other cardiac and immune irregularities (Splawski et al., 2004). Further 
work is required to identify their role in schizophrenia.  
 
Glutamate is the most abundant neurotransmitter acting on excitatory neurons 
across the brain (Erecinska & Silver, 1990). NMDA receptor-mediated glutamate 
transmission within the post-synaptic density is a prime candidate for 
dysfunction in schizophrenia (Harrison & Weinberger, 2005) Furthermore, 
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glutamate binds to NMDARs, which are responsible for changes in synaptic firing 
by altering long term potentiation that may cause structural changes at the 
synapse. These processes are considered to underpin synaptic plasticity and 
cognitive ability (Hunt & Castillo, 2012).  
 
Immune processes outside of the MHC were also implicated. In particular, genes 
contributing to the lineage of B-lymphocytes were enriched for schizophrenia 
associations (Schizophrenia Working Group of the Psychiatric Genetics 
Consortium, 2014).  These findings, along with consistent associations within the 
MHC provide support that genes regulating the immune response may 
contribute to schizophrenia pathogenesis.  
 
Despite the successes of GWAS, they do not yet explain the majority of 
heritability identified through twin studies of schizophrenia (and other 
diseases/traits). Often labelled as “missing heritability”, a number of theories 
have suggested possible explanations including the role of SNP (Zuk et al., 2012) 
and gene-environment interactions (Kaprio, 2012), although other studies have 
suggested this is attributable to incomplete linkage disequilibrium between SNPs 
tagged on genotyping platforms and their true causal counterparts (Yang et al., 
2010a).   
 
1.5.6 Polygenic risk scoring 
When testing for association with a phenotype, the majority of SNPs will not 
meet the threshold for genome wide significance. Nonetheless, these variants 
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may contribute substantially to the genetic architecture of the phenotype in 
question. Polygenic risk scoring (PRS) is a method designed to identify whether 
en masse, common genetic variants associated with a particular phenotype in a 
discovery sample can predict the same, or different phenotype in an independent 
target sample.  SNPs are selected based upon the strength of their association 
with the discovery phenotype using pre-specified p-value thresholds. Polygenic 
scores are calculated for each individual in the target sample by summing the 
number of susceptibility alleles of the reference SNP weighted by the log of the 
SNP odds ratios (or beta coefficient is the discovery phenotype is on a 
continuous scale).  
 
PRS analyses have shown common variants contribute substantially to 
schizophrenia. The first study to apply PRS used a training sample of 3322 
schizophrenia cases and 3587 controls (International Schizophrenia Consortium, 
2009). Using the Molecular Genetics of Schizophrenia - European American 
(MGS-EA) independent schizophrenia case/control sample, schizophrenia 
polygenic risk predicted approximately 3% of the variance for schizophrenia 
liability and achieved high levels of statistical significance (p=2x10-28).  
 
A larger study used a training set comprised of 6458 cases and 8971 controls 
(Schizophrenia PGC, 2011). A target sample of 2936 cases and 3492 controls 
showed that the variance of schizophrenia liability explained by schizophrenia 
polygenic risk, increased to 6%.  
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This demonstrates that the power of PRS analyses is more dependent on the size 
of the initial discovery sample, rather than the target set (Chatterjee et al., 2013; 
Dudbridge, 2013). The explanation for this lays in the inaccuracy of the estimates 
of SNP effect sizes in the discovery sample, where error decreases as sample size 
increases.  
 
The largest PRS analysis for schizophrenia was performed in the recent 
publication by the PGC (Schizophrenia Working Group of the Psychiatric 
Genetics Consortium, 2014). Using a discovery sample comprising of 32838 
cases and 44357 controls, it predicted 18.4% of the variance of schizophrenia 
liability in MGS-EA. The variance explained is substantially larger than previous 
studies, supporting previously simulated projections (International 
Schizophrenia Consortium, 2009).  
  
PRS have also been used to investigate the common genetic architecture across 
neuropsychiatric disorders. Schizophrenia polygenic risk explains between 2-
2.5% of variance of the liability of bipolar disorder (International Schizophrenia 
Consortium, 2009; Smoller et al., 2013), 0.75% of the liability for major 
depressive disorder and approximately 0.1% for liability of autistic spectrum 
disorders (Smoller et al., 2013).  
 
Common genetic risk of schizophrenia is not associated with non-psychiatric 
disorders including coronary heart disease, rheumatoid arthritis and types 1 & 2 
diabetes mellitus (International Schizophrenia Consortium, 2009). These 
findings show psychiatric disorders have a degree of common genetic overlap 
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that is not shared with unrelated disorders, with implications for classification, 
disease models and treatment (Smoller et al., 2013).  
 
1.5.7 Copy Number Variations (CNVs) 
CNVs are a source of structural variation in the genome, whereby a chromosomal 
section can be deleted or duplicated. Although CNVs constitute normal genetic 
variation within healthy populations (Sebat et al., 2004), enrichment of large 
(>100kb) and rare (population frequency < 1%) CNVs at multiple loci are 
observed in schizophrenia probands (Rees et al., 2014b) and other 
neuropsychiatric disorders including autism and intellectual disability (Malhotra 
& Sebat, 2012).  
 
A landmark paper by the ISC reported associations of CNV burden in 3391 
schizophrenia cases and 3181 controls (International Schizophrenia Consortium, 
2008). They found a 1.15 fold increase in rare (<1%) and large (>100kb) CNVs in 
schizophrenia cases, with particular enrichment of genic regions. Furthermore, 
the number of genes hit by CNVs was 1.41 times higher in schizophrenia cases 
compared to controls. CNVs at 1q21.1, 15q13.2 and 22q11.2 were also enriched 
in schizophrenia cases and conferred substantial increases in schizophrenia risk 
(odds ratios between 6.6-21.6).  
 
The latest meta-analysis of 15 loci with prior association to schizophrenia 
implicated eleven regions (1q21.1, NRXN1, 3q29, 15q.11.2, 15q13.3 and 22q11.2, 
and duplications at 1q21.2, WBS, Angelman/Prader-Willie Syndrome on 
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chromosome 15, 16p13.11 and 16p11.2) with odds ratios typically ranging 
between 2 and 50 (Rees et al., 2014b).   
 
Deletions at 22q11.2 show the strongest associations with schizophrenia, in 
addition to other physical, psychiatric and neurocognitive phenotypes 
collectively known as 22q11.2 Deletion Syndrome (22qDS) (Bassett & Chow, 
2008). 22q11.2 deletions typically span over 3 megabases covering 43 genes 
(International Schizophrenia Consortium, 2008). Approximately 25% of 
individuals with 22qDS will develop schizophrenia (Murphy et al., 1999), making 
it the largest genetic risk factor, second only to monozygotic twins (Gottesman, 
1991). Furthermore, the 22qDS schizophrenia phenotype is not clinically 
different compared to schizophrenia cases without the deletion (Bassett et al., 
2003).  
 
Interestingly, the reciprocal 22q11.2 duplication is associated with a protective 
effect against schizophrenia (Rees et al., 2014a) . They showed the rate of 
duplications at 22q11.2 in healthy controls (0.085%) was significantly higher 
compared to schizophrenia probands (0.014%). Conversely, carriers of the 
22q11.2 deletion are at greatest risk of developing schizophrenia, suggesting 
dosage effects for genes at this locus may pertain to both protective and 
damaging effects (Rees et al., 2014a).  
 
Neuropsychiatric CNVs typically span large genomic regions affecting multiple 
genes, therefore identifying single or multiple pathogenic genes is challenging. 
There are a number of exceptions where CNVs affect only one gene, for example, 
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deletions hitting exons in NRXN1, which are strongly associated with 
schizophrenia (Kirov et al., 2009b; Rujescu et al., 2009) and autism (Yan et al., 
2008).  
 
Functionally, neurexins and their binding partners neuroligins, have important 
roles in the organisation of GABAergic and glutamatergic synapses (Graf et al., 
2004). Knockdown models of NRXN1 using human induced pluripotent and 
embryonic stem cells demonstrate its role in biological networks needed for 
neurodevelopment (Zeng et al., 2013). Specifically, lowering the expression of 
NRXN1 caused significant changes in genes associated with cell adhesion and 
neuron differentiation (Zeng et al., 2013).   
 
Another exception is VIPR2. Duplication rates between 0.25-0.35% were 
observed in schizophrenia cases compared to 0.03-0.05% in controls (Levinson 
et al., 2011a; Vacic et al., 2011). However, both studies used the MGS and ISC 
datasets as secondary cohorts, thus their findings are not independent. Doubt 
over the validity of these findings came from a recent meta-analysis showing 
duplication rates in cases (0.015%) were lower than controls (0.095%), and 
after meta-analysis was no longer significant (Rees et al., 2014b).  
 
De-novo CNVs are observed in offspring, but not in either parent. Stefansson et al 
(2008) were the first to show an enrichment of deleterious de-novo CNVs at 
1q21.2, 15q11.2 and 15q13.3 in schizophrenia cases.  More generally, de-novo 
CNVs are more frequent in schizophrenia compared to healthy populations (Xu 
et al., 2008), and are a possible explanation for the persistence of schizophrenia 
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despite cases’ reduced fecundity (Rees et al., 2011). Furthermore, pathway 
analyses of de-novo CNVs also show enrichment for genes in the post-synaptic 
density, and more specifically, neuronal activity-regulated cytoskeleton-
associated protein (ARC) and N-methyl-D-aspartate receptor (NMDAR) 
complexes in schizophrenia cases (Kirov et al., 2012).   
 
1.5.8 Exome sequencing  
Exome sequencing is a method that identifies variation in exons, which are 
protein-coding regions in the genome. For each codon, SNVs and indels can be 
identified. SNVs are called as either synonymous (no amino acid change) or non-
synonymous (amino acid change) variants. Non-synonymous SNVs and indels 
can be further categorised according to “damaging” or “non-damaging” by their 
predicted effect on the resulting protein structure.  
 
To date no single rare exonic variants have been robustly associated with 
schizophrenia (Need et al., 2012). In addition, the largest exonic de-novo 
mutation study to date found no evidence of enrichment of de-novo mutations in 
schizophrenia cases (Fromer et al., 2014).  
 
Recently, rare disruptive variants within 2546 genes previously implicated with 
schizophrenia are found at a higher rate in cases compared to controls (Purcell 
et al., 2014). Furthermore, whilst significance for individual variants was modest, 
significant enrichment was observed for ARC, NMDAR and calcium channel 
pathways. The enrichment of ARC pathways shows consistency with other 
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findings from schizophrenia de-novo CNVs (Kirov et al., 2012) and SNVs (Fromer 
et al., 2014), whilst calcium channel SNPs show enrichment from the largest 
schizophrenia GWAS (Schizophrenia Working Group of the Psychiatric Genetics 
Consortium, 2014) and across other neuropsychiatric disorders (Smoller et al., 
2013). 
 
Some studies have indicated de-novo SNVs are enriched for genes that are 
expressed during gestation (Xu et al., 2012; Gulsuner et al., 2013). These genes 
are expressed in the developing dorsolateral and ventrolateral prefrontal cortex 
(Gulsuner et al., 2013). Furthermore, they regulate migration of neurons, 
synaptic transmission, and neuronal signaling/transportation (Gulsuner et al., 
2013).  However, other studies have found no evidence for enrichment of 
prenatally expressed genes (Fromer et al., 2014). Thus the contribution of de-
novo SNVs upon the developmental aetiology of schizophrenia remains unclear. 
1.5.9 Summary  
The hypothesis that schizophrenia is highly polygenic disease was first posited 
nearly 50 years ago (Gottesman & Shields, 1967). This polygenic model is now 
substantiated through evidence showing schizophrenia risk is conferred through 
common, rare and structural genetic variation.  This polygenic model has also 
shown that psychiatric disorders including schizophrenia, bipolar disorder, 
autism and attention deficit hyperactivity disorder share a degree of common 
(Smoller et al., 2013) and rare (Malhotra & Sebat, 2012) genetic risk across 
psychotic and autistic disorders (Craddock & Owen, 2010). With improved 
understanding of the complex genetic and molecular basis of schizophrenia, the 
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opportunity presents to develop novel therapeutic targets that look beyond 
dopaminergic antagonists that have underpinned schizophrenia treatment for 
the past 60 years (Lieberman et al., 2005). 
 
1.6 Genetic architecture of cognition 
1.6.1 Defining cognitive ability 
Intelligence is a broad term encapsulating mental processes responsible for 
many aspects of cognitive functioning including abstract thinking, problem 
solving, comprehending and applying complex ideas, learning and using acquired 
knowledge for future problems (Gottfredson, 1997). However, definitions and 
conceptualisations of cognition vary widely, and have included measures of 
emotional or social intelligence (Mayer et al., 2001) and creativity (Barron & 
Harrington, 1981).  
 
A number of theories regarding the structure of cognition have been posited, 
however perhaps the most widely accepted are those that stress the centrality of 
generalised cognitive ability (“g”). Originally conceptualised by Galton (Galton, 
1883), and mathematically conceived by Spearman, this theory proposes that a 
single general cognitive factor is a substantial mediator of performance across 
lower order cognitive ability (Spearman, 1904). “g” is the name given to the first 
unrotated principle component derived across tests measuring different 
cognitive abilities, and consistently explains approximately 40% of inter-test 
variability (Deary et al., 2010). Other measurements of general cognitive ability 
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include Wechsler Adult Intelligence Scale (WAIS) IQ or Raven’s Progressive 
Matrices (Sheppard & Vernon, 2008).  
 
1.6.1.1 Fluid & Crystallised Intelligence 
General cognitive ability can be subdivided into fluid and crystallised intelligence 
(Cattell, 1963). Fluid ability is a general term representing the ability to solve 
novel problems by utilising attention, working memory, processing speed and 
executive functioning (Blair, 2006). Conversely, crystallised intelligence 
represents the ability to use acquired skills relating to basic numeracy and 
general knowledge (Cattell, 1963). Both fluid and crystallised constructs are 
conceptually similar to Wechsler performance and verbal IQ respectively (Kline, 
1991; Deary, 1993).  
 
1.6.2 Heritability of cognitive ability  
1.6.2.1 Heritability of general cognitive ability across the lifespan 
General cognitive ability is under strong genetic influence. Heritability estimates 
derived from twin studies have identified intriguing patterns with respect to 
genetic effects and their influence upon general cognitive ability over time. A 
large study of 11000 twin pairs found heritability estimates for “g” increases 
linearly across childhood (41%), early adolescence (55%) and early adulthood 
(66%) (Haworth et al., 2010).  Heritability estimates derived from GCTA are 
similar to that of twin studies. Childhood “g” is approximately 26% (Trzaskowski 
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et al., 2013), increasing to between 24-45% in early adolescence (Deary et al., 
2012; Plomin et al., 2013; Trzaskowski et al., 2013).  
 
Heritability estimates continue to increase across the lifespan to approximately 
80% in old age (Pedersen et al., 1992).  This counterintuitive finding shows 
general cognitive ability is under stronger genetic influence in later life 
compared to childhood. One argument has suggested genetic effects on cognition 
during childhood results in environmental choices throughout adulthood that 
compliments their cognitive genetic propensity (Haworth et al., 2010).  
 
1.6.2.2 GCTA Heritability of fluid & crystallised intelligence 
In adults, the heritability estimates for individual cognitive tests measuring fluid 
and crystallised abilities are generally lower compared to that of general 
cognitive ability. However, GCTA estimates show that both fluid (51%) and 
crystallised (40%) are still highly heritable (Davies et al., 2011).  
 
1.6.2.3 Heritability of WAIS performance and verbal tests 
Using twin studies, heritability of individual cognitive tests are substantially 
lower than general cognitive ability, and have been calculated separately for 
some performance and verbal subtests of the WAIS. Heritability estimates for 
performance IQ vary between 43-83% (Posthuma et al., 2001; Wright et al., 
2001; Posthuma et al., 2003; Luciano et al., 2005). However, estimates for 
performance subtests are generally lower. Block design varies between 24-31% 
(Finkel et al., 1995; Rijsdijk et al., 2002), whereas digit symbol coding heritability 
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estimates are typically higher at 65% (Plomin et al., 1994; Posthuma et al., 
2003). Other heritability estimates for digit symbol coding are lower (24-41%) 
and show substantial differences across countries (Finkel et al., 1995). 
 
WAIS verbal IQ scores show higher heritability estimates between 55-85% 
(Posthuma et al., 2001; Wright et al., 2001; Rijsdijk et al., 2002; Posthuma et al., 
2003; Luciano et al., 2005). WAIS verbal tests have shown moderate heritability: 
similarities (40%), vocabulary (52%), information (44%) and arithmetic (53%) 
(Rijsdijk et al., 2002).  
  
1.6.2.4 Heritability of childhood IQ and socioeconomic status  
Some studies have questioned these findings, using socioeconomic status as a 
mediating factor for assessing the genetic contribution of general cognitive 
ability (Nisbett et al., 2012). Twin heritability estimates of general cognitive 
ability in children from affluent families are approximately 60%, whereas almost 
no genetic contribution to variance in cognition was reported in children from 
poor backgrounds (Turkheimer et al., 2003). These findings are supported by 
other studies reporting a large effect of shared environment in lower 
socioeconomic families (Hanscombe et al., 2012), Other results suggest common 
genetic variation contributes to the correlation between socioeconomic status 
and childhood IQ (Trzaskowski et al., 2014), and the literature remains 
inconclusive. 
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1.6.3 Linkage studies and cognition 
The first genome-wide linkage study for general cognitive ability was performed 
in 329 Australian and 100 Dutch families (Posthuma et al., 2005). 2q24.1-31.1 
showed linkage with performance IQ, and 6p25.3-22.3 showed suggestive 
linkage with full scale IQ. Other studies have reported suggestive linkage at 
2q24-31 with performance IQ and Cambridge reading tests (Luciano et al., 
2006).  Suggestive linkage at chromosome 6p to full scale IQ in individuals with 
alcohol dependence has also been identified (Dick et al., 2006); however, the 
functional variants contributing to cognition at these loci are unknown.  
 
1.6.4 Genome wide association studies of cognition 
1.6.4.1 Episodic  & Working Memory 
In 2006, a GWAS of episodic memory in 333 individuals identified a significant 
association at rs17070145 in KIBRA, and was replicated in two independent 
samples (Papassotiropoulos et al., 2006). Furthermore, this association was 
stronger for immediate word recall (p=4x10-6) compared to delayed recall 
(p=0.002). Since its publication, a number of studies have supported this 
association (Almeida et al., 2008; Schaper et al., 2008; Hayashi et al., 2010; 
Vassos et al., 2010), whilst others have not (Need et al., 2008).  
 
A meta-analysis tested the association between rs17070145 and episodic and 
working memory in 8909 and 4696 individuals respectively (Milnik et al., 2012). 
rs17070145 was significantly associated with episodic (p=0.001) and working 
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memory (p=0.018), explaining approximately 0.5% and 0.1% of their variances 
respectively, although effect sizes were low (d=0.14 and 0.07).  
 
KIBRA binds to the protein PICK1 and forms complexes with AMPA receptors 
(Makuch et al., 2011). Functionally, KIBRA knockout mice have altered long-term 
potentiation and depression in the hippocampus, and perform poorly on 
contextual fear memory paradigms (Makuch et al., 2011).  
 
1.6.4.2 Processing Speed 
A small number of GWAS for processing speed are reported in the literature. One 
study performed a GWAS on seven measures of processing speed and a 
generalised speed factor in a combined sample of 2958 individuals (Luciano et 
al., 2011). No variant achieved genome wide significance for association with any 
phenotype. These findings are concordant with a smaller GWAS for digit symbol 
coding in 1086 individuals, which failed to identify SNPs reaching genome-wide 
significance (Cirulli et al., 2010).  
 
1.6.4.3 Fluid/Crystalised Intelligence 
A GWAS of fluid and crystalised intelligence was performed in 3511 healthy 
individuals (Davies et al., 2011). No SNP reached genome-wide significance. 
Using a gene-based test, formin-binding protein 1-like (FNBP1L) reached 
genome wide significance for association with fluid intelligence (P = 9.2x10-7), 
although this failed to replicate at a nominally significant level in an independent 
sample.  
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1.6.4.4 General cognitive ability 
A GWAS of “g” in 7900 individuals did not identify any SNP reaching genome 
wide-significance (Davis et al., 2010). A handful of studies have performed GWAS 
for educational attainment, measuring school test results (Martin et al., 2011) 
and number of years spent in education (Rietveld et al., 2013). No SNPs reached 
genome wide significance for association with school test results (Martin et al., 
2011). However Rietveld and colleagues identified two SNPs reaching genome 
wide significance for association with a binary variable (individuals who 
completed college or not) at rs11584700 in MDM4 and rs4851266 proximal to 
BC105019. An intergenic SNP rs9320913 also reached genome wide significance 
for association with number of years in education; however, the number of 
identified loci was modest, and effect sizes were small. 
 
Other GWAS investigated change in general cognitive ability across the lifespan. 
Several studies have implicated APOE in normal cognitive aging (De Jager et al., 
2012) (Davies et al., 2014). Furthermore, the e4 isoform of APOE is the largest 
genetic risk factor for Alzheimer’s disease (Corder et al., 1993; Harold et al., 
2009) (Harold et al., 2009), which is traditionally characterised by severe 
cognitive decline in elderly populations. Healthy carriers of the e4 isoform have 
lower generalised cognitive ability, executive functioning, episodic memory and 
processing speed compared to non-carriers (Wisdom et al., 2011).  
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1.6.5 CNVs and Cognition 
The contribution of rare CNVs towards general cognitive ability in healthy 
populations appears limited, and will be discussed at greater length in Chapter 4. 
Briefly, studies have investigated various measures of rare CNV burden 
including: total CNV number, total CNV length and number of genes hit with 
respect to general cognitive ability (MacLeod et al., 2012; McRae et al., 2013; 
Kirkpatrick et al., 2014). Kirkpatrick et al (2014) found no association between 
total CNV number or length and IQ in over 6000 individuals, replicating findings 
from a smaller study of 800 controls (McRae et al., 2013). No association was 
observed between rare CNV burden and fluid/crystallised intelligence in over 
3000 individuals (MacLeod et al., 2012).  
1.6.6 Summary  
Despite the substantial genetic contribution to cognition identified through 
heritability studies, the identification of genetic variants associated with either 
general or specific cognitive measures in the general population remain elusive.  
No robust associations between SNPs and cognition have emerged, either in 
candidate genes, or through GWAS. Furthermore, rare CNVs appear to have little 
influence on general cognitive ability in healthy individuals. Substantially larger 
sample sizes are required to identify genetic variants influencing cognitive 
ability.   
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1.7 Cognitive Phenotype in Schizophrenia 
1.7.1 Overview of cognitive impairment in schizophrenia 
Deficits in cognitive functioning are present across psychotic disorders (Green, 
2006), however schizophrenia cases show the greatest impairment. An 
influential review showed schizophrenia cases performed poorly on tasks 
measuring processing speed, executive functioning, working memory, verbal 
learning, and general cognitive ability (Heinrichs & Zakzanis, 1998), and are 
typically 1-2 standard deviations below healthy controls (Reichenberg, 2005). 
Nonetheless, there is substantial heterogeneity across patients, with some 
individuals functioning at a level indistinguishable from the general population 
(MacCabe et al., 2012).  
 
Representing the structure of cognitive deficits in schizophrenia cases has 
proven difficult. The abundance of different cognitive batteries of varying length, 
type and methods of administration makes interpretation of results across 
studies challenging (Keefe et al., 2004). Furthermore, the length of some 
cognitive batteries is arduous and impractical for patients with schizophrenia, 
and considered a hindrance when applied during clinical trials (Harvey & Keefe, 
2001). 
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1.7.2 Development of the Measurement to Improve Cognition In 
Schizophrenia Initiative   
 
The Measurement to Improve Cognition In Schizophrenia (MATRICS) cognitive 
battery was designed to standardise cognitive testing in schizophrenia cases for 
use in research and clinical trial settings (Green et al., 2004). Their aims were to 
identify specific cognitive domains showing the greatest impairment in 
schizophrenia. Furthermore, they aimed to promote the use of pharmacological 
approaches by improving cognition in patients, leading to improvements in 
functional outcome (Marder, 2006).  
 
The MATRICS committee initially performed a comprehensive review of 
principle component/factor analytic studies of cognition in schizophrenia to 
identify recurring domains (Nuechterlein et al., 2004), with additional input 
from a committee of experts (Kern et al., 2004).  They identified 7 domains: 
attention/vigilance, processing speed, verbal learning, visual learning, 
reasoning/problem solving, social cognition and working memory as being core 
cognitive features of schizophrenia (Nuechterlein et al., 2004).  
 
Tests for each domain were required to fulfil several criteria including: good 
test-retest reliability with low practice effects, show associations with functional 
outcome, be tolerated by patients, have low inter-test correlations, and be 
suitable for repeated testing for research purposes and clinical trials (Green et 
al., 2004). The final version of the MATRICS comprised of 10 individual tests 
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measuring 7 cognitive domains, including a standardised composite score 
measuring general cognitive ability (Table 1.1).  
 
MATRICS Domain Test 
Attention/Vigilance Continuous Performance Test: Identical Pairs (CPT-IP) 
Reasoning/Problem 
Solving 
Neuropsychological Assessment Battery (NAB) Mazes 
Speed of Processing Brief Assessment of Cognition in Schizophrenia (BACS): 
Symbol-Coding  
Category Fluency: Animal Naming 
Trail Making Test (TMT): Part A 
 
Verbal 
Learning/Memory 
Hopkins Verbal Learning Test—Revised (HVLT-R) 
 
Visual 
Learning/Memory 
Brief Visuospatial Memory Test—Revised (BVMT-R) 
 
Social Cognition Mayer-Salovey-Caruso Emotional Intellgence Test 
(MSCEIT): Managing Emotions 
Working Memory Wechsler Memory Scale: 3rd Ed.  
(WMS-III): Spatial Span  
Letter-Number Span 
 
Table 1-1 - MATRICS domains and their respective cognitive tests 
   
The majority of MATRICS domains and the composite score are also correlated 
with IQ (see Table 1.2), although social cognition is not (Mohn et al., 2014).   
 
 
 
 
 
 
 
MATRICS Domain Correlation with IQ 
Attention/Vigilance 0.26 (p<0.01) 
Reasoning/Problem Solving 0.37 (p<0.01) 
Speed of Processing 0.39 (p<0.01) 
 
Verbal Learning/Memory 0.43 (p<0.01) 
 
Visual Learning/Memory 0.54 (p<0.01) 
 
Social Cognition 0.09 (p>0.05) 
Working Memory 0.51 (p<0.01) 
 
Composite 0.60 (p<0.01) 
Table 1-2 - Correlation with MATRICS domains and IQ (adapted from Mohn et al, 2014) 
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1.7.3 MATRICS Domains 
1.7.3.1 Attention/Vigilance 
Attention is the ability to selectively focus upon a stimulus, often within the 
context of suppressing information from distractive stimuli (vigilance), and are 
commonly measured using various versions of the CPT. Patients show large 
attentional deficits (Heinrichs & Zakzanis, 1998; Liu et al., 2002) that may result 
from a reduction in capacity to store information (Nuechterlein & Dawson, 1984) 
or poor encoding of information (Elvevag et al., 2000). 
 
1.7.3.2 Reasoning/Problem Solving (Executive Functioning) 
Schizophrenia cases perform poorly on the Tower of London (Morice & 
Delahunty, 1996) and Wisconsin Card Sorting Test (WCST) (Heinrichs & 
Zakzanis, 1998), which utilise higher-level cognitive abilities such as advanced 
planning, abstract thinking and other lower order cognitive abilities 
(Nuechterlein et al., 2004).  
 
1.7.3.3 Speed of Processing 
Processing speed represents the speed at which different cognitive functions can 
be performed. These tasks are typically measured using digit symbol coding, trail 
making test part A, or through verbal fluency tasks. Digit symbol coding 
measures the speed at which individuals can correctly draw a symbol under the 
corresponding number from a given key. The TMT-A measures the speed at 
which lines are drawn between sequentially increasing numbers. Verbal fluency 
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measures the number of words an individual can recall in a set time period in 
response to an overarching category such as naming animals.   
 
Schizophrenia cases perform particularly poorly on processing speed tasks when 
tested in tandem with other cognitive domains (Dickinson et al., 2007). A meta-
analysis of individual tests across cognitive domains measuring processing 
speed, episodic memory, executive functioning, working memory, attention, 
problem solving, motor speed and general cognitive ability showed that the 
largest deficit was present for the digit symbol coding task with an effect size of -
1.57 (Dickinson et al., 2007).  
 
Another meta-analysis showed digit symbol coding had an effect size of -1.40, 
second only to verbal episodic measures of story learning and memory 
(Dickinson et al., 2013a).  
 
Processing speed contributes to performance of other cognitive domains 
including working memory, verbal IQ, sustained attention, problem solving, 
verbal learning and memory, visual learning and memory, reaction time, 
executive functioning and motor dexterity in schizophrenia cases (Rodriguez-
Sanchez et al., 2007; Andersen et al., 2013). When processing speed was added 
as a covariate, differences between schizophrenia cases and controls for most 
cognitive domains (except general cognitive ability and verbal episodic memory) 
were not significant. Furthermore, a large study of around 7000 healthy 
adolescents between the ages of 13-17 showed that processing speed explained 
approximately 90% of the effect of “g” (Coyle et al., 2011). Other findings have 
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shown that processing speed is both mediated by, and independent of “g” across 
schizophrenia cases and controls (Dickinson et al., 2008).  
 
A meta-analysis in 2010 showed several variables moderate performance on 
digit symbol coding tasks (Knowles et al., 2010). First, more recent studies were 
likely to report smaller effect sizes. Second, substantial differences in IQ between 
patient and control populations were more likely to inflate effect sizes. Third, 
lower doses of the antipsychotic chlorpromazine were associated with smaller 
effect sizes. 
 
1.7.3.4 Social Cognition 
Social cognition refers to the ability to comprehend interpersonal interaction 
and to respond to social cues in an appropriate manner. Unlike more traditional 
cognitive domains, studies of social cognition in schizophrenia have become 
more prominent over the past decade (Green & Horan, 2010).  
 
In individuals who later develop schizophrenia, abnormal social interaction is 
observed during early childhood and into adolescence (Jones et al., 1994). 
Furthermore, children who subsequently develop schizophrenia show abnormal 
facial expressions in social situations, indicative of aberrant social behaviour 
(Walker et al., 1993; Schiffman et al., 2004).  
 
In adults, general cognitive ability contributes substantially to social cognition, 
which in turn mediates functional outcome (Schmidt et al., 2011). In particular, 
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tests measuring emotional perception and social knowledge explained a 
significant proportion of the relationship between cognition and functional 
outcome. In addition, a recent meta-analysis showed emotion perception was 
significantly impaired in schizophrenia cases, with a large effect size of 0.91 
(Kohler et al., 2010), which may result from abnormalities in the anterior and 
posterior cingulate cortex (Reske et al., 2009). 
 
1.7.3.5 Working Memory 
Factor analytic studies of cognition in schizophrenia commonly identify a 
working memory factor and comprised of tests including WAIS arithmetic, letter 
number sequencing and digit span and mental control (Nuechterlein et al., 
2004). Schizophrenia cases have severe deficits in working memory (Lee & Park, 
2005; Forbes et al., 2009) encompassing several stages of mental processing 
(Baddeley, 1981), that are linked to aberrant connectivity in the prefrontal 
cortex (Barch et al., 2002).  
 
Patients experience difficulties in almost all aspects of working memory, from 
initial encoding of information into short term memory (Hartman et al., 2003), to 
storage (Gold et al., 2010) and subsequent recalling of information (Aleman et al., 
1999).  
 
1.7.3.6 Verbal Memory/Learning 
A recent meta-analysis by Dickinson et al (2013) showed the largest deficits in 
schizophrenia cases were for story memory and story learning tasks, both 
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measures of verbal episodic memory. However, it is unclear what cognitive 
battery they were part of.  Nonetheless, these findings are concordant with 
previous a previous meta-analysis where the largest deficits were present for 
global verbal memory (Heinrichs & Zakzanis, 1998). 
 
The cognitive mechanisms underlying impairments in verbal learning suggest 
patients have initial problems encoding information (Cirillo & Seidman, 2003), 
which may be partly attributable to aberrant attention and processing speed 
(Brebion et al., 2000), rather than problems in retaining or retrieving 
information (Gold et al., 2000).  
1.7.3.7 Visual Memory/Learning 
Schizophrenia cases show reductions in performance on spatial memory tasks 
(Fleming et al., 1997; Park et al., 1999). Worse performance may be attributable 
to problems with the organisational processing and retention of visual 
information (Seidman et al., 2003), possibly caused by widespread and 
inefficient processing of information across both hemispheres in frontal, parietal 
and temporal brain regions (Lee et al., 2008).  
 
1.7.4 The generalised cognitive deficit in schizophrenia 
Schizophrenia cases show cognitive impairment across multiple cognitive 
domains. However, these domains are not necessarily independent (Dickinson & 
Harvey, 2009), and show substantial inter-correlation (Keefe et al., 2006). 
Furthermore, individual domains load strongly upon a single generalised factor.  
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63% of schizophrenia case/control variance associated with cognitive 
performance was attributable to “g” (Dickinson et al., 2008), however some 
additional case/control variance was also mediated through verbal memory 
(13.8%) and processing speed domains (9.1%). The proportion of cognitive 
variance explained by “g” is also more substantial in schizophrenia cases 
compared to healthy controls (Dickinson et al., 2008; Deary et al., 2010; 
Dickinson et al., 2011). This suggests general cognitive ability in schizophrenia is 
more unified compared to healthy individuals. Furthermore, given “g” is 
substantial in schizophrenia cases, identifying neurobiological mechanisms 
underlying the generalised deficit may be more informative in contrast to 
individual cognitive domains.   
 
Other ways of assessing the generalised deficit include the MATRICS composite 
score, or IQ. The MATRICS cognitive battery derives a composite score reflective 
of the generalised deficit using scores across each of the 7 individual domains. 
Furthermore, composite scores are strongly correlated with IQ (r~0.7) (Kern et 
al., 2008; August et al., 2012). Other studies have found the MATRICS composite 
score is approximately 1 standard deviation lower compared to their projected 
composite score based upon premorbid IQ estimates (Gray et al., 2013), 
suggesting differences between current “g” and premorbid IQ .  
  
Performance and verbal IQ scores are also affected in schizophrenia cases. 
Whilst there are not substantial differences between their premorbid scores 
(Woodberry et al., 2008), longitudinal studies have shown performance IQ has 
the largest decline between childhood and adulthood compared to verbal and 
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full scale IQ (Meier et al., 2014). This is in concordance with several meta-
analyses showing performance IQ is the most impaired measure of general 
cognitive ability in schizophrenia cases (Heinrichs & Zakzanis, 1998; Dickinson 
et al., 2013a). 
 
1.7.5 The developmental course of cognitive deficits in schizophrenia 
Individuals with sub-clinical psychotic experiences during childhood are more 
likely to develop psychotic disorders in adulthood (Poulton et al., 2000). A meta-
analysis of 1188 individuals with high risk of psychosis (HR) showed significant 
impairment on measures of general intelligence, attention, executive functioning, 
processing speed (digit symbol coding), social cognition, verbal fluency, verbal 
and visual memory (Fusar-Poli et al., 2012).  
 
Niarchou et al (2013) investigated the association between self-reported 
psychotic experiences and cognitive ability based on the MATRICS domains in 
children at ages 8 and 12. Children with lower processing speeds at age 8 
showed association with increased risk of psychosis- like symptoms at age 12 
(Niarchou et al., 2013). Although not all individuals with HR will develop a 
psychotic disorder, these findings nonetheless suggest early psychotic 
experiences are accompanied by lower cognitive ability, which are reliable 
precursors to schizophrenia.  
 
Schizophrenia cases exhibit signs of milder cognitive impairment preceding the 
onset of psychosis. Infants and children who take longer to develop motor 
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coordination and language capabilities are at greater risk of developing 
schizophrenia (Jones et al., 1994; Isohanni et al., 2001). In addition, children with 
low IQ measured as early as age 4 have increased risk of developing 
schizophrenia in later life (David et al., 1997; Cannon et al., 2000; Zammit et al., 
2004). Furthermore, childhood general cognitive ability is associated with 
psychotic experiences in the adult general population (Barnett et al., 2012).  
 
1.7.6 Longitudinal studies of cognitive ability in schizophrenia during 
childhood/adolescence  
Several longitudinal studies have been conducted on independent birth cohorts 
providing insights into cognitive ability across childhood/adolescence in 
individuals who later develop schizophrenia. The New Zealand Dunedin cohort 
reported children aged 7-13 who later developed schizophrenia performed 
between 0.25-0.45 standard deviations lower than controls for IQ, performance 
IQ, block design, picture completion, verbal IQ, information, similarities, 
vocabulary and arithmetic tasks (Meier et al., 2014).  
 
MacCabe and colleagues investigated the change in verbal, spatial and inductive 
performance in Swedish adolescents between the ages 13 and 18 (MacCabe et al., 
2013). Individuals who developed schizophrenia showed marked deterioration 
on verbal tests, with similar deterioration observed for individuals with affective 
and non-affective psychosis. Spatial ability was also affected in schizophrenia 
cases, although this decline was less pronounced.  
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A separate study showed that prospective schizophrenia cases in the USA 
experienced a decline in reading, verbal, executive functioning and general 
cognitive ability between the ages of 13-16 (Fuller, 2002).  
 
A large meta-analysis compared premorbid IQ in individuals who later 
developed schizophrenia against age-matched controls (Woodberry et al, 2008). 
Individuals who developed schizophrenia had significantly lower IQ. 
Furthermore, impairments in both verbal and performance IQ were present, 
although no evidence of decline was observed across childhood and adolescence.  
 
Cognitive impairment is a key prodromal feature of schizophrenia with evidence 
suggestive of neurodevelopmental aetiology. These findings show individuals 
who develop schizophrenia in adulthood have cognitive impairments from early 
stages of development, which persists through childhood and adolescence. 
However, it is unclear if these deficits represent a causal influence on 
schizophrenia development, or whether neurobiological mechanisms 
contributing to schizophrenia also influence cognitive ability.  
 
1.7.7 Cognitive ability and schizophrenia symptom dimensions 
Understanding the relationship between symptom dimensions and cognitive 
performance may provide an opportunity for treatment intervention with 
reciprocal benefits for patients.  
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Dominguez and colleagues performed the largest review of cognition and 
symptom dimensions in over 5000 individuals (Dominguez et al., 2009). They 
looked at the association between 9 cognitive domains: attention, executive 
control, reasoning/problem solving, processing speed, verbal fluency, verbal 
learning/memory, verbal working memory, visual learning/memory, and full 
scale IQ), and 4 symptom clusters: depressive, disorganised, positive and 
negative.  
 
Verbal fluency, verbal learning and full scale IQ were significantly associated 
with negative symptoms, although effect sizes were small (-0.21 to -0.29)). 
Disorganised symptoms significantly correlated with attention, visual learning 
and full scale IQ, again with small effect sizes -0.21 to -0.28. Positive symptoms 
showed a weak association with processing speed, however no significant 
correlations were observed with the other cognitive domains. Depressive 
symptoms showed no association with any cognitive domain.  
 
The low correlation between positive symptoms and cognitive deficits could be 
attributable to selection bias, whereby patients with severe psychotic episodes 
are less likely to be included for selection for studies (Keefe & Harvey, 2012). 
Alternatively, this may simply reflect that severity of positive symptoms is not 
related to cognitive ability.  
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1.7.8 Treating Cognitive Symptoms In Schizophrenia 
1.7.8.1 Pharmacological Targets 
Cognitive deficits are not significantly treated by current medications or other 
treatment approaches. A large meta-analysis investigating the effects of anti-
psychotic medication upon cognitive functioning was performed in 1513 
schizophrenia cases across 14 studies (Woodward et al., 2005). They found 
atypical anti-psychotics (clozapine, olanzapine, quetiapine & risperidone) 
improved general cognitive ability, processing speed, verbal learning, fluency 
and motor skills. However, these improvements were approximately 1/3 of one 
standard deviation, suggesting for the majority of patients this will not 
remediate their cognitive functioning to within a normal range.  
 
Several potential confounders are present for studies investigating anti-
psychotic treatment and cognitive improvements, including practice and placebo 
effects (Goldberg et al., 2010). Where studies administer the same, or similar 
cognitive test over a specific time period, individuals undergoing testing have 
greater familiarity with the task, and may show improvement due to practice 
effects. Thus, better cognitive performance may be attributed to anti-psychotic 
medication, however practice, rather than medication effects may contribute to 
this improvement.  
 
Anti-psychotic medication may modestly, but not substantially improve 
cognitive functioning in schizophrenia cases. Thus, the development of 
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pharmacological targets that improves cognitive functioning would be of 
substantial benefit to patients (Gold, 2004; Buchanan et al., 2005).  
 
A number of potential molecular compounds targeting cholinergic, muscarinic, 
glutamatergic, dopaminergic, serotonergic, adrenergic and GABAergic receptors 
may benefit cognitive functioning in schizophrenia (Gray & Roth, 2007).  
 
NMDA receptors are a promising target for treatment due to strong evidence 
from genetic studies in schizophrenia (Kirov et al., 2012; Fromer et al., 2014) and 
their association with cognition through synaptic plasticity (Hunt & Castillo, 
2012).  
 
Buchanan et al (2007) reported the results of a 16-week double blind trial in 157 
schizophrenia cases investigating the clinical efficacy of glycine, a co-transmitter 
with glutamate for NMDARs, and D-cycloserine, which is a partial NMDAR 
agonist. Changes in negative symptoms and performance on neurocognitive 
domains (speed of processing, verbal fluency, motor speed, verbal memory, 
visual memory, auditory memory, visuo-spatial ability, attention and executive 
functioning, composite) were recorded at baseline and at the end of the trial. 
Unequivocally, there was no improvement across any neurocognitive measure or 
in the reduction of negative symptoms (Buchanan et al., 2007). This null finding 
was replicated in a second study of 195 patients (Weiser et al., 2012), however 
they noted that this could partially be explained by a higher than expected 
placebo response in the control group.  
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Other studies have investigated the effects of nicotinergic agents. High rates of 
smoking are found in schizophrenia populations relative to the general 
population, suggesting patients use nicotine as a form of self- medication 
(Kumari & Postma, 2005). Whilst some studies have shown nicotinic agonists 
may improve attention (Freedman et al., 2008; Quisenaerts et al., 2014), working 
memory and negative symptom severity (Freedman et al., 2008), possibly 
through the enhancement of glutamatergic synapses in the dorsolateral 
prefrontal cortex (Yang et al., 2013), their efficacy for targeted intervention is 
currently unknown.  
  
In general, pharmacological trials have produced disappointing results regarding 
their impact on cognitive functioning. A review of 118 studies documenting 
change in cognitive functioning resulting from pharmacological intervention 
found many clinical trials used designs that are not optimal for detecting 
improvements in cognition (Keefe et al., 2013). Specifically, studies have small 
sample sizes and thus low power, whilst demographics are commonly limited to 
older males with chronic schizophrenia. These individuals may respond more 
poorly to treatment compared to recent onset patients who are generally 
younger.  
 
1.7.8.2 Cognitive Remediation Behavioural Therapy (CRBT) 
Non-pharmacological treatments have also been used to improve cognitive 
ability in schizophrenia cases, the most popular being CRBT. A recent meta-
analysis reported a moderate effect size (d=0.45) for cognitive remediation 
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improving global cognitive ability in patients, although effect sizes for individual 
cognitive domains are typically lower (Wykes et al., 2011). However, it is unclear 
whether CRBT improves cognitive functioning sufficiently to produce meaningful 
long-term benefits relating to functional outcome.  
 
1.8 Cognition as a schizophrenia endophenotype 
The heterogeneous phenotype of schizophrenia, combined with inconclusive 
genetic results through linkage lead to a resurgence of the endophenotype 
approach (Gottesman, 2003). Endophenotypes are unobservable traits 
associated with disease under stronger genetic rather than environmental 
influence, and considered to be less complex and heterogeneous than the 
overarching disease. Gottesman and Shields proposed several criteria for 
defining an endophenotype (Gottesman & Shields, 1973) : 
 
1) They show association with disease. 
2) They are heritable. 
3) They are independent of disease state and show consistency across time. 
4) They are closely aligned with disease in families. 
5) Within families, endophenotypes show greater association with 
unaffected family members compared to the general population. 
 
Identifying genes underlying endophenotypic traits may provide an easier 
method for revealing genes or biological pathways in disease populations. 
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Furthermore, genes associated with endophenotypes are ideal candidates for 
modelling their biological function within animals (Gould & Gottesman, 2006).  
 
1.8.1 Heritability of neurocognitive traits in schizophrenia families 
The Consortium on the Genetics of Schizophrenia (COGS) is an on-going family 
study with the purpose of identifying reliable endophenotypes in schizophrenia. 
The study uses families where at least one proband is affected, and information 
on both parents and at least one unaffected sibling is required. Cognition is 
measured using a shortened version of the computerised neurocognitive battery 
(CNB) and other tests measuring attention, working memory, verbal memory, 
spatial memory/processing and emotional recognition (Calkins et al., 2007; Gur 
et al., 2007).  
 
Heritability estimates were between 0.24 and 0.55 for all cognitive tasks, 
demonstrating a consistent low to moderate effect (Greenwood et al., 2007). 
These findings are in concordance with estimates from other schizophrenia 
family studies (Glahn et al., 2007). 
 
1.8.2 State independence  
State independence refers to the stability of an endophenotypic trait over time, 
regardless of other disease processes. Longitudinal studies measuring change in 
cognitive ability over time have showed performance is stable across time for 
both specific and generalised cognitive ability, and not influenced by changes in 
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symptom severity (Heaton, 2001) for at least a decade after initial 
hospitalisation (Hoff et al., 2005). 
 
1.8.3 Aligned with disease in families 
For a trait to be considered an endophenotype it must be observed in unaffected 
relatives of the proband, demonstrating probable genetic influence. A number of 
studies have investigated the cognitive profiles of biologically related individuals 
with affected schizophrenia probands relative to the population.  
 
Unaffected siblings have lower performance on general cognitive ability (Wisner 
et al., 2011), processing speed (Wisner et al., 2011) and working memory 
(Conklin et al., 2005; Wisner et al., 2011). One meta-analysis used results from 
58 studies encompassing: attention/working memory, verbal memory, visual 
memory, executive functioning, spatial ability, motor function, language function 
and general cognitive ability in affected first degree relatives (Snitz et al., 2006). 
They identified moderate effect sizes (d > 0.5) for tasks measuring attention and 
executive functioning, with lower effect sizes (d > 0.4) for verbal and spatial 
tests. These findings suggest unaffected family members also exhibit cognitive 
impairments relative to population controls, but not to the extent of affected 
schizophrenia probands. 
 
1.8.4 Other endophenotype approaches 
An alternative approach is to test the association between genetic variants 
associated with disease and endophenotypic candidates in healthy individuals 
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(Walters & Owen, 2007). Walters & Owen (2007) described five viewpoints on 
the relationship between genotype, phenotype and endophenotypic candidates: 
 
1) Genetic factors are causal to endophenotypes on the disease pathway, 
which in turn influences phenotypic presentation of a symptom.  
2) The endophenotype is the resulting factor of the disease symptomatology, 
or arise through treatment intervention. 
3) Genetic factors demonstrate pleiotropy for both a symptom and the 
endophenotype 
4) Non-overlapping genetic factors contribute independently to symptoms 
and the endophenotype. 
5) The endophenotype influencing symptoms is the product of 
environmental factors.  
 
In these scenarios, only the first and third scenarios may be useful for 
investigating either disease mechanisms or shared genetic aetiology (Walters & 
Owen, 2007).  
 
In the absence of robust genetic variants associated with cognition, the approach 
of testing the association between genetic variants associated with 
schizophrenia and cognitive ability is currently more widely used.  
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1.9 Genetic Overlap of Schizophrenia and Cognition  
Quantifying the genetic effects underlying schizophrenia and cognitive ability is 
important for assessing their suitability as endophenotypes. Several studies have 
used genetic modelling of twin pairs to answer this question.   
 
Using a mixture of 267 monozygotic and dizygotic schizophrenia and healthy 
twin pairs, a strong phenotypic correlation between schizophrenia and IQ was 
observed (r=-0.61), with 92% of this correlation attributable to shared genetic 
influences (Toulopoulou et al., 2007).  
 
A larger study using 657 schizophrenia cases, 674 first-degree relatives and 725 
controls found approximately 89% of the correlation between schizophrenia and 
general cognitive ability was attributable to genetic factors (Toulopoulou et al., 
2010). In addition, they also showed that genetic factors contributing to the 
phenotypic correlation between schizophrenia, and immediate and delayed 
recall were 72% and 86% respectively (Toulopoulou et al., 2010).   
 
A separate study using 1986 MZ and 2253 DZ Swedish twins showed greatly 
reduced phenotypic correlation between psychosis and premorbid IQ (r= -0.11) 
(Fowler T, 2012), although the proportion of this correlation attributable to 
genetic factors was 91%, similar to the findings by Toulopoulou and colleagues. 
However, this study provided additional details showing genetic factors 
associated with psychosis are largely independent of IQ; only 6.8% was shared. 
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The authors conclude that using IQ as an endophenotype is likely to be 
uninformative in finding genes for schizophrenia.  
 
1.10 Genetic Risk of Schizophrenia and Its Associations with 
Cognition 
A number of studies have investigated the genetic basis of cognitive impairment 
in schizophrenia at the level of single SNPs, overall polygenic risk, and to a lesser 
extent CNVs.  
 
1.10.1 Candidate schizophrenia SNPs and their association with cognition 
This section will briefly describe studies that have investigated SNPs in 
schizophrenia candidate genes, and those discovered through schizophrenia 
GWAS with respect to their associations with cognition.  
 
BDNF 
BDNF was a schizophrenia functional candidate gene (Muglia et al., 2003), and 
resides within the neurotrophin gene family. These genes regulate neuronal 
differentiation and proliferation and may contribute to synaptic plasticity in the 
hippocampus (An et al., 2008).  
 
Over 20 studies have been performed investigating the Val66Met genotype at 
rs6265 in BDNF and cognitive functioning. A large meta-analysis in 2012 
investigated this association in 7095 cases and controls collectively (Mandelman 
 52 
& Grigorenko, 2012). They found no association between the Val66Met genotype 
and general cognitive ability, executive functioning, verbal fluency, visual ability, 
or memory. Although this study pooled cases and controls, thus removing 
possible associations with cognition that are case specific, the findings 
nonetheless suggest rs6265 has no role upon cognitive functioning across 
healthy and schizophrenia populations.   
 
COMT 
The Val158/108Met polymorphism in COMT is a regulator of dopamine in the 
prefrontal cortex.  A large meta-analysis of 46 studies investigated associations 
between the val/met genotype and 6 cognitive phenotypes; n-back task, trail 
making task, verbal recall, verbal fluency, Wisconsin card sorting and IQ (Barnett 
et al., 2008). The val/met genotype had a low effect size (d=0.06) and explained 
approximately 0.1% of the variance of IQ. No significant associations were 
observed between the val/met genotype and other cognitive phenotypes.  
 
APOE 
The APOE locus is the most strongly associated risk factor for developing 
Alzheimer’s Disease (AD) (Harold et al., 2009), with the e4 allele conveying the 
largest disease risk (Corder et al., 1993). AD is largely characterised by severe 
cognitive decline in later life. Furthermore, APOE also contributes to a cognitive 
decline in later life within healthy individuals (Davies et al., 2014). The role of 
APOE in cognitive decline makes this a plausible candidate gene for the aetiology 
of cognitive deficits in schizophrenia.   
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No association was observed between APOE-e4 and schizophrenia through meta-
analysis (Xu et al., 2006). Furthermore, schizophrenia cases carrying the risk 
APOE-e4 genotype carriers do not have lower IQ scores compared to 
non=carriers (Thibaut et al., 1998). This suggests APOE-e4 does not contribute 
towards cognitive impairment in schizophrenia. However, its effect upon 
longitudinal changes in cognition in schizophrenia is unknown.   
 
1.10.1.1  Schizophrenia GWAS associated SNPs their association with cognition 
Nitric oxide synthase 1 (NOS1) 
rs6490121 in NOS1 was one of the earliest SNPs to show association at a level 
just below genome wide significance with schizophrenia (O'Donovan et al., 
2008a). In hippocampal neurons, nitric oxide is released from the post-synaptic 
membrane and acts upon the presynaptic terminal, altering long term 
potentiation (Arancio et al., 1996). Furthermore, NOS1 couples with the N-
methyl-D-aspartate receptors (NMDAR) in the post-synaptic density (PSD), 
which is strongly enriched for de novo CNVs in schizophrenia (Kirov et al., 2012) 
and linked to synaptic plasticity (Malenka & Nicoll, 1993) . In mice, knock out 
effects of nitric oxide synthase reduces memory and learning capacity using 
performance on the Morris water maze (Weitzdoerfer et al., 2004). One study 
investigated the effect of rs6490121 genotypes on general and specific cognitive 
ability in both schizophrenia cases and healthy controls (Donohoe et al., 2009). 
They showed homozygous carriers of the risk “G” allele at rs6490121 had lower 
verbal IQ and working memory, but not attention impairments.  
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TCF4  
Several studies have investigated the association between rs9960767 genotype 
and cognition. One study of 173 schizophrenia cases showed carriers of the “C” 
risk allele had lower performance on the MATRICS reasoning/problem solving 
domain, with no other significant associations observed for the remaining 
cognitive domains (excluding social cognition) and general cognitive ability 
(Albanna et al., 2014). Other studies have found the “C” allele is associated with 
less impaired verbal memory in 401 schizophrenia cases, but not delayed recall 
or IQ (Lennertz et al., 2011).  
 
ZNF804A 
rs1344706, in the gene ZNF804A , is a SNP reaching genome wide significance for 
schizophrenia (Schizophrenia Working Group of the Psychiatric Genetics 
Consortium, 2014) and broader psychosis (O'Donovan et al., 2008a). Several 
studies have investigated the association between rs1344706 genotype and 
cognition.  
 
Walters and colleagues looked at the association between the “A” risk allele at 
rs1344706 and IQ, verbal working memory, episodic memory and attention 
(Walters et al., 2010). Counterintuitively, proband carriers of the “A” allele were 
less cognitively impaired on verbal and spatial working memory tasks. Post hoc 
tests showed the homozygous AA group was significantly less impaired 
compared to the CC group. However, these results are not suggestive that risk 
carriers display preserved cognitive functioning. Interestingly, these results 
were not observed within healthy controls.  
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A separate study has shown differential patterns of working memory and 
executive functioning in schizophrenia cases with high (>100) and low (<100) IQ 
when grouping by rs1344706 genotype (Chen et al., 2012). Patients in the high 
IQ group with the homozygous AA genotype had significantly lower performance 
on both working memory and executive functioning tasks, whereas those in the 
low IQ group had more spared cognitive ability.  
 
The counterintuitive finding that homozygous AA cases have less impaired 
cognitive functioning in working memory tasks may be partially explained by 
relatively preserved grey matter in the hippocampus (Donohoe et al., 2011a).  
 
rs1344706 also shows association with differential activation in the right 
dorsolateral prefrontal cortex using a facial working memory paradigm (Linden 
et al., 2013). Separately Esslinger and colleagues measured working memory and 
emotional recognition with respect to the rs1344706 genotype using fMRI 
(Esslinger et al., 2011). They observed no phenotypic differences grouping by 
genotype, however risk allele carriers showed decreased connectivity across the 
prefrontal cortex and hippocampal regions.  
  
NRGN 
Several neurobiological functions relating to NRGN and cognition have been 
identified. Specifically, neurogranin is strongly enriched in hippocampal 
pyramidal neurons (Huang et al., 2007), and particularly concentrated in 
dendritic spines (Zhabotinsky et al., 2006). Furthermore, mouse models have 
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been used to show NRGN is important for hippocampal synaptic plasticity and 
subsequent performance on spatial learning tasks (Pak et al., 2000). However, its 
role in cognition in humans seems to be limited (Donohoe et al., 2011b; Walters 
et al., 2013). 
 
MHC 
Whilst SNPs in the MHC shows substantial association with schizophrenia, its 
association with cognition is not well defined. A recent study found rs6904071 
was most robustly associated with delayed episodic memory, and the 
schizophrenia risk allele was associated with poorer cognitive performance 
(Walters et al., 2013). Furthermore, the risk allele was also associated with lower 
hippocampal volume, which itself has links to episodic memory (Chadwick et al., 
2010). It is unknown whether this association is attributable to the role immune 
system or via other pathways. Evidence is now immerging showing MHC class I 
proteins may influence synaptic functioning (Lee et al., 2014), possibly through 
localisation with postsynaptic density protein 95 in hippocampal dendrites 
(Goddard et al., 2007).   
 
CACNA1C 
A number of studies have investigated the association between rs1006737 in 
CACNA1C and cognitive ability in schizophrenia patents and healthy controls.  
One study reported homozygous and heterozygous schizophrenia cases carrying 
the “A” risk allele were significantly impaired on a logical memory task (Hori et 
al., 2012). One study in over 500 healthy males found no association between 
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rs1006737 genotype and general cognitive ability, executive functioning, verbal 
learning and memory (Roussos et al., 2011). 
 
1.10.2   Summary of candidate/GWAS SNPs and their association with 
cognition 
Studies investigating schizophrenia or candidate SNPs with respect to effects of 
genotype on cognition have typically had little success. Although associations 
may be identified in small samples, effect sizes are typically small, not always in 
the expected direction of effect, or have inconsistent effects across studies. 
Furthermore, for well-studied variants such as COMT and BDNF, findings from 
large meta-analyses have failed to show strong associations between the risk 
genotype and cognition, despite initial successes of smaller studies. For SNPs 
recently identified through GWAS, large sample sizes are required to show 
meaningful associations to prevent false positive associations found in earlier 
smaller studies.  
 
1.11 GWAS of Cognition in Schizophrenia 
There have been a limited number of GWAS of cognition in schizophrenia 
reported in the literature, which is most likely due to issues with small sample 
sizes. However, Dickinson and colleagues recently performed a GWAS for 
association with “g” (Dickinson et al., 2014). Using a discovery cohort of 339 
schizophrenia probands and 363 controls, they identified two SNPs (rs10174400 
and rs10182570) reaching genome wide significance within SCN2A, with the 
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former SNP explaining over 10% of the variance of “g”. rs10174400 was 
nominally significant in unaffected siblings (p=0.03) explaining 3.4% of the 
variance of “g”. In healthy controls, this association was not significant, and the 
direction of effect was reversed. Furthermore, this effect was substantially lower 
in their replication sample, where rs10174400 was less significant (p=0.02) and 
explained approximately 1% of the variance of “g”, suggesting a “winners curse” 
effect (Kraft, 2008). Larger studies are required to replicate this finding.   
 
1.12 Polygenic risk of schizophrenia and its association with 
cognition  
Recently, common polygenic risk of schizophrenia has been applied to test 
associations with potential cognitive endophenotypes in the general population. 
Increased polygenic risk of schizophrenia was associated with lower 
performance on general cognitive ability (Lencz et al., 2014) and a decline in 
general cognitive ability across the lifespan (McIntosh et al., 2013). Whilst these 
findings support the hypothesis that increased genetic risk of schizophrenia is 
associated with poorer cognition, it explains only modest proportions (%r2≈1) of 
general cognitive ability, and have not consistently replicated (van Scheltinga et 
al., 2013). Conversely, a reverse approach showed polygenic scores for “g” was 
associated with schizophrenia status, albeit with a very limited degree of 
variance explained (%r2<0.5) (Lencz et al., 2014).  
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1.13 SNVs and their association with cognition in schizophrenia  
The contribution of SNVs and their association with cognitive ability in 
schizophrenia is largely unknown. A single study reported higher rates of rare 
de-novo loss of function mutations in individuals with low academic 
achievement (Fromer et al., 2014). Individuals with the lowest grades (D & C) 
had approximately double the number of loss of function mutations compared to 
those achieving higher grades (A & B).  
 
1.14 Neuropsychiatric CNVs and their association with cognition 
Neuropsychiatric CNVs are structural genetic variants implicated in 
schizophrenia, autism and intellectual disability (Stefansson et al., 2014). These 
psychiatric disorders share a common theme of cognitive impairment, thus their 
risk CNVs may contribute to cognitive ability. A recent study by Stefansson and 
colleagues showed healthy carriers of neuropsychiatric CNVs had cognitive 
scores between that of schizophrenia cases and other healthy controls, which 
was largely driven by general cognitive ability. This study was the first to show 
neuropsychiatric CNVs have a detrimental impact upon cognition in the absence 
of a psychiatric diagnosis.   
 
1.15 Summary 
Identifying genetic variants contributing to both schizophrenia and cognitive 
ability may substantially improve our understanding of their underlying biology, 
with the prospect of potential therapeutic targets that could be of benefit to 
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patients. However they are both highly polygenic traits with a complex genetic 
architecture, and dissecting their shared biology has been arduous. To date, no 
genetic variant has been robustly associated schizophrenia and cognition.   
Whilst the MATRICS cognitive battery has led to improvements regarding the 
assessment and standardisation of cognitive ability, pharmacological targets are 
still elusive for the treatment of cognitive symptoms. At least part of this failure 
can be attributed to a poor understanding of genetic factors that underpin both 
cognitive ability and schizophrenia.  
 
1.16 Thesis aims and Hypotheses  
This thesis investigated the effect of common and rare schizophrenia genetic 
variation, and their associations with specific and general cognitive ability in 
schizophrenia cases and healthy controls.  
 
Chapter 2 investigated the common polygenic risk of schizophrenia and bipolar 
disorder and their association with specific and generalised cognitive ability 
within the general population.  Previous studies have identified schizophrenia 
polygenic risk is associated with lower general cognitive ability in healthy 
populations. This chapter expanded upon these findings by using three GWAS 
discovery datasets for schizophrenia, bipolar disorder and schizophrenia versus 
bipolar. Secondly, polygenic risk scores were calculated in two independent 
cognition datasets using tests measuring individual cognitive domains and 
general cognitive ability.  This chapter addresses the following hypotheses:  
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1) Increased polygenic risk of schizophrenia would be associated with lower 
cognitive ability. 
2) Increased polygenic risk of bipolar disorder would be associated with 
lower cognitive ability. 
3) Polygenic risk scores derived from SNPs associated specifically with 
schizophrenia (and not bipolar disorder) would be associated with lower 
cognitive ability.  
  
Chapter 3 investigated the hypothesis that gene sets related to brain function, 
development, behaviour and cognition are a priori more likely to be enriched for 
SNPs influencing general cognitive ability. 155 gene-sets were used and grouped 
into six biological categories relating to behaviour, cellular physiology, cellular 
morphology, development, region tract morphology and subcellular neuronal.  
Expanding on findings from chapter 2, it is unclear whether schizophrenia 
polygenic risk is associated with general cognitive ability using polymorphisms 
within specific biological pathways. In addition, it is unknown what pathways 
are important for the generalised cognitive deficit in schizophrenia cases.  This 
chapter examines the following hypotheses: 
 
1. Do schizophrenia polygenic risk scores derived from common SNPs in 
candidate pathways predict general cognitive ability measured through 
performance IQ in healthy controls, and the MATRICS composite score a 
schizophrenia patient sample?  In addition, are there differences in 
association between the different pathway categories? 
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2. Using Brown’s method, is there an enrichment of SNPs in candidate 
pathways that show association with general cognitive ability in a 
schizophrenia patient sample?  In addition, are there differences in 
association between the different pathway categories? 
 
Chapter 4 examined the association between rare CNVs and general cognitive 
ability in schizophrenia cases. Healthy carriers of well-supported 
neuropsychiatric CNVs have lower cognitive ability compared to non-carriers, 
however no study to our knowledge has investigated this within a schizophrenia 
cohort. In addition, the impact of CNV burden in schizophrenia cases is poorly 
defined, along with their impact upon biological pathways relating to brain 
function, development, behaviour and cognition. This chapter addresses the 
following hypotheses:  
 
1. Do schizophrenia carriers with well-supported neuropsychiatric CNVs 
have lower general cognitive ability compared to non-carriers? 
 
2. Does total rare (frequency <1%) CNV burden of small (15-100kb) and 
large (>100kb) CNVs, their total length or number of genes hit show 
association with general cognitive ability? Furthermore, does the type of 
CNV (deletions or duplications) show the same, or differential 
associations? 
 
3. Does the number of genes hit by CNVs within 155 candidate pathways 
show association with general cognitive ability in schizophrenia cases?   
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2 Polygenic Risk of Schizophrenia and Bipolar Disorder and 
their Associations with Cognition  
2.1 Summary 
Schizophrenia and bipolar disorder are severe psychiatric conditions with a 
substantial genetic aetiology. This chapter used established polygenic risk score 
methodology to assess whether large numbers of common genetic variants 
associated with schizophrenia, bipolar disorder and their differences are 
associated with cognition in healthy adults and children at age 8.  
 
Increased polygenic risk of schizophrenia was consistently associated with lower 
performance IQ using three different schizophrenia discovery datasets, across 
multiple training thresholds in two independent cognition samples.  
Schizophrenia polygenic risk predicted up to 0.59% of the performance IQ 
variance in 936 adult controls, and 0.34% in over 5500 controls in ALSPAC.  
 
Increased polygenic risk of bipolar disorder was associated with lower 
processing speed at the 0.1 training threshold (%r2=0.1), and better social 
cognition at the 0.0001 training threshold (%r2=0.08).  
 
Polygenic risk scores of schizophrenia relative to bipolar disorder were 
associated with lower performance on full scale IQ (%r2=0.3), verbal IQ (%r2= 
0.3) and performance IQ (r2=0.1%).  
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2.2 Introduction 
Schizophrenia and bipolar disorder are common psychiatric disorders with 
lifetime prevalence estimated to be around 1% (McGrath et al., 2004b; 
Merikangas et al., 2007). Schizophrenia is characterised by positive (irrational 
beliefs/ delusions/hallucinations/paranoia) and negative symptoms (alogia, 
blunted affect, anhedonia) (van Os & Kapur, 2009). Bipolar disorder is 
predominantly a mood disorder characterised by extreme fluctuations in mental 
state, specifically mania or hypomania and depression (Phillips & Kupfer, 2013). 
Manic episodes are characterised by elevated or irritable mood, impulsivity, 
lowered inhibition, and at times psychosis. Conversely, depressive symptoms 
mirror those of major depressive disorder including anhedonia, low motivation 
and sleep disturbances. Bipolar disorder is categorised by two subtypes; bipolar 
I, and bipolar II. The differentiating factor between bipolar diagnoses is the 
severity of mania, which is lower in bipolar II cases (Phillips & Kupfer, 2013). 
There are no psychotic symptoms restricted to either schizophrenia or bipolar 
disorder, however, the frequency and severity of psychosis typically varies 
between the two disorders, for example schizophrenia cases are more likely to 
report persistent and severe hallucinations compared to bipolar cases (Baethge 
et al., 2005). 
 
2.2.1 Common genetic architecture of schizophrenia and bipolar disorder 
 
Schizophrenia and bipolar disorder have a strong genetic aetiology. Heritability 
estimates from twin studies are approximately 80% for schizophrenia (Sullivan 
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et al., 2003) and bipolar disorder (Cardno et al., 1999). Common genetic variants 
of small effect contribute substantially to the genetic architecture of 
schizophrenia (International Schizophrenia Consortium, 2009).  The most recent 
analysis by the schizophrenia PGC used a discovery sample comprising of 32838 
cases and 44357 controls, predicting 18.4% of the variance of schizophrenia 
liability in MGS-EA (Schizophrenia Working Group of the Psychiatric Genetics 
Consortium, 2014). The variance explained is substantially larger than the 3% 
identified using ISC discovery sample (International Schizophrenia Consortium, 
2009). An equivalent analysis for bipolar disorder showed common genetic 
variants explained approximately 3% of variance of bipolar liability  (PGC 
Bipolar Disorder Working Group, 2011).  
 
For analyses relating to schizophrenia, increases in the variance of schizophrenia 
liability explained by common genetic variation over time is attributable to 
increasingly large schizophrenia discovery samples. Statistical modelling of 
polygenic risk score analyses show that increases in discovery sample size lead 
to more reliable effect sizes for individual SNPs, resulting in better predictive 
power to detect association with a phenotype in an independent sample 
(Chatterjee et al., 2013; Dudbridge, 2013)  
 
Common genetic architecture of schizophrenia and bipolar disorder has 
overlapping features. Schizophrenia polygenic risk predicts between 2-2.5% of 
variance for bipolar disorder liability (International Schizophrenia Consortium, 
2009; Smoller et al., 2013). In addition, schizophrenia polygenic risk is a better 
predictor of bipolar cases with psychotic traits (Hamshere et al., 2011), 
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suggesting the genetic risk of psychosis is dimensional rather than discrete 
(Craddock et al., 2009).  
 
Individual loci also show association for schizophrenia and bipolar disorder. 
Genome wide association studies (GWAS) have shown individual risk loci for 
schizophrenia such as ZNF804A become strengthened with the inclusion of 
bipolar individuals (O'Donovan et al., 2008a). Conversely, CACNA1C originally 
associated with bipolar disorder (PGC Bipolar Disorder Working Group, 2011) 
has also been reported as genome wide significant in schizophrenia 
(Schizophrenia Working Group of the Psychiatric Genetics Consortium, 2014). In 
addition, a GWAS combining schizophrenia and bipolar cases into a unitary 
phenotype identified a novel locus within PIK3C2A reaching genome wide 
significance (Ruderfer et al., 2014). This locus was not previously identified 
using individual GWAS of the two disorders, showing common genetic variants 
can be identified using a broader psychosis phenotype despite increased 
phenotypic heterogeneity,   
 
The role of copy number variations (CNVs) in schizophrenia will be discussed at 
greater length in Chapter 4. Briefly, specific large, rare (both inherited and de-
novo) CNVs are highly enriched in schizophrenia probands (Rees et al., 2011; 
Rees et al., 2014b). De-novo CNVs are also enriched in bipolar probands 
(Malhotra et al., 2011), although large CNVs are less robustly associated with 
bipolar disorder compared to schizophrenia (Grozeva et al., 2010). Furthermore, 
neuropsychiatric CNVs enriched in schizophrenia probands are not more 
common in bipolar probands relative to controls (Grozeva et al., 2010). In 
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summary, schizophrenia and bipolar have aspects of shared genetic architecture, 
however their genetic differences may contribute to their separable phenotypes.  
 
2.2.2 Cognitive Deficits in Schizophrenia and Bipolar Disorder 
 
Schizophrenia cases show greater cognitive impairment compared to individuals 
with bipolar disorder (Murray et al., 2004; Green, 2006). Differences in 
premorbid impairment are also observed, for example general cognitive ability is 
associated with increased risk of schizophrenia but not bipolar disorder (Zammit 
et al., 2004; Sorensen et al., 2012).  
 
Schizophrenia is characterised by premorbid deficits across multiple cognitive 
domains from performance (block design, picture completion) and verbal 
(information, similarities, vocabulary and arithmetic) tasks (Meier et al., 2014). 
In contrast, less is known regarding premorbid cognitive ability in bipolar 
disorder.  Individuals with both inferior and superior school ability have an 
increased risk of developing bipolar disorder (MacCabe et al., 2010), and 
particular impairments on visuospatial reasoning have been identified (Tiihonen 
et al., 2005).  
 
After the onset of psychosis, schizophrenia cases show the greatest deficits on 
general cognitive ability (Dickinson et al., 2008) and specific domains of 
attention/vigilance, reasoning/problem solving, speed of processing, social 
cognition, verbal learning/memory, visual learning/ working memory 
(Nuechterlein et al., 2004). Euthymic bipolar cases exhibit cognitive impairment 
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in several domains affected in schizophrenia (Green, 2006), and a meta-analysis 
of cognitive impairment in bipolar disorder have shown the largest impairments 
are in domains of verbal memory and executive functioning (Robinson et al., 
2006; Arts et al., 2008; Bora et al., 2009).  
 
Other studies have tested cognition in bipolar individuals using the MATRICS 
cognitive battery making results more easily comparable with schizophrenia. 
Burdick and colleagues found bipolar I cases could be separated into 3 
subgroups using cognitive performance (Burdick et al., 2014). The first showed 
normal performance across all domains, but cases have superior social cognition. 
The second showed selective deficits on speed of processing, attention, verbal 
learning and social cognition, whilst the third demonstrated severe deficits 
across all 7 domains. However, this study was performed in a small sample of 
136 bipolar cases, and larger studies are required to replicate these findings. 
Another study in 50 bipolar cases found deficits in processing speed, working 
memory, verbal and visual learning (Van Rheenen & Rossell, 2014). However, 
studies using the MATRICS cognitive battery are performed in substantially 
smaller samples when compared to meta-analyses, and it is unclear whether 
these domains accurately measure impairments in cognitive domains that 
impact cases with bipolar disorder.   
 
The association between symptom domains and cognition also varies across 
disorders. Cognitive impairment shows no association with the positive 
symptoms of schizophrenia (Dominguez et al., 2009). In contrast, the level of 
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cognitive impairment in bipolar cases may be mediated by the severity of 
psychosis (Simonsen et al., 2011).  
 
Differences in bipolar type I and II have also been observed. A meta-analysis 
(Bora et al., 2011) of cognitive impairment in bipolar I and II cases showed the 
biggest difference was in the domain of verbal learning, although significant 
impairments were also observed for semantic fluency and visual memory.  
 
In summary. these findings indicate that cognitive deficits in schizophrenia are 
substantial, and effect multiple cognitive domains and general cognitive ability. 
The findings from bipolar disorder are suggestive of less substantial impairment 
across fewer cognitive domains. In addition, symptom dimensions have no 
association with of schizophrenia, although differences may be present across 
bipolar subtypes.  
 
2.2.3 Heritability estimates of cognition in schizophrenia and bipolar 
disorder 
The genetic basis to cognitive deficits in schizophrenia and bipolar disorder has 
been investigated using twin and sibling study designs. The Consortium on the 
Genetics of Schizophrenia (COGS) (Calkins et al., 2007) is an on-going family 
study with the purpose of identifying reliable endophenotypes in schizophrenia. 
The study uses families with at least one affected proband, and information on 
both parents and at least one unaffected sibling is required. Cognition was 
measured using a shortened version of the CNB  and other tests measuring 
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attention, working memory, verbal memory, spatial memory/processing and 
emotional recognition (Calkins et al., 2007). Heritability estimates were between 
0.24 and 0.55 for all cognitive tasks (Greenwood et al., 2007), demonstrating a 
low to moderate effect. Other studies have shown IQ is more heritable compared 
to individual cognitive traits in schizophrenia cases and unaffected family 
members (Husted et al., 2009; Owens et al., 2011). Unaffected siblings of 
schizophrenia probands also show lower cognitive ability on “g” (Wisner et al., 
2011), processing speed (Wisner et al., 2011) and working memory (Conklin et 
al., 2005; Wisner et al., 2011) compared to healthy controls. 
 
A meta-analysis of cognitive traits in bipolar cases and their first-degree 
relatives showed both had deficits on attention, verbal memory, executive 
functioning, inhibition and set shifting (Bora et al., 2009). Deficits in speed of 
processing, verbal fluency and visual memory were seen exclusively in cases. 
Heritability studies of cognition in bipolar families are suggestive of genetic 
influence on executive functioning (h2~0.6), processing speed (h2=0.72) and 
verbal ability (h2=0.96) (Antila et al., 2007), suggesting a genetic basis for 
cognitive deficits in bipolar disorder. 
 
En masse, cognitive deficits are heritable and present in unaffected siblings, thus 
making them potential endophenotypic candidates. Endophenotypes are 
unobservable traits associated with disease under stronger genetic than 
environmental influence, and considered to be less complex and heterogeneous 
than the overarching disease (Gottesman, 2003). One approach is to test the 
association between genetic variants associated with disease and 
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endophenotypic candidates (Walters & Owen, 2007). The following section 
discusses the use of polygenic risk scoring to test this association.   
  
2.2.4 Polygenic Scores and Cognition 
Given that schizophrenia is characterised by severe deficits in cognitive 
functioning, several studies have used polygenic risk score analysis to investigate 
the association between schizophrenia polygenic risk and general cognitive 
ability in healthy individuals. By testing cognition in healthy controls, this 
removes potentially confounding variables present within schizophrenia cohorts 
including illness duration, symptom severity and medication effects. Three 
previous publications have investigated the relationship between cognition in 
the general population and schizophrenia using polygenic score analysis. 
Increased polygenic risk of schizophrenia was associated with lower general 
cognitive ability (Lencz et al., 2014) and a decline in general cognitive ability 
across the lifespan (McIntosh et al., 2013). However, these studies only explain 
modest proportions (%r2≈1) of cognitive variance, and have not consistently 
replicated (van Scheltinga et al., 2013). Conversely, a direct assessment of the 
endophenotype approach showed polygenic scores for “g” were associated with 
schizophrenia caseness, however only a small proportion of variance for 
schizophrenia liability (%r2<0.5) was found (Lencz et al., 2014).  
 
A limitation of these studies was that they all limited their investigation to global 
measures of IQ or g, which neglects possible associations between schizophrenia 
polygenic risk and individual cognitive domains, or across verbal or non-verbal 
ability. Furthermore, the identification of cognitive domains most closely aligned 
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with genetic risk of schizophrenia would be useful for future endophenotype 
studies.  
 
2.2.5 Aims/Hypotheses 
 
This chapter builds upon previous research by investigating polygenic risk of 
schizophrenia, bipolar disorder and their differences, to assess their association 
with measures of generalised and specific cognitive ability. The following 
hypotheses are addressed:  
 
1) Is increased polygenic risk of schizophrenia associated with lower cognitive 
ability using various measures of generalised cognition and specific cognitive 
domains? This hypothesis is tested by training on three different schizophrenia 
datasets: PGC1 (Schizophrenia PGC, 2011), CLOZUK (Hamshere et al., 2013) and 
PGC2 (Schizophrenia Working Group of the Psychiatric Genetics Consortium, 
2014). Polygenic risk of schizophrenia was tested for association with cognitive 
ability in an adult German cohort (Rujescu et al., 2003) and in the ALSPAC 
sample(Golding et al., 2001), a UK longitudinal cohort with results of cognitive 
testing available at age 8.  
 
The following analyses were performed:  
i) Schizophrenia PGC1 to German Cognition 
ii) Schizophrenia PGC1 to ALSPAC 
ii) CLOZUK to ALSPAC  
iii) PGC2 to ALSPAC  
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2) Is polygenic risk of bipolar disorder associated with lower cognitive ability 
using various measures of generalised cognition and specific cognitive domains? 
This hypothesis was tested using one bipolar dataset (PGC Bipolar Disorder 
Working Group, 2011), with polygenic risk of bipolar disorder tested for 
association with cognition in ALSPAC.  
 
3) Given differences in the cognitive profiles of schizophrenia and bipolar cases, 
are common variants associated with increased risk of schizophrenia relative to 
bipolar disorder associated with performance on the cognitive domains outlined 
previously? This hypothesis was tested using a discovery GWAS of schizophrenia 
versus bipolar (case/control) (Ruderfer et al., 2014). Polygenic risk of 
schizophrenia relative to bipolar disorder was tested for association with 
cognition in ALSPAC.  
 
 
2.3 Methods 
2.3.1 Schizophrenia/Bipolar Samples 
2.3.1.1 PGC1 
The stage 1 discovery sample of the PGC1 was comprised of 9394 schizophrenia 
cases and 12462 controls across 17 separate studies. Genotyping was performed 
separately for each sample, but combined imputation and quality control was 
performed by the PGC Bipolar Disorder Working Group. As described in PGC 
Bipolar Disorder Working Group, 2011, SNPs with <5% missing data, individuals 
were retained if the missing genotype rate per individual was less than 2%. 
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Subsequently, SNPs were retained if the missing genotype rate per SNP was less 
than 2%, the missing genotype rate between cases and controls per SNP was less 
than 2%, Hardy-Weinberg equilibrium (controls) P > 1 × 10−6 and the frequency 
difference to the HapMap reference was <0.15. Data was imputed using BEAGLE 
3.0.4, with phased HapMap phase 3 data as a reference panel.  
 
Using the publically available PGC1 schizophrenia GWAS summary statistics, we 
subsequently included SNPs in the present study if they had an INFO score > 0.9 
and a minor allele frequency > 0.01.   
 
2.3.1.2 CLOZUK 
CLOZUK is a UK sample comprising of 5,554 schizophrenia cases and 6299 
controls (Schizophrenia Working Group of the Psychiatric Genetics Consortium, 
2014).  Cases were ascertained through collaboration with Norvartis, a 
manufacturer of the atypical antipsychotic Clozapine (Clozaril) in the UK. Cases 
with a diagnosis of treatment-resistant schizophrenia (at least two unsuccessful 
courses of previous anti-psychotic treatment) were included based upon 
clozapine registration forms completed by treating psychiatrists. The controls 
were from the Wellcome Trust Case Control Consortium (WTCCC), National 
Blood Service and 1958 British Birth Cohort. Samples were genotyped on the 
Illumina OmniExpress (Illumina Inc.).  
 
CLOZUK samples were genotyped in two waves on the Illumina Omni Express 
and Illumnia Combo.  Quality control measures for SNPs were performed by 
(Schizophrenia Working Group of the Psychiatric Genetics Consortium, 2014) 
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and outlined below. The quality control parameters for retaining SNPs and 
subjects were: SNP missingness < 0.05 (before sample removal); subject 
missingness < 0.02; autosomal heterozygosity deviation (| Fhet | < 0.2); SNP 
missingness < 0.02 (after sample removal); difference in SNP missingness 
between cases and controls < 0.02; and SNP Hardy-Weinberg equilibrium (P > 
10−6 in controls or P > 10−10 in cases). Genotype imputation was performed 
using the pre-phasing/imputation stepwise approach implemented in IMPUTE2 
/ SHAPEIT (chunk size of 3 Mb and default parameters). The imputation 
reference set consisted of 2,186 phased haplotypes from the full 1000 Genomes 
Project dataset (August 2012, 30,069,288 variants, release “v3.macGT1”). We 
retained SNPs that were imputed with high quality  (imputation information 
score INFO) > 0.9) and a minor allele frequency of > 1% for subsequent analysis.  
 
2.3.1.3 PGC2 
The PGC2 discovery dataset was comprised of 52 separate studies. QC of the 
individual datasets was described above. They tested all 52 GWAS datasets 
separately for association with schizophrenia using an additive logistic 
regression model in PLINK using population principal components as covariates 
(Schizophrenia Working Group of the Psychiatric Genetics Consortium, 2014). 
They performed a meta-analysis of the 52 sets of results using an inverse-
weighted fixed effects model. Summary statistics were available for 35476 
schizophrenia cases and 46839 controls.  Only SNPs with high confidence 
(imputation information score > 0.9) and minor allele frequency greater than 1% 
were used for further analysis.  
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2.3.1.4 PGC1 Bipolar 
Publically available data from the PGC bipolar disorder primary sample was 
used. This comprised of 7841 individuals with bipolar disorder and 9250 
controls from eleven samples collected across Europe and America (PGC Bipolar 
Disorder Working Group, 2011). Bipolar cases had a diagnosis of either Bipolar 
Disorder type I or II, schizoaffective bipolar or “other” bipolar illness. Genotyping 
was performed separately for each sample, but combined imputation and quality 
control was performed by the PGC Bipolar Disorder Working Group. As 
described in PGC Bipolar Disorder Working Group, 2011), SNPs with <5% 
missing data, individuals were retained if the missing genotype rate per 
individual was less than 2%. Subsequently, SNPs were retained if the missing 
genotype rate per SNP was less than 2%, the missing genotype rate between 
cases and controls per SNP was less than 2%, Hardy-Weinberg equilibrium 
(controls) P > 1 × 10−6 and the frequency difference to the HapMap reference 
was <0.15. Data was imputed using BEAGLE 3.0, with phased HapMap phase 2 
data as a reference.  
 
Using the publically available PGC bipolar GWAS summary statistics, we 
subsequently included SNPs in the present study if they had an INFO score > 0.9 
and a minor allele frequency > 0.01.   
 
2.3.1.5 PGC Schizophrenia vs Bipolar Disorder 
 
A GWAS was performed comparing 7129 schizophrenia cases (cases) against  
9252 bipolar cases (controls) (Ruderfer et al., 2014) using data from the PGC. All 
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quality control steps are described from (Ruderfer et al., 2014). Quality control 
was performed separately on the on the 31 datasets. To generate reliable SNP 
data from across the different datasets, individuals (low genotyping rates < 0.98, 
IBD < 0.1, abnormal heterozygosity F > 0.15) and SNPs (minor allele frequency < 
0.01, genotyping < 0.98, Hardy-Weinberg equilibrium P < 1E-6, and missing data 
> 0.02 between cases and controls) underwent additional quality control. 
Samples were imputed using BEAGLE and HapMap Phase 3+TSI was used as the 
reference panel.  
 
Using GWAS summary statistics from this analysis, we included SNPs with an 
INFO score > 0.9 and minor allele frequency > 1% for the current analysis.   
 
2.3.2 Cognition Samples 
2.3.2.1 Sample description/Genotyping 
2.3.2.1.1 German sample 
Individuals of German decent were recruited at random via mail invitation in the 
city of Munich (Rujescu et al., 2003). Individuals and their first-degree relatives 
were screened for psychiatric diagnoses. The sample was genotyped on an 
Affymetrics 5 custom chip and underwent standard quality control. Specifically, 
individuals were removed for ambiguous sex coding, abnormal heterozygosity, 
high identity by decent (IBD) and genotyping rates less than 98%. SNPs were 
filtered by minor allele frequency (>0.01), a genotyping rate of 99%  and Hardy–
Weinberg equilibrium (p>1E-06). After quality control, 955 unrelated 
individuals and 698,308 genotyped SNPs were available for analysis.  
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2.3.2.1.2 ALSPAC 
The Avon Longitudinal Study of Parents and Children (ALSPAC) is an on-going 
longitudinal study of over 14000 mothers and their offspring born in Avon 
between April in 1991 and the end of December in 1992 (Golding et al., 2001; 
Boyd et al., 2013). They were recruited via “expression of interest” through 
media communication, community centres and health services. Mothers 
interested in partaking in the study were invited to contact ALSPAC for further 
information. In total, 14676 women enrolled, in phase 1. A large amount of 
behavioural, cognitive, health and environmental data has been collected in 
children across 68 time points between time of birth and age 18. During this time 
period, both mothers and children were followed up via 59 questionnaires 
measuring health, social behaviour and physical development. Nine clinical 
assessments between the ages of 7-17 were used to obtain physiological 
information, cognitive information and psychological/social wellbeing. Attrition 
is problematic for any longitudinal study. Approximately 3000 families have 
partaken in every assessment, whilst approximately 5800 families have 
completed at least 75% of assessments. Furthermore, whilst some individuals 
have been lost due to mortality, have withdrawn from the study or become 
untraceable, currently nearly 12000 children are eligible for follow up 
assessments.  
 
In addition to phenotypic collection, a large number of individuals have also been 
genotyped as part of the study. To date, 9912 children were genotyped using the 
Illumina HumanHap550. Samples underwent routine quality control. Specifically, 
individuals were removed for ambiguous sex coding, abnormal heterozyogisty, 
 79 
high IBD, genotyping rates less than 97%, and population outliers were removed 
using multidimensional scaling analysis. SNPs were filtered by minor allele 
frequency (>1%), a 95% genotyping rate, and Hardy–Weinberg equilibrium 
(p>5E-07). After quality control, 8,365 unrelated individuals and 500,527 
genotyped SNPs were available for analysis. EIGENSTRAT analysis revealed no 
additional obvious population stratification (Price et al., 2006). Data was 
imputed using MACH 1.0.16 Markov Chain Haplotype software (Li et al., 2010) 
and HapMap phase 2 CEPH population (HG18, release 22) was used as a 
reference panel.  
2.3.2.2 Cognition testing 
2.3.2.2.1 Cognitive assessment in the German sample 
936 individuals had complete data on the HAWIE-R (Tewes, 1991), a German 
version of the WAIS-R. This measures five performance tests, six verbal tests, 
and provides performance, verbal and full scale IQ scores. Brief descriptions of 
the individual tests are given below.  
 
Verbal tests: 
Arithmetic - individuals are told stories containing mathematical information 
and are asked questions relating where they are required to use  mental 
arithmetic.  
 
Comprehension - individuals are asked questions relating to real life situations 
requiring social judgement and awareness of social norms.  
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Digit span - individuals are asked to repeat a set a numbers forwards and 
backwards. The length of the number string increases during the test.  
 
Information - individuals are asked general knowledge questions.  
 
Similarities - individuals hear word pairings, and asked to say in what way the 
two words are alike.  
 
Vocabulary - individuals are asked to explain the meaning of words that increase 
in difficulty during the test.  
 
Performance tests:  
Block design - individuals manipulate cubes coloured with red and white 
patterns, and arrange them to match a shown pattern.  
 
Digit Symbol Coding - A printed key that contains 9 matching pairs of numbers 
and symbols. Individuals are given a sheet containing numbers and are asked to 
draw the corresponding symbol in a blank space underneath.  
 
Object Assembly - individuals are asked to make complete objects using 
individual jigsaw style pieces.  
 
Picture Arrangement - individuals are required to arrange a scrambled set of 
cards telling a story into a logical order.  
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Picture Completion - Individuals are presented with pictures containing a 
missing section. They are asked to identify what is missing from each picture.  
 
Scaled test scores for performance and verbal tests are summed separately, and 
converted to performance and verbal IQ scores respectively using standardised 
tables, which adjusts for sex and age. The scaled scores for all tests are summed 
and converted to full-scale IQ scores using standardised tables, adjusting for sex 
and age.   
 
We chose to include a subset of the WAIS tests for further analysis based upon 
their similarity with the MATRICS domains (Nuechterlein et al., 2004) as 
cognitive domains most affected in schizophrenia cases may be under stronger 
influence from schizophrenia genetic risk factors. Three WAIS tests were 
considered to reliably test the following MATRICS domains: verbal working 
memory (digit span), speed of processing (digit symbol coding), 
reasoning/problem solving (block design).  We also used performance and 
verbal IQ as composite measures of non-verbal and verbal ability, and full scale 
IQ as a measure of general cognitive ability.  
 
2.3.2.2.2 Cognitive assessment in ALSPAC 
Phenotype data was taken from the ALSPAC collection undertaken when the 
child was 8 years old. Individuals were administered the short form Wechsler 
Intelligence Scale for Children (WISC-III)(Wechsler et al., 1992) (alternate items 
used for all subtests except the coding subtest) as well as two additional items 
taken from the Test of Everyday Attention for Children (TEACh)(Robertson et al., 
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1996) and the Diagnostic Analysis of Nonverbal Accuracy (DANVA).(Nowicki & 
Duke, 1994).  
Cognitive tests were selected a priori based on their similarity to the MATRICS 
domains based on our previous work (Niarchou et al., 2013). The following tasks 
were selected from the WISC-III, with their representative cognitive constructs 
in parenthesises: coding (processing speed), digit span backward (working 
memory), and block design (reasoning and problem solving). As a measure of 
verbal learning, we used the total number of non-words correctly recalled from 
an adapted version of the Nonword Repetition Test.(Gathercole et al., 1994) 
From the TEACh, the Sky Search task was selected as our measure of attention., 
after adjusting for motor speed. The DANVA was used to create a social cognition 
variable by creating a total number of errors (incorrect assignment of emotions) 
across all four emotional domains. WISC IQ scores for verbal, performance and 
total IQ were used as measures of verbal, nonverbal and general cognitive ability.  
2.3.3 Polygenic analyses 
 
GWAS summary statistics were publically available for PGC1 (Schizophrenia 
PGC, 2011), whilst CLOZUK and PGC2 summary statistics were obtained through 
collaboration with the PGC (Schizophrenia Working Group of the Psychiatric 
Genetics Consortium, 2014). SNPs were filtered by a minor allele frequency of 
less than 1% and imputation (INFO) score < 0.9. To maximise the number of 
variants for each individual analysis, SNPs were selected if they appeared in both 
the psychiatric discovery sample and cognition target sample under 
investigation.  
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Linkage disequilibrium (LD) based clumping selects the most significant SNP 
within a sliding LD block. This was performed in Plink (Purcell et al., 
2007)across SNPs in common across datasets for each analysis (500kb sliding 
window, r2 =0.25, minimum association p=0.5). For the analysis using the 
German cognition sample, clumped SNPs were extracted from schizophrenia 
datasets and filtered by 4 p-value thresholds (p < 0.001, 0.01, 0.1 and 0.5). For 
analyses using ALSPAC, Genetic clumped SNPs were extracted from 
schizophrenia datasets and filtered by 5 p-value thresholds (p < 0.0001, 0.01, 0.1, 
0.3, 0.5).  The ‘score’ command in PLINK was used to calculate polygenic scores 
(Purcell et al., 2007). Polygenic scores are calculated by summing the number of 
susceptibility alleles of the reference SNP weighted by the log of the SNP odds 
ratios. Schizophrenia polygenic scores were calculated for each individual in 
ALSPAC and German cognition samples.  
 
Linear regressions were performed in R, where schizophrenia polygenic scores 
were used as predictors of performance on the cognitive tasks. Analyses using 
the German cognition sample covaried for age, sex and the first principle 
component from Eigenstrat. Analyses performed in ALSPAC used no covariates.  
There was no population stratification in ALSPAC, and individuals completed 
cognitive tests at the same developmental time point. All p-values are 
uncorrected for multiple comparisons.  
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For the German cognition sample, polygenic scores, WAIS tests and covariate 
data was available in 936 individuals. For ALSPAC the number of individuals 
with polygenic scores and cognitive data can be found in Table 2.1. 
 
Cognitive Domain N Individuals 
Attention 5319 
Problem Solving 5500 
Processing Speed 5557 
Social Cognition 5110 
Verbal Learning 5553 
Working Memory 5421 
Performance IQ 5536 
Verbal IQ 5541 
Full scale IQ 5518 
Table 2-1 - Number of individuals in ALSPAC with polygenic scores and cognition
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2.4 Results 
2.4.1 PGC1 to cognition in German sample  
 
Schizophrenia polygenic risk (at 4 training thresholds; 0.5, 0.1, 0.01 and 0.001) 
was tested for association with cognition in in 936 adult controls. Full results can 
be found in Table 2.2 and Figure 2.1.   
 
Increased polygenic risk of schizophrenia was associated with performance IQ at 
0.5 and 0.01 training thresholds (%r2~0.5-0.6). This association was in the 
predicted direction of effect (increased schizophrenia polygenic risk was 
associated with lower performance IQ). These findings were replicated at a trend 
level for 0.1 and 0.001 training thresholds in the same direction of effect  
 
Significant associations were also observed between schizophrenia polygenic 
risk and processing speed at 0.5, 0.1 and 0.01 training thresholds (%r2~0.5-1.1). 
Again, this association was in the predicted direction of effect (increased 
schizophrenia polygenic risk was associated with lower processing speed). This 
association was observed at a trend level for the 0.001 training threshold in the 
same direction of effect.  
 
No significant associations were observed between schizophrenia polygenic risk 
and reasoning/problem solving, working memory, verbal IQ or full scale IQ.  
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Training 
Dataset 
Training 
Threshold Target Cognition 
Uncorrected 
P (2-Tailed) %r2 
Direction of 
Coefficient 
PGC1 0.01 Processing Speed 0.005 1.06 - 
PGC1 0.1 Processing Speed 0.016 0.76 - 
PGC1 0.01 Performance IQ 0.030 0.59 - 
PGC1 0.5 Processing Speed 0.043 0.52 - 
PGC1 0.5 Performance IQ 0.048 0.53 - 
PGC1 0.001 Processing Speed 0.058 0.66 - 
PGC1 0.001 Performance IQ 0.064 0.48 - 
PGC1 0.1 Performance IQ 0.089 0.39 - 
PGC1 0.1 Verbal IQ 0.271 0.08 + 
PGC1 0.01 Full scale IQ 0.293 0.20 - 
PGC1 0.01 Problem Solving 0.310 0.34 - 
PGC1 0.001 Problem Solving 0.314 0.40 - 
PGC1 0.5 Verbal IQ 0.317 0.04 + 
PGC1 0.5 Working Memory 0.321 0.03 + 
PGC1 0.001 Full scale IQ 0.351 0.22 - 
PGC1 0.1 Problem Solving 0.558 0.21 - 
PGC1 0.1 Working Memory 0.588 < 0.01 + 
PGC1 0.5 Full scale IQ 0.741 0.07 - 
PGC1 0.5 Problem Solving 0.854 0.14 - 
PGC1 0.1 Full scale IQ 0.903 0.02 - 
PGC1 0.001 Verbal IQ 0.903 0.01 + 
PGC1 0.01 Verbal IQ 0.964 < 0.01 + 
PGC1 0.001 Working Memory 0.978 < 0.01 - 
PGC1 0.01 Working Memory 0.985 < 0.01 + 
Table 2-2 - Regression analyses for schizophrenia polygenic risk (PGC1) predicting 
cognition in the adult German sample 
 
Training threshold refers to the discovery sample SNP p-threshold. Direction of coefficient refers to whether 
increased polygenic risk of schizophrenia is associated with lower cognition (-), or better cognition (+)
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Figure 2.1 - Polygenic risk of schizophrenia (PGC1) and its association with cognition in 
German sample 
 
%r2 refers to the percentage of cognitive variance explained by schizophrenia 
polygenic risk at the four training thresholds. The 4 bars for each cognitive 
domain represent each of the different training threshold p-values. The number 
inside parentheses refers to the number of SNPs used for that training set. Bars 
with a positive %r2 show associations are in the predicted direction of effect, 
whereby increased polygenic risk is associated with poorer performance. 
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2.4.2 CLOZUK to cognition in ALSPAC 
This analysis derived schizophrenia polygenic risk from CLOZUK (Table 2.), and 
tested for association in ALSPAC on attention, problem solving, processing speed, 
social cognition, verbal learning, working memory., performance IQ, verbal IQ 
and full  IQ. Full results can be found in Table 2.3 and Figure 2.2.  
 
Polygenic risk of schizophrenia was significantly associated with verbal learning 
and performance IQ. The association between schizophrenia polygenic risk and 
performance IQ was found at 0.5, 0.3, 0.1 and 0.01 training thresholds 
(%r2~0.07-0.09), and in the predicted direction of effect (increased 
schizophrenia polygenic risk was associated with lower performance IQ). 
 
The association with verbal learning was observed for 0.5, 0.3 and 0.1 training 
thresholds (%r2~0.09-0.13). However, this association was against the predicted 
direction of effect (increased schizophrenia polygenic risk was associated with 
better verbal learning). These findings replicated in the same direction of effect 
at a trend level for 0.01 and 0.0001 training thresholds. 
 
Schizophrenia polygenic risk was not significantly associated with attention, 
problem solving, processing speed, social cognition, working memory, verbal IQ 
or full scale IQ even at a trend level.  
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Training 
Dataset 
Training 
Threshold Target Cognition 
Uncorrected 
P (2-Tailed) %r2 
Direction of 
Coefficient 
CLOZUK 0.3 Verbal Learning 0.007 0.13 + 
CLOZUK 0.5 Verbal Learning 0.011 0.11 + 
CLOZUK 0.01 Performance IQ 0.022 0.09 - 
CLOZUK 0.1 Verbal Learning 0.026 0.09 + 
CLOZUK 0.1 Performance IQ 0.035 0.08 - 
CLOZUK 0.3 Performance IQ 0.037 0.08 - 
CLOZUK 0.5 Performance IQ 0.045 0.07 - 
CLOZUK 0.01 Verbal Learning 0.061 0.06 + 
CLOZUK 0.0001 Verbal Learning 0.068 0.06 + 
CLOZUK 0.3 Processing Speed 0.120 0.04 - 
CLOZUK 0.5 Social Cognition 0.173 0.04 - 
CLOZUK 0.1 Social Cognition 0.189 0.03 - 
CLOZUK 0.1 Processing Speed 0.214 0.03 - 
CLOZUK 0.0001 Verbal IQ 0.230 0.03 - 
CLOZUK 0.5 Processing Speed 0.238 0.02 - 
CLOZUK 0.3 Verbal IQ 0.271 0.02 + 
CLOZUK 0.01 Full scale IQ 0.273 0.02 - 
CLOZUK 0.1 Verbal IQ 0.278 0.02 + 
CLOZUK 0.5 Verbal IQ 0.284 0.02 + 
CLOZUK 0.1 Attention 0.298 0.02 + 
CLOZUK 0.3 Social Cognition 0.338 0.02 - 
CLOZUK 0.3 Attention 0.349 0.02 + 
CLOZUK 0.5 Attention 0.361 0.02 + 
CLOZUK 0.01 Problem Solving 0.386 0.01 - 
CLOZUK 0.01 Social Cognition 0.426 0.01 + 
CLOZUK 0.0001 Full scale IQ 0.430 0.01 - 
CLOZUK 0.0001 Working Memory 0.485 0.01 + 
CLOZUK 0.1 Working Memory 0.487 0.01 + 
CLOZUK 0.1 Full scale IQ 0.544 0.01 - 
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CLOZUK 0.01 Attention 0.574 0.01 + 
CLOZUK 0.3 Full scale IQ 0.590 0.01 - 
CLOZUK 0.5 Full scale IQ 0.599 < 0.01 - 
CLOZUK 0.0001 Problem Solving 0.648 < 0.01 - 
CLOZUK 0.3 Working Memory 0.675 < 0.01 + 
CLOZUK 0.01 Processing Speed 0.676 < 0.01 - 
CLOZUK 0.0001 Processing Speed 0.700 < 0.01 + 
CLOZUK 0.5 Working Memory 0.736 < 0.01 + 
CLOZUK 0.5 Problem Solving 0.791 < 0.01 + 
CLOZUK 0.01 Verbal IQ 0.795 < 0.01 + 
CLOZUK 0.0001 Performance IQ 0.822 < 0.01 - 
CLOZUK 0.01 Working Memory 0.849 < 0.01 + 
CLOZUK 0.3 Problem Solving 0.886 < 0.01 + 
CLOZUK 0.1 Problem Solving 0.914 < 0.01 - 
CLOZUK 0.0001 Social Cognition 0.917 < 0.01 - 
CLOZUK 0.0001 Attention 0.966 < 0.01 + 
Table 2-3 - Regression analyses for schizophrenia polygenic risk (CLOZUK) predicting 
cognition in ALSPAC 
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Figure 2.2 - Polygenic risk of schizophrenia (CLOZUK) and its association with cognition in ALSPAC 
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2.4.3 PGC1 to cognition in ALSPAC 
This analysis derived schizophrenia polygenic risk from PGC1, and tested for 
association in ALSPAC on attention, problem solving, processing speed, social 
cognition, verbal learning, working memory, performance IQ, verbal IQ and full 
scale IQ. Full results can be found in Table 2.4 & Figure 2.3. 
 
Polygenic risk of schizophrenia was significantly associated with processing 
speed, performance IQ, verbal IQ and full scale IQ. The strongest associations 
were for schizophrenia polygenic risk and performance IQ at 0.5, 0.3, 0.1 and 
0.01 training thresholds (%r2~0.21-0.28), and in the predicted direction of effect 
(increased schizophrenia polygenic risk was associated with lower performance 
IQ). 
 
Increased polygenic risk of schizophrenia was also significantly associated with 
lower full scale IQ at 0.5, 0.3, 0.1 and 0.01 training thresholds (%r2~0.08-0.8). 
Significant associations in the predicted direction of effect were also observed 
with verbal IQ at 0.1 and 0.01 training thresholds (%r2~0.08-0.09).  
 
Regarding individual cognitive domains, increased polygenic risk of 
schizophrenia was associated with lower processing speed at 0.5 and 0.3 
training thresholds (%r2~0.09-0.12).  
 
Associations between schizophrenia polygenic risk and both attention and 
working memory were also observed at a trend level against the predicted 
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direction of effect (increased polygenic risk was associated with better 
performance).  
 
Training 
Dataset 
Training 
Threshold Target Cognition 
Uncorrected 
P (2-Tailed) %r2 
Direction of 
Coefficient 
PGC1 0.5 Performance IQ 8.35E-05 0.2794 - 
PGC1 0.3 Performance IQ 1.05E-04 0.2715 - 
PGC1 0.1 Performance IQ 7.25E-04 0.2063 - 
PGC1 0.3 Full scale IQ 0.002 0.1767 - 
PGC1 0.5 Full scale IQ 0.002 0.1700 - 
PGC1 0.1 Full scale IQ 0.003 0.1571 - 
PGC1 0.5 Processing Speed 0.011 0.1150 - 
PGC1 0.3 Processing Speed 0.022 0.0949 - 
PGC1 0.01 Verbal IQ 0.027 0.0888 - 
PGC1 0.01 Full scale IQ 0.030 0.0855 - 
PGC1 0.1 Verbal IQ 0.036 0.0790 - 
PGC1 0.3 Verbal IQ 0.057 0.0653 - 
PGC1 0.5 Attention 0.076 0.0593 + 
PGC1 0.5 Verbal IQ 0.076 0.0567 - 
PGC1 0.5 Working Memory 0.076 0.0579 + 
PGC1 0.1 Processing Speed 0.077 0.0564 - 
PGC1 0.1 Working Memory 0.082 0.0558 + 
PGC1 0.01 Performance IQ 0.082 0.0546 - 
PGC1 0.3 Attention 0.093 0.0531 + 
PGC1 0.3 Working Memory 0.094 0.0516 + 
PGC1 0.1 Attention 0.115 0.0466 + 
PGC1 0.01 Verbal Learning 0.131 0.0412 + 
PGC1 0.3 Verbal Learning 0.216 0.0276 + 
PGC1 0.5 Verbal Learning 0.249 0.0239 + 
PGC1 0.01 Working Memory 0.275 0.0220 + 
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PGC1 0.01 Processing Speed 0.277 0.0213 - 
PGC1 0.01 Attention 0.304 0.0199 + 
PGC1 0.5 Social Cognition 0.332 0.0184 + 
PGC1 0.1 Social Cognition 0.333 0.0184 + 
PGC1 0.3 Social Cognition 0.355 0.0168 + 
PGC1 0.1 Verbal Learning 0.363 0.0149 + 
PGC1 0.0001 Processing Speed 0.371 0.0144 + 
PGC1 0.01 Problem Solving 0.393 0.0133 + 
PGC1 0.0001 Performance IQ 0.411 0.0122 - 
PGC1 0.0001 Working Memory 0.518 0.0077 - 
PGC1 0.01 Social Cognition 0.645 0.0042 + 
PGC1 0.0001 Full scale IQ 0.649 0.0038 - 
PGC1 0.0001 Attention 0.780 0.0015 + 
PGC1 0.0001 Verbal IQ 0.878 0.0004 - 
PGC1 0.0001 Verbal Learning 0.907 0.0002 + 
PGC1 0.0001 Problem Solving 0.920 0.0002 - 
PGC1 0.1 Problem Solving 0.924 0.0002 + 
PGC1 0.5 Problem Solving 0.959 0.0000 + 
PGC1 0.0001 Social Cognition 0.986 0.0000 - 
PGC1 0.3 Problem Solving 0.987 0.0000 - 
Table 2-4 - Regression analyses for schizophrenia polygenic risk (PGC1) predicting 
cognition in ALSPAC
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Figure 2.3 - Polygenic risk of schizophrenia (PGC1) and its association with cognition in ALSPAC 
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2.4.4 PGC2 to cognition in ALSPAC 
This analysis derived schizophrenia polygenic risk from PGC2, the largest of the 
schizophrenia discovery samples, and was tested for association with cognition 
in ALSPAC (Table 2.5 & Figure 2.4).  
 
Polygenic risk of schizophrenia was robustly associated with performance IQ, 
and nominally significant for processing speed and full scale IQ. Highly 
significant associations between schizophrenia polygenic risk and performance 
IQ were found at 0.5, 0.3, 0.1 and 0.01 training thresholds (%r2~0.22-0.34), and 
in the predicted direction of effect (increased schizophrenia polygenic risk was 
associated with lower performance IQ). 
 
Significant associations were also observed between schizophrenia polygenic 
risk and full scale IQ at 0.1 and 0.01 training thresholds (%r2~0.1-0.13), and 
processing speed at 0.5, 0.3 and 0.1 training thresholds (%r2~0.12-0.17) in the 
predicted direction of effect.  
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Training 
Dataset 
Training 
Threshold Target Cognition 
Uncorrected 
P (2-Tailed) % R2 
Direction of 
Coefficient 
PGC2 0.1 Performance IQ 1.23E-05 0.34 - 
PGC2 0.5 Performance IQ 2.75E-04 0.24 - 
PGC2 0.01 Performance IQ 3.76E-04 0.23 - 
PGC2 0.3 Performance IQ 5.34E-04 0.22 - 
PGC2 0.1 Processing Speed 0.002 0.17 - 
PGC2 0.5 Processing Speed 0.005 0.14 - 
PGC2 0.1 Full scale IQ 0.008 0.13 - 
PGC2 0.3 Processing Speed 0.009 0.12 - 
PGC2 0.01 Full scale IQ 0.019 0.10 - 
PGC2 0.5 Verbal Learning 0.064 0.06 + 
PGC2 0.5 Full scale IQ 0.069 0.06 - 
PGC2 0.0001 Performance IQ 0.070 0.06 - 
PGC2 0.3 Full scale IQ 0.074 0.06 - 
PGC2 0.01 Processing Speed 0.081 0.05 - 
PGC2 0.0001 Attention 0.082 0.06 + 
PGC2 0.3 Verbal Learning 0.084 0.05 + 
PGC2 0.5 Attention 0.090 0.05 + 
PGC2 0.01 Working Memory 0.109 0.05 + 
PGC2 0.01 Attention 0.119 0.05 + 
PGC2 0.0001 Full scale IQ 0.126 0.04 - 
PGC2 0.3 Attention 0.146 0.04 + 
PGC2 0.1 Attention 0.177 0.03 + 
PGC2 0.0001 Verbal IQ 0.248 0.02 - 
PGC2 0.01 Problem Solving 0.298 0.02 - 
PGC2 0.1 Problem Solving 0.308 0.02 - 
PGC2 0.0001 Working Memory 0.317 0.02 + 
PGC2 0.1 Verbal Learning 0.370 0.01 + 
PGC2 0.01 Social Cognition 0.373 0.02 + 
PGC2 0.01 Verbal IQ 0.443 0.01 - 
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PGC2 0.0001 Social Cognition 0.459 0.01 + 
PGC2 0.01 Verbal Learning 0.511 0.01 + 
PGC2 0.1 Verbal IQ 0.572 0.01 - 
PGC2 0.0001 Processing Speed 0.572 0.01 - 
PGC2 0.1 Social Cognition 0.576 0.01 + 
PGC2 0.5 Problem Solving 0.590 0.01 - 
PGC2 0.3 Problem Solving 0.633 < 0.01 - 
PGC2 0.5 Social Cognition 0.647 < 0.01 + 
PGC2 0.3 Social Cognition 0.709 < 0.01 + 
PGC2 0.0001 Problem Solving 0.762 < 0.01 + 
PGC2 0.0001 Verbal Learning 0.805 < 0.01 - 
PGC2 0.3 Working Memory 0.840 < 0.01 + 
PGC2 0.5 Working Memory 0.842 < 0.01 + 
PGC2 0.1 Working Memory 0.858 < 0.01 + 
PGC2 0.5 Verbal IQ 0.941 < 0.01 + 
PGC2 0.3 Verbal IQ 0.978 < 0.01 - 
Table 2-5 - Regression analyses for schizophrenia polygenic risk (PGC2) predicting 
cognition in ALSPAC 
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Figure 2.4 - Polygenic risk of schizophrenia (PGC2) and its association with cognition in ALSPAC 
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2.4.5 PGC1 Bipolar to cognition in ALSPAC 
This analysis derived bipolar polygenic risk from the bipolar PGC1 GWAS, and 
tested for association in ALSPAC on attention, problem solving, processing speed, 
social cognition, verbal learning, working memory, performance IQ, verbal IQ 
and full scale IQ (Table 2.6 & Figure 2.5).  
 
Polygenic risk of bipolar disorder was significantly associated with processing 
speed using the 0.1 training threshold (%r2=0.11) in the predicted direction of 
effect (increased bipolar polygenic risk was associated with lower processing 
speed). However, bipolar polygenic risk was not significantly associated with 
processing speed at 0.5, 0.3, 0.01 and 0.0001 training thresholds even at the 
trend level.  
 
Significant associations were observed between bipolar polygenic risk and social 
cognition at the 0.0001 training threshold (%r2=0.08) against the predicted 
direction of effect (increased polygenic risk was associated with better social 
cognition). This trend was also observed for 0.5 and 0.3 training thresholds. 
Increased bipolar polygenic risk was also associated with better working 
memory at a trend level for 0.5, 0.3, 0.01, although none reached nominal levels 
of significance.   
 
No robust association was observed between bipolar polygenic risk and 
attention, problem solving, processing speed, performance IQ, verbal IQ or full 
scale IQ.  
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Training 
Dataset 
Training 
Threshold Target Cognition 
Uncorrected 
P (2-Tailed) % R2 
Direction of 
Coefficient 
PGC1 Bipolar 0.1 Processing Speed 0.012 0.1116 - 
PGC1 Bipolar 0.0001 Social Cognition 0.039 0.0823 + 
PGC1 Bipolar 0.3 Social Cognition 0.051 0.0736 + 
PGC1 Bipolar 0.5 Social Cognition 0.064 0.0663 + 
PGC1 Bipolar 0.3 Working Memory 0.068 0.0607 + 
PGC1 Bipolar 0.1 Performance IQ 0.068 0.0593 - 
PGC1 Bipolar 0.5 Working Memory 0.073 0.0587 + 
PGC1 Bipolar 0.01 Verbal IQ 0.074 0.0568 + 
PGC1 Bipolar 0.01 Working Memory 0.080 0.0557 + 
PGC1 Bipolar 0.1 Attention 0.100 0.0503 + 
PGC1 Bipolar 0.01 Problem Solving 0.102 0.0480 + 
PGC1 Bipolar 0.0001 Problem Solving 0.102 0.0480 + 
PGC1 Bipolar 0.3 Attention 0.107 0.0483 + 
PGC1 Bipolar 0.1 Working Memory 0.135 0.0407 + 
PGC1 Bipolar 0.1 Social Cognition 0.155 0.0390 + 
PGC1 Bipolar 0.0001 Processing Speed 0.180 0.0319 + 
PGC1 Bipolar 0.3 Processing Speed 0.183 0.0315 - 
PGC1 Bipolar 0.01 Social Cognition 0.196 0.0322 + 
PGC1 Bipolar 0.0001 Working Memory 0.208 0.0289 + 
PGC1 Bipolar 0.0001 Verbal IQ 0.227 0.0260 + 
PGC1 Bipolar 0.0001 Full scale IQ 0.234 0.0253 + 
PGC1 Bipolar 0.01 Full scale IQ 0.260 0.0226 + 
PGC1 Bipolar 0.5 Processing Speed 0.285 0.0203 - 
PGC1 Bipolar 0.5 Attention 0.294 0.0204 + 
PGC1 Bipolar 0.5 Problem Solving 0.309 0.0186 + 
PGC1 Bipolar 0.1 Full scale IQ 0.321 0.0176 - 
PGC1 Bipolar 0.0001 Performance IQ 0.337 0.0165 + 
PGC1 Bipolar 0.3 Problem Solving 0.448 0.0103 + 
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PGC1 Bipolar 0.5 Verbal Learning 0.465 0.0095 + 
PGC1 Bipolar 0.3 Verbal Learning 0.503 0.0080 + 
PGC1 Bipolar 0.3 Full scale IQ 0.523 0.0073 - 
PGC1 Bipolar 0.3 Performance IQ 0.536 0.0068 - 
PGC1 Bipolar 0.01 Attention 0.662 0.0035 + 
PGC1 Bipolar 0.5 Full scale IQ 0.663 0.0034 - 
PGC1 Bipolar 0.0001 Verbal Learning 0.702 0.0026 + 
PGC1 Bipolar 0.5 Performance IQ 0.703 0.0026 - 
PGC1 Bipolar 0.3 Verbal IQ 0.764 0.0016 - 
PGC1 Bipolar 0.01 Processing Speed 0.800 0.0011 + 
PGC1 Bipolar 0.0001 Attention 0.820 0.0010 - 
PGC1 Bipolar 0.5 Verbal IQ 0.831 0.0008 - 
PGC1 Bipolar 0.1 Verbal Learning 0.858 0.0006 - 
PGC1 Bipolar 0.01 Performance IQ 0.907 0.0002 - 
PGC1 Bipolar 0.1 Problem Solving 0.929 0.0001 - 
PGC1 Bipolar 0.01 Verbal Learning 0.935 0.0001 + 
PGC1 Bipolar 0.1 Verbal IQ 0.998 0.0000 - 
Table 2-6 - Regression analyses for bipolar polygenic risk predicting cognition in ALSPAC.  
P-values are two-tailed and uncorrected 
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Figure 2.5 - Polygenic risk of bipolar disorder and its association with cognition in ALSPAC 
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2.4.6 Schizophrenia vs Bipolar to cognition in ALSPAC 
This analysis derived schizophrenia versus bipolar disorder polygenic risk, and 
tested for association in ALSPAC on attention, problem solving, processing speed, 
social cognition, verbal learning, working memory, performance IQ, verbal IQ 
and full scale IQ (Table 2.7 & Figure 2.6).  
 
Increased polygenic risk of schizophrenia relative to bipolar disorder was 
significantly associated with full IQ, verbal IQ and performance IQ at 0.5, 0.3, 0.1 
and 0.01 training thresholds (full IQ %r2=0.13-0.27; verbal IQ %r2 =0.09-0.27; 
performance IQ %r2 =0.10-0.17). Polygenic risk scores were also significantly 
associated with problem solving at 0.3 and 0.1 training thresholds (%r2 =0.07-
0.08). 
 
No robust association was observed between schizophrenia vs bipolar polygenic 
risk and attention, processing speed, social cognition, verbal learning or working 
memory.  
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Training Dataset 
Training 
Threshold 
Target 
Cognition 
Uncorrected 
P (2-Tailed) % R2 
Direction of 
Coefficient 
PGC1 SCZ vs Bipolar Full scale IQ 0.1 1.03E-04 0.2732 - 
PGC1 SCZ vs Bipolar Verbal IQ 0.1 1.21E-04 0.2666 - 
PGC1 SCZ vs Bipolar Verbal IQ 0.3 1.65E-04 0.2559 - 
PGC1 SCZ vs Bipolar Full scale IQ 0.3 1.72E-04 0.2556 - 
PGC1 SCZ vs Bipolar Full scale IQ 0.5 1.96E-04 0.2512 - 
PGC1 SCZ vs Bipolar Verbal IQ 0.5 2.31E-04 0.2446 - 
PGC1 SCZ vs Bipolar Performance IQ 0.1 0.002 0.1693 - 
PGC1 SCZ vs Bipolar Performance IQ 0.3 0.004 0.1510 - 
PGC1 SCZ vs Bipolar Performance IQ 0.5 0.004 0.1492 - 
PGC1 SCZ vs Bipolar Full scale IQ 0.01 0.006 0.1380 - 
PGC1 SCZ vs Bipolar Performance IQ 0.01 0.019 0.0999 - 
PGC1 SCZ vs Bipolar Verbal IQ 0.01 0.019 0.0994 - 
PGC1 SCZ vs Bipolar Problem Solving 0.01 0.034 0.0822 - 
PGC1 SCZ vs Bipolar Problem Solving 0.3 0.048 0.0713 - 
PGC1 SCZ vs Bipolar Problem Solving 0.5 0.058 0.0653 - 
PGC1 SCZ vs Bipolar Problem Solving 0.1 0.080 0.0559 - 
PGC1 SCZ vs Bipolar Social Cognition 0.0001 0.081 0.0598 + 
PGC1 SCZ vs Bipolar Attention 0.01 0.162 0.0367 + 
PGC1 SCZ vs Bipolar Verbal IQ 0.0001 0.163 0.0351 - 
PGC1 SCZ vs Bipolar Verbal Learning 0.01 0.178 0.0327 - 
PGC1 SCZ vs Bipolar Verbal Learning 0.1 0.211 0.0282 - 
PGC1 SCZ vs Bipolar Processing Speed 0.5 0.233 0.0256 - 
PGC1 SCZ vs Bipolar Full scale IQ 0.0001 0.250 0.0240 - 
PGC1 SCZ vs Bipolar Verbal Learning 0.3 0.268 0.0221 - 
PGC1 SCZ vs Bipolar Processing Speed 0.3 0.308 0.0187 - 
PGC1 SCZ vs Bipolar Verbal Learning 0.5 0.330 0.0171 - 
PGC1 SCZ vs Bipolar Performance IQ 0.0001 0.426 0.0114 - 
PGC1 SCZ vs Bipolar Problem Solving 0.0001 0.447 0.0105 - 
PGC1 SCZ vs Bipolar Working Memory 0.1 0.465 0.0098 - 
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PGC1 SCZ vs Bipolar Processing Speed 0.1 0.496 0.0084 - 
PGC1 SCZ vs Bipolar Working Memory 0.0001 0.530 0.0073 + 
PGC1 SCZ vs Bipolar Processing Speed 0.0001 0.538 0.0068 + 
PGC1 SCZ vs Bipolar Social Cognition 0.3 0.573 0.0062 + 
PGC1 SCZ vs Bipolar Working Memory 0.01 0.609 0.0048 + 
PGC1 SCZ vs Bipolar Attention 0.5 0.642 0.0041 + 
PGC1 SCZ vs Bipolar Attention 0.0001 0.667 0.0035 + 
PGC1 SCZ vs Bipolar Social Cognition 0.01 0.697 0.0030 - 
PGC1 SCZ vs Bipolar Social Cognition 0.5 0.755 0.0019 + 
PGC1 SCZ vs Bipolar Working Memory 0.3 0.803 0.0011 - 
PGC1 SCZ vs Bipolar Attention 0.3 0.814 0.0010 + 
PGC1 SCZ vs Bipolar Verbal Learning 0.0001 0.836 0.0008 - 
PGC1 SCZ vs Bipolar Processing Speed 0.01 0.848 0.0007 - 
PGC1 SCZ vs Bipolar Social Cognition 0.1 0.854 0.0007 + 
PGC1 SCZ vs Bipolar Attention 0.1 0.882 0.0004 + 
PGC1 SCZ vs Bipolar Working Memory 0.5 0.887 0.0004 - 
Table 2-7 - Polygenic risk of schizophrenia versus bipolar disorder and its association with 
cognition
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Figure 2.6 - Polygenic risk of schizophrenia versus bipolar disorder and its association with cognition in ALSPAC 
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2.5 Discussion 
2.5.1 Polygenic risk of schizophrenia and its association with cognition  
The first hypothesis in this chapter postulated that increased polygenic risk of 
schizophrenia was associated with lower performance across various measures 
of generalised and specific cognition. This was tested using three schizophrenia 
training datasets, and two independent cognition samples.  
 
We observed an association between schizophrenia polygenic risk and 
performance IQ. This result was consistent across all analyses, and in the 
predicted direction of effect whereby increased polygenic risk was associated 
with lower performance IQ. When training on PGC1 where the target sample was 
comprised of 936 healthy adults, the proportion of performance IQ variance 
explained by schizophrenia polygenic risk was between 0.5-0.6% in regression 
analyses reaching nominal levels of significance.  This is substantially higher 
than the variance of performance IQ explained within ALSPAC. The variance of 
performance IQ in ALPSAC explained by CLOZUK was 0.1%, PGC1 was 0.28%, 
increasing to 0.34% using PGC2.  
 
These findings are also supported using a traditional endophenotype approach 
with regards to polygenic risk scoring (Hubbard et al., submitted). Polygenic 
scores for performance IQ explain between 0.04-0.09% of the variance of 
schizophrenia liability when compared against individual cognitive domains of 
attention, problem solving, processing speed, social cognition, working memory, 
verbal learning, verbal IQ and full scale IQ. Furthermore, within this study, 
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bivariate GCTA analyses showed a substantial genetic correlation between 
schizophrenia and performance IQ in ALSPAC (rg~ -0.22 to –0.38); the largest of 
all the cognitive phenotypes tested. Collectively, these findings provide strong 
evidence showing that schizophrenia and performance IQ show the strongest 
genetic relationship with respect to common genetic variation. However, 
validation of these results outside of our group would be beneficial.  
 
The relatively low increase in variance between PGC1 and PGC2 suggests further 
increasing the size of the schizophrenia training set is unlikely to explain 
substantially greater amounts of performance IQ variance. Given the severity of 
cognitive deficits in schizophrenia cases, the modest proportion of the variance 
explained across cognitive domains, even amongst the most strongly associated 
tests, is surprising given the large sample sizes available.  
 
 
Processing speed is one of the most impaired cognitive domains in schizophrenia 
cases (Dickinson et al., 2007). The results from the present study found 
increased polygenic risk of schizophrenia was associated with lower processing 
speed, providing evidence for a degree of genetic relatedness. However, there 
were notable differences using different schizophrenia training sets and 
cognition samples. The largest processing speed variance (>1%) was observed at 
one training threshold in the German cognition sample. However, within 
ALSPAC, processing speed was not significant using CLOZUK (the smallest of the 
schizophrenia training sets), although 4/5 training thresholds were in the 
predicted direction of effect. Furthermore, processing speed showed greater 
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association training on PGC1 and PGC2 datasets, although the proportion of the 
variance explained (0.2-0.3%) was substantially lower compared to the German 
sample. However, the German sample contained over 4000 fewer individuals 
compared to ALSPAC. Possible inflation of results may have occurred due to 
sample bias in the German sample caused by low numbers, thus these results 
may have overestimated the variance explained of processing speed and 
performance IQ in relation to schizophrenia polygenic risk. 
 
2.5.2 Polygenic risk of bipolar disorder and its association with cognition  
The second hypothesis in this chapter asked whether polygenic risk of bipolar 
disorder was associated with lower cognitive ability. The findings from both 
specific and general cognitive domains generally show no such association. A 
weak association was observed showing increased polygenic risk of bipolar 
disorder was associated with lower processing speed at a single training 
threshold (0.1). A nominally significant association was observed showing 
increased bipolar polygenic risk was associated with better social cognition at a 
single training threshold (0.0001), continuing at a trend level for the other 
training thresholds.  
 
Several studies have reported upon social cognition in bipolar cases. A tentative 
explanation comes from one study that investigated performance on the 
MATRICS cognitive battery in 136 bipolar cases and 148 controls (Burdick et al., 
2014). They identified cases were categorised by three clusters based upon 
MATRICS performance. One cluster was comprised of cases with relatively 
preserved cognitive functioning relative to controls, but with superior social 
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cognition. However, only 43 bipolar cases were assigned to this cluster, and thus 
are not characteristic of the majority of bipolar cases.   
 
Heritability studies of cognition in bipolar families are suggestive of genetic 
influence on executive functioning, processing speed and verbal ability (Antila et 
al., 2007), which generally have large effect sizes in bipolar cases (Bora et al., 
2009). However, our results suggest polygenic risk of bipolar disorder does not 
contribute to these cognitive domains in healthy individuals.  
 
2.5.3 Polygenic risk of schizophrenia versus bipolar disorder and its 
association with cognition  
The third hypothesis in this chapter investigated whether common genetic 
variants associated with increased risk of schizophrenia relative to bipolar 
disorder were associated with cognitive ability. This analysis used a 
schizophrenia (case) / bipolar (control) GWAS, where genetic variants showing 
stronger association had a higher allelic frequency in schizophrenia cases 
compared to bipolar cases. Conversely, SNPs with weak association meant no 
significant differences in the allelic frequency. Differences in the common genetic 
architecture of schizophrenia and bipolar disorder may explain differences their 
respective phenotypes of these disorders, and within the context of this study, 
cognition.  
 
The results of this analysis showed differences in the common genetic 
architecture of schizophrenia and bipolar disorder were robustly associated with 
verbal and full scale IQ. One interpretation is that genetic differences between 
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schizophrenia and bipolar disorder may explain premorbid differences in 
cognitive ability. Low premorbid IQ is associated with increased risk of 
schizophrenia but not bipolar disorder (Zammit et al., 2004). Common genetic 
variation between these two disorders may reflect neurodevelopmental 
differences resulting in earlier, and more severe cognitive impairment in 
schizophrenia relative to bipolar disorder.  
 
2.5.4 Strengths/Limitations  
This study has several strengths and limitations. First, this study has used the 
largest schizophrenia training set to date (PGC2) for investigating polygenic 
overlap with cognition, which is almost 4 times larger than previous studies 
(McIntosh et al., 2013; Lencz et al., 2014). This is particularly important for 
polygenic analyses, as the power to detect associations is largely attributable to 
the size of the training set (Dudbridge, 2013). Second, the number of individuals 
with cognitive data in ALSPAC is larger than previous studies (McIntosh et al., 
2013; van Scheltinga et al., 2013; Lencz et al., 2014) and homogeneous regarding 
cognitive domains investigated, collection of cognitive data at a fixed time point 
(thus reducing the confounding effects of age) and low impact of population 
stratification. A third strength was the availability of two cognition samples, 
allowing replication of results in an independent dataset. However, it is unclear 
how comparable the results are for polygenic risk of schizophrenia and cognition 
between child and adult samples. Specifically, heritability of general cognitive 
ability becomes stronger across the lifespan, thus genetic factors influencing 
cognitive ability differ in children and adults. Furthermore, late childhood and 
early adolescence is when prospective schizophrenia cases begin to notably lag 
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behind their peers in cognitive tests (Reichenberg et al., 2010), meaning 
schizophrenia genetic risk variants may contribute more strongly to cognition 
before adulthood.  
 
However, there are several limitations. Firstly, the schizophrenia datasets are 
not independent. Whilst PGC1 and CLOZUK samples do not overlap, both 
samples are included within the PGC2.  
 
Secondly, it is unclear how comparable the results are for polygenic risk of 
schizophrenia and cognition between child and adult samples.  Specifically, 
genetic factors exert stronger influence on cognition across the lifespan (Deary 
et al., 2012). Genetic factors influencing schizophrenia also modestly overlap 
with cognition (Fowler T, 2012). The differences in variance explained between 
processing speed and performance IQ in the adult German sample compared 
ALSPAC may therefore be attributable to a greater genetic influence over 
cognition in adults.  
 
Third, although we used SNPs that were imputed with high quality, different 
imputation procedures were performed for ALSPAC, PGC1 and CLOZUK/PGC2 
datasets that could contribute to differences in the results (Marchini & Howie, 
2010) 
 
2.5.5 Further work  
Schizophrenia polygenic risk is associated with a negative change in general 
cognitive ability over the adult lifespan (McIntosh et al., 2013). However, relative 
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to healthy peers, cognitive lag during childhood and adolescence in prospective 
schizophrenia cases (Reichenberg et al., 2010) may be indicative of 
schizophrenia genetic factors exerting influence over cognitive ability during 
these developmental stages. Associations between schizophrenia polygenic risk 
and change in cognitive ability between childhood and adolescence may 
therefore be stronger in comparison to cognitive ability at age 8 alone. It may be 
change in cognition that the schizophrenia polygenic risk is associated with. 
Should go onto to say that this would explain the lesser degree of variance 
explained in our study compared to those with target datasets in adult 
populations as well as McIntosh results. 
 
Although polygenic risk of bipolar disorder could not reliably predict any single 
cognitive phenotype, the PGC bipolar discovery dataset use a combination of 
type I and II cases. Cognitive deficits in bipolar disorder may be more prominent 
in type I relative to type II cases (Schenkel et al., 2012). If SNPs associated with 
cognitive ability was used as the training phenotype, cognition polygenic scores 
could be used to predict bipolar type I and type II individuals. This method may 
be more successful at identifying cognitive endophenotypes within bipolar 
subtypes.  
 
2.5.6 Conclusion 
We investigated whether increased polygenic risk of schizophrenia, bipolar 
disorder and their differences were associated with specific cognitive domains 
most affected in schizophrenia,  
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Common schizophrenia genetic variation en masse did not contribute 
substantially to cognitive ability within the general population. However, our 
evidence consistently demonstrated increased polygenic risk of schizophrenia 
was associated with lower performance IQ. These findings have important 
implications for future endophenotypic studies of neurocognition in 
schizophrenia and bipolar disorder. Previous studies have focused on 
schizophrenia and full scale IQ or “g” for deriving estimates of shared genetic 
variance (Toulopoulou 2007;Fowler et al, 2012) and common polygenic risk 
(Lencz et al., 2014). However, of the cognitive domains tested in the present 
study, this shows schizophrenia is most genetically related, at least in the context 
of common alleles, to performance IQ.  
 
Polygenic risk of bipolar disorder was not strongly associated with any of the 
cognitive domains tested.  
 
An analysis using a schizophrenia versus bipolar case control GWAS showed 
schizophrenia variants were associated with full and verbal IQ. Further 
interrogation of these variants may be useful for identifying genes associated 
with the generalised cognitive deficit in schizophrenia and provide clues 
pertaining to neurodevelopmental processes.  
 
Selecting cognitive measures with the strongest genetic association with 
schizophrenia and bipolar disorder are required to maximise the benefit from 
future endophenotypic studies, thus providing greater insight into the 
neurobiology of mental illness. 
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3 Functional Pathways Underlying Cognitive Phenotypes in 
Schizophrenia cases and Healthy Controls 
3.1 Summary 
This chapter investigated the hypothesis that gene sets related to brain function, 
development and behaviour are a priori more likely to be enriched for SNPs 
influencing general cognitive ability. 155 gene-sets were used and grouped into 
six overarching categories: behaviour, cellular physiology, cellular morphology, 
development, region tract morphology and subcellular neuronal.  
 
Two hypotheses were addressed. Firstly, does schizophrenia polygenic risk from 
common SNPs in brain related gene-sets predict general cognitive ability? It was 
found that schizophrenia polygenic scores for individual gene-sets were not 
predictive of performance IQ in 936 controls, or the MATRICS composite score in 
496 cases after correction for multiple testing. Furthermore, there was no 
evidence that polygenic scores for gene-sets in specific categories showed 
greater association with general cognitive ability.   
 
Secondly, are brain related gene-sets enriched for common SNPs associated with 
general cognitive ability in 496 schizophrenia cases?  Using Brown’s method 
implemented in set-screen there was no evidence of enrichment for any of the 
gene-sets tested. A comparison of the broader gene-set categories using the 
Mann-Whitney U-Test showed that gene-sets related to abnormal brain region 
and fibre tract morphology were ranked more highly.  
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3.2 Introduction  
Over the past decade, it has emerged that schizophrenia has a complex polygenic 
architecture comprised of common polygenic risk (Schizophrenia Working 
Group of the Psychiatric Genetics Consortium, 2014), rare CNVs (Rees et al., 
2014b), and rare de novo CNVs (Malhotra et al., 2011).    
 
Progress in schizophrenia genetics can be attributed to increasingly large sample 
sizes and advances in genotyping technology allowing greater coverage of the 
genome, thus increasing the ability to detect both common and rare genetic 
variation. However, using this mass of information to further understand 
biological mechanisms contributing to disease poses several challenges. When 
considering findings from GWAS, the majority of SNPs show either weak, or no 
association with disease (Balding, 2006). In the largest schizophrenia GWAS to 
date, odds ratios for SNPs reaching genome wide-significance were typically less 
than 1.2 (Schizophrenia Working Group of the Psychiatric Genetics Consortium, 
2014). This suggests that individual polymorphisms do not contribute 
substantially to schizophrenia liability. Modelling the functional effects of single 
SNPs or genes through cellular or animal based techniques is time consuming 
and expensive. Furthermore, the effects may be small, or change, depending on 
interactions with other genetic variants or environmental influences (Purcell, 
2002).  
 
To overcome these limitations, increasingly gene set-based approaches are 
utilised to identify the convergence of genetic signals upon specific biological 
 118 
processes (Civelek & Lusis, 2014). Biological systems, pathways or gene-sets are 
comprised of genes with functional relatedness (Schadt, 2009), and thus are 
potentially more informative and more powerful for detecting association with a 
trait (Evangelou et al., 2012). An increasing number of databases with functional 
annotations are now available.  
 
Gene ontology (GO) is one of the largest publically available databases. Pathways 
are organised in in a hierarchical structure based upon their associations with 
molecular functions, cellular components or biological processes (Ashburner et 
al., 2000). Molecular functions represent any biochemical reaction that results 
from a gene; cellular components document the cellular location where these 
biochemical reactions may occur, and biological processes represents the 
function of these biochemical reactions (Ashburner et al., 2000). These 
annotations may be derived experimentally, curated using non-experimentally 
derived data, electronic curation, or come from unknown sources (Rhee et al., 
2008). Whilst the majority of annotations are derived from electronic curation, 
the proportion of manually curated entries is substantially increasing (Gene 
Ontology Consortium et al., 2013).  
 
Other databases provide additional information by linking genes with 
quantitative or anatomical traits observed through the study of animal models. 
The mouse genome database is curated partially via automated processing of 
peer reviewed papers, and partially from groups who provide data directly to the 
database (Bult et al., 2013). This database links over 10,000 phenotypes to genes 
from experimental mouse models, and is a powerful translational resource that 
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can be applied to human models of disease or traits (Bult et al., 2013). Gene sets 
manually curated by experts are increasing in popularity because of their higher 
quality compared to automated methods (Wang et al., 2010).  
 
A number of methods have been devised to analyse the association of SNPs in 
gene sets with a trait. Whilst it is recognised that different gene-set analytic 
methods are unlikely to produce identical results due to differences in their 
approaches and assumptions when modelling the data (Duncan et al., 2014), 
they are nonetheless valuable for extending results from GWAS. 
   
Over-representation methods use genes containing an associated SNP below a 
specific p-threshold. The number of genes that reach significance are counted for 
each gene-set, and compared against the number of significant genes that are not 
within the gene-set (Holmans, 2010; Evangelou et al., 2012). Gene-sets are 
enriched when the proportion of significant genes associated with a trait is 
significantly higher than those not in the gene set (Holmans, 2010). Gene set 
enrichment analysis (GSEA) is an alternative method that ranks genes using the 
most significant SNP or gene-wide p-value (Subramanian et al., 2005). The 
Kolmogorov-Smirnov test compares whether genes within specified pathways 
are ranked significantly higher than genes in random pathways. This method 
negates the need to specify a p-value threshold for association used in 
overrepresentation analyses (Holmans, 2010).  
 
Self-contained tests use a different approach by taking the association results for 
a set of SNPs within a gene set. A statistic is derived for all SNPs collectively to 
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test for association with a disease or trait. Set-based statistics may use the mean 
of SNP p-values (Purcell et al., 2007), kernel logistic regression (Wu et al., 2010) 
or Brown’s approximation of Fisher’s statistics (Moskvina et al., 2011). Brown’s 
approximation utilises Fisher’s approach for combining probabilities for non-
independent tests (Brown, 1975), and is suitable for gene-set based analyses 
where SNPs within genes are unlikely to be independent due to LD.  
 
Set-based tests are advantageous over overrepresentation analyses when 
multiple SNPs within the same gene contribute independently or semi-
independently with a disease or trait. However, in large genes where only one 
causal variant is present, taking the combined p-value of all SNPs within the gene 
is likely to deflate the association signal (Duncan et al., 2014).  
 
Several general methodological considerations exist for gene set analyses. There 
is little consensus regarding the contribution of SNPs within gene windows, 
referring to the area outside of the transcriptional start and end position of a 
gene. Some studies have used no gene window (Moskvina et al., 2011), whilst 
others have used between 5-500kb (Torkamani et al., 2008; Wang et al., 2010). 
SNPs within gene windows may have regulatory effects up to 20kb away 
(Veyrieras et al., 2008), although others will have no functional role and have a 
confounding effect (Holmans, 2010; Ramanan et al., 2012). This issue is partly an 
artefact of older genotyping technology before the implementation of genotype 
imputation, whereby the number of SNPs available for analysis was limited to 
genotyped SNPs exclusively. Imputation has resulted in a more dense 
distribution of SNPs within genes; meaning genic SNPs may also capture 
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regulatory signals through linkage disequilibrium. Thus, the usefulness of 
allocating gene windows is currently unclear (Holmans, 2010).  
 
Second, if an associated SNP is located within more than one gene, and these 
genes are members of the same gene-set, the gene-set may show artificial 
association with the trait under investigation (Ramanan et al., 2012). This would 
have a greater impact upon overrepresentation analyses where the most 
significant SNP within a gene is used, however the use of bootstrapping would 
partly mitigate against this. Set-based tests are less likely to be affected as all 
available SNPs within the gene set are used, although spurious results could 
arise if SNP coverage in a gene is low. Third, if linkage disequilibrium is not 
accounted for between SNPs, this may result in false positive associations within, 
or across genes in an LD window because multiple SNPs may tag the true causal 
variant. Finally, larger genes are likely to contain more SNPs. Thus, gene-sets 
containing larger genes are more likely to show association with a trait due to 
chance. 
 
Little is known regarding gene-sets underling cognitive ability in either healthy 
individuals or schizophrenia cases, or those that overlap between schizophrenia 
and general cognitive ability. Their identification could provide an additional 
opportunity for treatment intervention for the cognitive symptoms of 
schizophrenia.   
 
A number of studies have investigated candidate gene-sets and their associations 
with cognition. One study using GSEA showed polymorphisms within genes 
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encoding for proteins in the mouse NMDA receptor complex were associated 
with fluid intelligence in 3511 healthy controls, but not crystallised intelligence, 
working memory or processing speed (Hill et al., 2014a). However, it is unclear 
how much variation in fluid intelligence NMDA genes explained. Other post-
synaptic density gene-sets including mGlu5, AMPA and ARC were not associated 
with cognition, which may be indicative of a lack of power, or rather NMDA 
genes have specific roles in fluid intelligence, whereas other glutamatergic post-
synaptic complexes do not.  
 
Common SNPs in genes coding for synaptic G-protein receptors have been 
shown to be associated with general cognitive ability (Ruano et al., 2010), 
although this finding has not been replicated elsewhere (Hill et al., 2014b). 
Synaptic G-protein receptors contribute to synaptic transmission (Klose et al., 
2010), synaptic plasticity and abnormal learning/memory in mice (Cooper et al., 
2012). However, their role in human cognition remains uncertain. 
 
A recent paper highlighted differential association of common SNPs in pathways 
relating to fluid and crystallised intelligence using Ingenuity (Christoforou et al., 
2014). Pathways related to long-term synaptic depression were associated with 
crystallised intelligence. Synaptic depression is one form of synaptic plasticity 
(Collingridge et al., 2010) and may influence cognitive abilities such as long-term 
memory (Ge et al., 2010). In addition, gene-sets influencing neuronal density, 
morphology and integrity were associated with fluid intelligence. Gene-sets that 
overlapped between fluid and crystallised intelligence were related to structural 
properties including dendritic development, organisation of microtubles and 
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migration of GABAergic neurons (Christoforou et al., 2014). However, after 
correction for gene length, these associations were noted to be weaker, and it is 
unclear whether they reached nominal levels of significance.  
 
Gene-sets underlying cognitive impairment in schizophrenia have received less 
attention. One group has applied polygenic risk scores to common SNPs in 
candidate pathways to test associations with cognition in cases with psychosis. 
(Nicodemus et al., 2014). Whilst autosomal polygenic risk scores can be used to 
broadly assess the common genetic overlap of the same, or different traits, this 
method lacks specificity when looking at biological processes that may be shared 
between traits. Nicodemus and colleagues investigated SNPs within ZNF804A 
and their functionally related genes (Hill et al., 2012). ZNF804A polygenic 
pathway scores showed association with performance IQ, spatial working 
memory and social cognition in 424 patients with psychosis, predicting between 
1-3% of cognitive variance. However, significant associations were not 
consistently observed across all training thresholds. 
 
Although these studies provide some insight into possible biological mechanisms 
underlying cognitive ability, many findings have not been externally replicated, 
or show weak levels of association.  
 
3.3 Aims & Hypotheses 
It is unclear whether common genetic risk factors contributing to schizophrenia 
are associated with general cognitive ability when restricted to polymorphisms 
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within specific biological pathways. In addition, it is unknown what pathways 
are specifically involved in the general cognitive deficit in schizophrenia cases.  
Using two separate methodologies, the following hypotheses were investigated:  
 
3. Do schizophrenia polygenic risk scores derived from common SNPs in 
candidate pathways predict general cognitive ability measured through 
performance IQ in healthy controls and the MATRICS composite score in a 
schizophrenia patient sample?  In addition, are there differences in 
association between the different pathway categories? 
 
4. Using Brown’s method, is there an enrichment of SNPs in candidate 
pathways that show association with general cognitive ability in a 
schizophrenia patient sample?  In addition, are there differences in 
association between the different pathway categories? 
 
3.4 Methods 
3.4.1 Samples 
3.4.1.1 Schizophrenia Discovery Samples (Polygenic Pathways) 
Information for the individual sample recruitment, ascertainment and diagnoses 
for all samples used in PGC2 can be found in the supplementary data in the 
original paper (Schizophrenia Working Group of the Psychiatric Genetics 
Consortium, 2014). Briefly, all cases included in the analysis had a diagnosis of 
schizophrenia or schizoaffective disorder. Population matched controls were 
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available for all samples. Summary statistics were available for 35476 
schizophrenia cases and 46839 controls. SNPs with high confidence imputation 
scores (INFO > 0.9), and a minor allele frequency greater than 0.01 were used to 
generate polygenic risk scores predicting performance IQ in the German 
cognition sample. 
 
A second schizophrenia discovery sample used all individuals in the 
schizophrenia PGC sample described above, but without CLOZUK and Cardiff 
COGS samples. The number of individuals in this dataset was 29415 
schizophrenia cases and 40101 controls. Schizophrenia polygenic risk was used 
to predict general cognitive ability in the Cardiff COGS sample, meaning both 
discovery and target datasets were independent.  
 
3.4.1.2 Cognition Samples 
3.4.1.2.1 German cognition sample 
See section 2.3.2.2.1 for sample and genotype information regarding the German 
cognition sample. 936 individuals had available data for performance IQ, which 
were used in the present study.  Analyses using controls were restricted to 
performance IQ because this cognitive measure showed the strongest 
association with schizophrenia polygenic risk in Chapter 2. 
 
Individuals within the German cognition sample were used as controls within 
the PGC2 schizophrenia case/control analysis, thus these datasets are not 
independent. However, the aims these studies were different; specifically the 
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target variable in the present study is performance IQ rather than association 
with schizophrenia. 
 
3.4.1.2.2 Cardiff COGS 
CardiffCOGS is comprised of patients diagnosed with schizophrenia from across 
the UK, recruited from in-patient, community and voluntary mental health 
sectors. They were interviewed with the Schedules for Clinical Assessment in 
Neuropsychiatry (Wing et al., 1990), and best estimate lifetime diagnosis was 
based upon a review of case notes and their concordance with DSM-IV criteria. 
496 schizophrenia cases were used in the present study.  
 
Cardiff COGS were genotyped on the Illumnina HumanOmniExpressExome-8v1. 
Genotype quality control and imputation for Cardiff COGS was performed by the 
PGC Statistical Analysis Group. The quality control parameters for retaining SNPs 
and subjects were: SNP missingness < 0.05 (before sample removal); subject 
missingness < 0.02; autosomal heterozygosity deviation (| Fhet | < 0.2); SNP 
missingness < 0.02 (after sample removal); difference in SNP missingness 
between cases and controls < 0.02; and SNP Hardy-Weinberg equilibrium (P > 
10−6 in controls or P > 10−10 in cases). Genotype imputation was performed 
using IMPUTE2 / SHAPEIT (chunk size of 3 Mb) using phased haplotypes from 
the full 1000 Genomes Project dataset (August 2012).  
 
Dosage data was obtained for Cardiff COGS through the Schizophrenia PGC. 
Dosage files were converted into Plink bed/bim/fam format using 
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“gprobs2beagle” (http://faculty.washington.edu/browning/beagle 
utilities/utilities.html#gprobs2beagle) and “beagle2linkage” 
(http://faculty.washington.edu/browning/beagle 
utilities/utilities.html#beagle2linkage) java applications. SNPs with an INFO 
score > 0.9 and minor allele frequency greater than 1% were retained for further 
analysis. 
 
3.4.2 Cardiff COGS cognition data 
Patients completed the MATRICS cognitive battery (Kern et al., 2008; 
Nuechterlein et al., 2008), which measures ability on 10 separate tests 
encompassing 7 cognitive domains (attention/vigilance, reasoning/problem 
solving, speed of processing, social cognition, verbal learning/memory, visual 
learning/memory and working memory).  
 
All subtests were normally distributed apart from the Trail Making Test , which 
underwent log transformation. The direction of the sign was reversed indicating 
longer task duration was associated with worse performance. Standardised 
domain z-scores were calculated in cases relative to performance of 103 
controls. A composite z-score was derived using the standardized sum of the 
domain z-scores relative to controls.  
 
Domain score calculations and imputation of missing individual test/domain 
scores were performed according to the instructions within the MATRICS 
manual (Nuechterlein & Green, 2006)  (see Appendix A for additional details).  
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All further analyses used the MATRICS composite score only. The rationale 
behind this decision was firstly because previous studies observed the largest 
effects for general cognitive ability (Stefansson et al., 2014). Secondly, general 
cognitive ability is highly correlated with individual cognitive domains 
(Dickinson et al., 2008), and finally this strategy minimises the burden of 
multiple testing.   
 
3.4.3 Candidate Gene-Sets 
Gene-sets from the MGI Mammalian Phenotype database were previously 
categorised according to 5 overarching categories: behaviour, cellular 
physiology, cellular morphology, development and region tract morphology. The 
Mammalian Phenotype (MP) ontology and gene annotations were downloaded 
from the Mouse Genome Informatics (MGI) database 
(ftp://ftp.informatics.jax.org/pub/reports/index.html). These represent data 
from pharmacological and functional genetic studies in mice.  Gene annotations 
arising from transgene and multi-gene manipulations were removed. Parent 
terms were identified for each MP term and assigned to all genes annotated with 
that child term. Genes were mapped from mouse to human using the mapping 
file HMD Human5.rpt, also downloaded from MGI.  
 
Behavioural pathways pertain to abnormal behavioural or cognitive traits. 
Cognitive traits include abnormal temporal memory, spatial learning, motor  
learning and object recognition. Other behavioural traits include emotional 
affect, aggressive behaviour, and other abnormal social interactions.   
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Cellular morphology gene-sets are functionally related to abnormal structural 
properties of neurons and synapses. Several neuronal types are represented 
including dopaminergic, GABAergic, pyramidal and glial cells. Furthermore, axon, 
dendritic and synaptic malformations are also included. 
 
Cellular physiology pathways pertain to abnormal synaptic processes. This 
includes abnormal synaptic transmission, excitatory and inhibitory potentials. 
Other synaptic properties include abnormal synaptic plasticity, long-term 
potentiation and depression.  
 
Developmental gene-sets categorise malformations of different brain regions 
during neurodevelopment. This includes abnormal hippocampal, cerebellum, 
and forebrain amongst others. Other gene-sets include synaptic malformations 
between the axon and other neural or central nervous system tissues, and 
abnormal neuron differentiation.  
 
Region tract morphology gene-sets are associated with abnormal structural 
properties within, and across brain regions. They include, but are not limited to 
enlarged ventricles, abnormal brain size, abnormal white matter morphology, 
abnormal temporal and parietal lobes, and other structures, including the 
hippocampus and hypothalamus.  
 
Separately, subcellular neuronal gene-sets were derived from proteomic studies 
in rodents and humans that are predominantly associated with pre and 
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postsynaptic components.  A subset of these pathways (ARC and NMDA 
receptors) previously showed enrichment for de novo CNVs in schizophrenia 
cases (Kirov et al., 2012). Definitions of all gene-sets and their respective 
pathway membership can be found in Appendix B.  
 
3.4.4 Polygenic Pathway Analysis 
Polygenic risk scores were derived for each individual pathway within the 6 
overarching categories described above, and tested for association with 
performance IQ in controls and the MATRICS composite score in schizophrenia 
cases. The analysis proceeded as follows:: 
 
1) Overlapping SNPs between schizophrenia PGC and German cognition 
sample were identified. Separately, overlapping SNPs between 
schizophrenia PGC minus CLOZUK/Cardiff COGS and Cardiff COGS 
were identified. Where differences in strand alignment differences 
were found, strand flipping was performed in Plink where 
appropriate.  
2) For each pathway, genomic coordinates of genes were identified 
according to the build of the target set (human genome (HG) assembly 
18 for the German cognition sample, and HG19 assembly for Cardiff 
COGS). Only SNPs that were located within the transcriptional start 
and end position of the genes were taken forward for further analysis.   
3) Schizophrenia SNPs within each pathway were filtered by INFO score 
> 0.9, and assigned to one of two training sets based upon association-
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p values below 0.5 and 0.05. Polygenic pathway scores were derived 
using the “score” function in Plink.  
4) For the German cognition sample, performance IQ was regressed 
against polygenic risk for each pathway separately, and the first 
principle component from Eigenstrat was used as a covariate. 
Performance IQ was already corrected for age and sex, and these 
variables were not used as covariates. For Cardiff COGS, the MATRICS 
composite score was regressed against polygenic risk for each 
pathway separately. Age and sex were used as covariates.  
5) To correct for multiple testing, stages 4 and 5 were repeated 10,000 
times by randomising the performance IQ score within the German 
sample, and the MATRICS composite score in Cardiff COGS. Permuted 
regression p-values are 2-tailed, reflecting the original analysis and do 
not account for direction of effect. The corrected regression p-value 
represents the number of times the original regression p-value for a 
pathway was less than the lowest permuted p-value across all 
pathways. 
6) To assess whether association between the pathways and general 
cognitive ability differentiated across pathway categories, Mann-
Whitney U-Tests were performed. This tested whether pathways 
belonging to a specific category were ranked more highly (based upon 
their two-tailed regression p-value) compared to the remaining 5 
categories.  
7) We used permutations to generate empirical p-values for each 
category that would correct for overlap between gene-sets. Using the 
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10,000 simulated datasets created in step 5, step 6 was repeated by 
randomising the performance IQ score within the German sample, and 
the MATRICS composite score in Cardiff COGS. The corrected Mann-
Whitney p-value represents the number of times the original Mann-
Whitney p-value for a pathway was less than the lowest permuted p-
value across all pathways. 
 
3.4.5 Brown’s Method 
The enrichment of SNPs in gene-sets influencing general cognitive ability in 488 
schizophrenia cases was performed using the following method:  
 
1) A linear GWAS was performed for the MATRICS composite score in Plink 
with age and sex included as covariates. SNP p-values were adjusted for 
genomic inflation using the “--adjust" flag in Plink.  
2) For each gene, only SNPs within the transcriptional start and end were 
used. 
3) Brown’s method (Morton, 1975) was implemented in the Plink set-screen 
test (Purcell et al., 2007; Moskvina et al., 2011). The 1000 Genomes 
Project “Phase1 integrated release version3” (released in April 2012, 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20110521/) was used 
to infer LD structure. A p-value for enrichment of common SNPs 
associated with the MATRICS composite score was produced for each of 
the 155 pathways.   
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4) A permutation approach was used to correct for the number of pathways 
tested. First, the MATRICS composite score was permuted across all 
individuals 1000 times. Stages 2-4 were repeated. Brown’s corrected p-
value represents the number of times the original brown p-value for a 
pathway was less than the lowest permuted p-value across all pathways. 
5) To investigate differences amongst pathway categories, Brown’s p-values 
for individual pathways were grouped by membership of their specific 
pathway category. Mann-Whitney U Tests were performed to assess 
whether Brown’s p-values for pathways in a particular category were 
ranked more highly compared to the other 5 categories.  
6) Permutations were used to correct for differences amongst the pathway 
categories by comparing the original Mann-Whitney p-value against that 
of 1000 simulations. The category corrected p-value represents the 
number of times the original Mann-Whitney p-value for a category was 
less than the lowest permuted p-value across all pathways. 
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3.5 Results 
3.5.1 Polygenic Pathways (Controls) 
Using alleles weighted by the log odds ratio in the full PGC dataset, polygenic 
pathway scores based upon all SNPs within each of the 6 categories were 
regressed against performance IQ at two training thresholds (0.5 & 0.05).  Table 
3.1 contains results for regressions of individual pathways reaching nominal 
significance.  Appendix C contains results for all pathways. 
 
Increased polygenic risk of schizophrenia in the pathway “abnormal 
hypothalamus morphology” was associated with lower performance IQ (training 
threshold = 0.05, corrected p=0.049, %r2=0.807). Polygenic risk of other 
pathways was not significantly associated with performance IQ after correction 
for multiple testing.  
 
Individual pathways belonging to each category were ranked by their regression 
p-values separately for 0.5 and 0.05 training thresholds, and combined.  
Each pathway category was compared against the remaining categories using the 
Mann-Whitney U-Test (Table 3.2). After correction for multiple testing, there 
was no evidence to suggest specific gene-set categories showed greater 
association with performance IQ.  
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Pathway Pathway Category Training Threshold P 
P 
(Corrected) %R2 
Direction 
of Effect 
abnormal hypothalamus morphology region tract morphology 0.05 0.006 0.049 0.807 - 
abnormal neuron morphology cellular morphology 0.5 0.007 0.063 0.797 + 
abnormal basal ganglion morphology region tract morphology 0.5 0.010 0.088 0.727 + 
abnormal neurite morphology cellular morphology 0.5 0.011 0.099 0.662 - 
abnormal spinal cord morphology region tract morphology 0.05 0.013 0.118 0.662 + 
abnormal social conspecific interaction behaviour 0.05 0.014 0.124 0.651 + 
abnormal neuron morphology cellular morphology 0.05 0.015 0.131 0.658 + 
abnormal social investigation behaviour 0.5 0.015 0.131 0.635 + 
abnormal nervous system development development 0.05 0.015 0.134 0.647 + 
abnormal long term potentiation cellular physiology 0.05 0.018 0.157 0.607 - 
abnormal telencephalon development development 0.5 0.020 0.178 0.582 + 
abnormal nervous system morphology region tract morphology 0.05 0.021 0.186 0.592 + 
abnormal learning  memory behaviour 0.05 0.021 0.190 0.571 + 
abnormal emotion affect behaviour behaviour 0.5 0.022 0.194 0.565 - 
abnormal midbrain morphology region tract morphology 0.5 0.023 0.207 0.575 - 
abnormal nervous system morphology region tract morphology 0.5 0.026 0.226 0.558 + 
abnormal brain morphology region tract morphology 0.05 0.026 0.229 0.550 + 
abnormal associative learning behaviour 0.5 0.027 0.243 0.522 + 
abnormal glial cell morphology cellular morphology 0.5 0.030 0.262 0.535 + 
abnormal forebrain morphology region tract morphology 0.5 0.031 0.273 0.528 + 
abnormal synaptic depression cellular physiology 0.05 0.031 0.274 0.494 + 
abnormal spinal cord morphology region tract morphology 0.5 0.036 0.317 0.492 + 
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abnormal parental behaviour behaviour 0.05 0.037 0.324 0.475 + 
abnormal eating drinking behaviour behaviour 0.05 0.038 0.340 0.474 + 
abnormal paired pulse facilitation cellular physiology 0.5 0.040 0.354 0.456 + 
abnormal postnatal subventricular zone 
morphology region tract morphology 0.05 0.041 0.364 0.466 - 
abnormal inhibitory postsynaptic currents cellular physiology 0.5 0.042 0.368 0.432 + 
abnormal behavioural response to xenobiotic behaviour 0.5 0.042 0.368 0.450 + 
abnormal behavioural response to xenobiotic behaviour 0.05 0.043 0.376 0.441 + 
abnormal social conspecific interaction behaviour 0.5 0.045 0.395 0.441 + 
abnormal forebrain morphology region tract morphology 0.05 0.045 0.397 0.457 + 
abnormal brain morphology region tract morphology 0.5 0.047 0.418 0.447 + 
abnormal learning  memory behaviour 0.5 0.048 0.429 0.422 + 
abnormal basal ganglion morphology region tract morphology 0.05 0.051 0.448 0.415 + 
Table 3-1 – Polygenic Pathways predicting performance IQ in healthy controls with regression p<0.05 
Direction of effect refers to the sign of the regression coefficient. “+” means increased schizophrenia polygenic risk of that pathway was 
associated with better performance IQ. “–“ means increased polygenic risk of that pathway was associated with worse performance IQ. 
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Pathway Category Mann Whitney 
(Corrected P)  
Mann Whitney 
(Corrected P) 
(0.5) 
Mann 
Whitney 
(Corrected P) 
(0.05) 
Behaviour 1 0.8721 1 
Cellular Morphology 0.7645 1 0.1089 
Cellular Physiology 0.5623 1 0.5241 
Development 1 1 1 
Region Tract 
Morphology 0.0873 0.1432 0.1563 
Subcellular Neuronal 1 1 0.9234 
Table 3-2 - Mann-Whitney P-values for pathway categories (healthy controls) 
 
Mann-Whitney U-Test p–values comparing each pathway category against the 5 remaining categories for combined, 0.5 and 0.05 
training thresholds
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3.5.2 Polygenic Pathways (Schizophrenia Cases) 
Polygenic pathway scores based upon all SNPs within each of the 6 categories 
were regressed against the MATRICS composite score at two training thresholds 
(0.5 & 0.05) (See Table 3.3 for results reaching uncorrected p<0.05, and 
Appendix D for a complete list of results).  
 
No schizophrenia polygenic pathway scores were associated with the MATRICS 
composite score after correction for multiple testing.  
 
Individual pathways belonging to each category were ranked by their regression 
p-values separately for 0.5 and 0.05 training thresholds, and combined.  
Each pathway category was compared against the remaining categories using the 
Mann-Whitney U-Test (Table 3.4). After correction for multiple testing, there 
was no evidence to suggest specific gene-set categories showed greater 
association with the MATRICS composite score.  
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Gene-set Gene-set category 
Training 
threshold P P (Corrected) %R2 
Direction 
of Effect 
Abnormal cerebellum development Development 0.5 0.0105 0.0854 1.3312 + 
Abnormal depression related behaviour Behaviour 0.05 0.0119 0.0967 1.2864 - 
Abnormal hippocampus development Development 0.05 0.0194 0.1576 1.1126 + 
Abnormal oligodendrocyte morphology Cellular morphology 0.05 0.0217 0.1762 1.0731 + 
Abnormal depression related behaviour Behaviour 0.5 0.0246 0.1996 1.0293 - 
Dilated third ventricle Region tract morphology 0.5 0.0252 0.2044 1.0100 - 
Abnormal temporal memory Behaviour 0.5 0.0277 0.2254 0.9866 - 
Abnormal hippocampus development Development 0.5 0.0307 0.2496 0.9511 + 
Abnormal glial cell morphology Cellular morphology 0.05 0.0366 0.2976 0.8900 + 
Abnormal fear anxiety related behaviour Behaviour 0.5 0.0395 0.3207 0.8643 - 
Abnormal seizure response to inducing agent Behaviour 0.5 0.0451 0.3660 0.8189 - 
Abnormal contextual conditioning behaviour Behaviour 0.5 0.0456 0.3703 0.8149 - 
Table 3-3 - Polygenic Pathways predicting the MATRICS composite score in schizophrenia cases with regression p<0.05 
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Pathway Category Mann Whitney 
(Corrected P)  
Mann Whitney 
(Corrected P) (0.5) 
Mann Whitney 
(Corrected P) 
(0.05) 
Behaviour 0.0610 0.4441 0.1365 
Cellular Morphology 1 1 1 
Cellular Physiology 1 1 1 
Development 0.6686 0.4759 1 
Region Tract 
Morphology 1 1 1 
Subcellular Neuronal 1 1 1 
Table 3-4 – Mann-Whitney P-values for pathway categories (schizophrenia cases) 
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3.5.3 Brown’s Test  
Brown’s test was used to investigate the hypothesis that SNPs en masse in the 
pathways tested would show association with the MATRICS composite score. 
Table 3.5 reports the top 10 most significant associations (complete results can 
be found in Appendix E). No single pathway showed nominal levels of 
significance (p>0.05) with the MATRICS composite score before correction for 
multiple testing.  
 
To assess whether association could be localised to a particular pathway 
category, a Mann-Whitney U Test was performed comparing the ranks of p-
values for a particular category against all other categories. After permutation 
corrections for gene-set overlap and multiple testing, gene sets associated with 
region tract morphology (p=0.002) had en masse higher p-values than those in 
other pathway categories (see Table 3.6 for full results).
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Pathway Category Pathway N SNPs P P (Corrected) 
Behaviour Abnormal motor learning 12793 0.056 0.0951 
Behaviour Abnormal discrimination learning 5607 0.073 0.1240 
Development Abnormal CNS synapse formation 5657 0.075 0.1274 
Region Tract Morphology Abnormal hindbrain morphology 78393 0.083 0.1409 
Cellular Physiology Abnormal GABA mediated receptor currents 5186 0.094 0.1596 
Cellular Physiology Abnormal miniature inhibitory postsynaptic currents 5658 0.119 0.2021 
Region Tract Morphology Abnormal cerebrum morphology 87344 0.121 0.2055 
Region Tract Morphology Abnormal lateral ventricle morphology 16676 0.121 0.2055 
Region Tract Morphology Abnormal telencephalon morphology 109098 0.134 0.2275 
Region Tract Morphology Abnormal forebrain morphology 132002 0.136 0.2309 
Table 3-5 – Top 10 most significant Brown p-values for enrichment of MATRICS SNPs in tested pathways (schizophrenia cases) 
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Pathway Category Mann-Whitney P (1-Tailed) Mann-Whitney Corrected P (1-Tailed) 
Behaviour 0.997 1 
Cellular Morphology 0.464 0.784 
Cellular Physiology 0.339 0.543 
Development 0.011 0.241 
Region Tract Morphology 3.9x10-5 0.002 
Subcellular Neuronal 1.000 1 
Table 3-6 - Mann-Whitney P-values ranks of p-values for a particular category against all other categories (schizophrenia cases). 
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3.6 Discussion 
3.6.1 Polygenic risk scores in candidate pathways and their association 
with cognition 
155 candidate pathways within 6 functional categories were tested for 
association with general cognitive ability using a polygenic risk score approach 
in a schizophrenia sample, and independently in 936 healthy controls.   
 
In healthy controls, at the 0.05 training threshold, increased schizophrenia 
polygenic pathway risk for “abnormal hypothalamus morphology” was 
associated with lower performance IQ after correction for multiple testing. 
However. given the corrected p-value is only marginally significant, the size of 
the cognition sample is small, and as the equivalent analysis at the less stringent 
threshold of 0.5 showed no association, this is unlikely to represent a true 
association. 
 
There was also no evidence to suggest that polygenic scores from gene-sets in 
particular categories were preferentially associated with performance IQ.  
 
Schizophrenia polygenic pathway scores were not associated with the MATRICS 
composite score in schizophrenia cases after correction for multiple testing in 
either individual pathways, or across the 6 pathway categories.  
 
These results suggest the application of polygenic risk scores to SNPs across 
large numbers of gene-sets is unlikely to be informative in small cognition 
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samples due to low power and multiple testing burdens. In addition, the findings 
from Chapter 2 using SNPs from across the autosomes showed schizophrenia 
polygenic risk only predicted a small proportion of performance IQ variance in a 
substantially larger cognition sample. Effect sizes for individual pathways 
influenced by common schizophrenia genetic risk that may also contribute to 
performance IQ in healthy controls are likely to be low. In addition to large 
schizophrenia discovery samples, large target cognition samples are also likely 
to be required to identify pathways contributing to schizophrenia liability and 
cognition.  
 
3.6.2 GWAS of cognition in schizophrenia / Brown’s method 
A linear GWAS for association with the MATRICS composite score was 
performed in 490 schizophrenia cases. No SNP reached genome wide 
significance for association with the MATRICS composite score. Other large 
GWAS of general cognitive ability have yet to identify genome-wide associations 
between single polymorphisms and general cognitive ability.  Thus, it is 
unsurprising we failed to detect any genome-wide significant loci.  Although one 
study recently reported a genome-wide significant association at SCN2A with 
general cognitive ability in schizophrenia, this finding has yet to be replicated 
(Dickinson et al., 2014). 
 
Brown’s method was used to test for associations between SNPs in the 155 
candidate pathways and general cognitive ability in schizophrenia cases. 
Brown’s method was preferred over overrepresentation methods because 
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general cognitive ability is highly polygenic, with no single SNP showing genome-
wide association in healthy individuals (Davis et al., 2010). Thus, we reasoned 
that multiple semi-independent SNPs within brain genes (which are typically 
larger and more likely to contain multiple semi-independent SNPs) were more 
likely to contribute towards general cognitive ability as opposed to only one 
causal SNP.  
 
No single pathway reached nominal levels of significance before correction for 
multiple testing, suggesting common SNPs in these pathways are not associated 
with general cognitive ability in schizophrenia cases. 
 
Brown’s p-values for individual brain region/fibre tract morphology pathways 
were significantly higher than those in other pathway categories. The MGI 
definitions of region tract morphology gene-sets are based upon structural 
abnormalities of the mouse brain. Approximately 1653 genes are present across 
44 region tract morphology gene-sets. They share on average 5 genes, thus the 
observed association cannot be explained by a substantial overlap in genes, 
which were also accounted for using permutations.  
 
To relate these findings to existing literature, structural MRI has revealed 
differences in brain structure between schizophrenia cases and healthy controls. 
The most robust findings include decreases in grey and white matter (Olabi et al., 
2011) and enlarged ventricles (Lawrie & Abukmeil, 1998) in patients. How 
structural changes correspond with cognitive ability may show particular brain 
regions that are involved with cognitive symptoms in schizophrenia (Pantelis et 
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al., 2005). One longitudinal study showed a reduction in white matter within the 
frontal lobe as associated with decreased ability on attention, verbal learning 
and working memory tasks (Andreasen et al., 2011). Furthermore, decreased 
white matter in the temporal lobes was also associated with decreased ability on 
attention, problem solving, fluency, verbal learning and working memory 
(Andreasen et al., 2011). However, this study had several limitations. First, no 
result would have survived correction for multiple testing. Second, structural 
MRI findings are subject to confounding effects from a variety of sources. 
Changes in grey and white matter may partly be mediated by anti-psychotic 
medication (Fusar-Poli et al., 2013), cannabis (Cousijn et al., 2012) and smoking 
(Yu et al., 2011). These confounders were not addressed in Andreasen et al’s 
(2011) study.   
 
The relationship between longitudinal brain changes and cognition in adult 
patients may not be particularly informative regarding the developmental 
aetiology of the general cognitive deficit. Specifically, cognitive impairment is 
observed through childhood (Meier et al., 2014) and further declines around the 
onset of psychosis (Wood et al., 2007). However, cognitive ability remains 
relatively stable thereafter, thus continuing structural changes within the brain 
are unlikely to be the primary cause of cognitive symptoms in adult 
schizophrenia cases.  
 
Support from structural MRI for brain structure affecting cognition in 
schizophrenia is tentative. Whilst the results of the present study provide limited 
evidence that common genetic variation in genes affecting brain structure is 
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associated with general cognitive ability in schizophrenia, replication in a large 
independent schizophrenia cognition sample is required.   
 
3.6.3 Strengths/Limitations 
A strength of the present study was its use of gene-sets stratified by their 
functional relevance to brain structure, function, behaviour and cognition. These 
pathways are a priori more likely to be enriched for SNPs influencing general 
cognitive ability. By choosing a more narrow set of pathways in comparison with 
those of the full MGI database, or gene ontology, this reduced multiple testing 
burdens considerably, allowing greater power to detect associations between 
the 155 gene-sets and general cognitive ability. However, the results indicate we 
were still underpowered.  
 
This study has several limitations. A major limitation is that of sample size, as 
both control and schizophrenia cognition samples were small. Furthermore, 
when testing pathways with SNP data using association p-values from small 
samples, caution is warranted over the interpretation of results. Specifically, 
negative results may result from poorly defined pathways or low power (Duncan 
et al., 2014). Further studies may benefit from analysing a smaller number of 
candidate pathways until samples are adequately sized and powered to detect 
robust associations that can withstand multiple correction burdens.    
 
Secondly, SNPs were assigned to genes only if they were within the 
transcriptional start and end sites. Widening the gene window size around each 
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gene may capture regulatory elements that are currently missed in the present 
analysis. Conversely, their addition may simply add noise. The balance between 
including SNPs that may have functional relevance to the gene with those that do 
not is not easily solved. A possible solution is to use functional annotations 
provided by ENCODE (Encode Project Consortium, 2012) to identify SNPs with 
functional relatedness to gene outside of its transcriptional boundaries.  
 
Third, no pathways were used as negative controls. However, as the analyses 
performed on the 155 candidate pathways did not yield robust associations with 
general cognitive ability in schizophrenia cases or controls across the two 
methods, the addition of negative control pathways would not change the 
interpretation of the present findings.  
 
Fourth, set-screen and polygenic risk scores are complementary but distinct 
methodologies making it difficult to directly compare results. Set-based tests 
have some advantages over polygenic risk scoring. For example, polygenic risk 
scores are typically calculated using SNPs that are in low linkage disequilibrium 
(LD) using either LD based clumping. However, when applied to gene sets, the 
number of SNPs remaining in genes after clumping may be low, and thus there is 
insufficient variability in the polygenic risk score to show association with the 
phenotype under investigation. In addition, in genes where there are multiple 
independent signals, these may also be removed through LD-based clumping. 
Whilst we used an alternative approach that omitted clumping procedures 
(Nicodemus et al., 2014), this means results may potentially be inflated due to 
the inclusion of SNPs in LD. Brown’s method has the advantage of using p-values 
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from all available SNPs within the gene set whilst accounting for the underlying 
LD structure (Moskvina et al., 2011).  
 
 
3.7 Conclusion 
This chapter used two methods to investigate the association of candidate gene-
sets and their overarching biological functions, with cognitive ability in 
schizophrenia cases and healthy controls.  
 
First, schizophrenia polygenic pathway scores were used to predict the MATRICS 
composite score in schizophrenia cases, and performance IQ in healthy 
individuals. No robust evidence was found associating polygenic pathway scores 
with general cognitive ability in patients or controls after correction for multiple 
testing.  
 
Brown’s test used SNPs associated with the MATRICS composite score to assess 
whether they collectively showed association with specific gene-sets and their 
respective categories. No single gene-set was shown to be significantly 
associated with the MATRICS composite score, however a comparison of the 
pathway categories showed region tract morphology pathways were ranked 
more highly compared to the remaining five.  
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Future analyses will require larger samples in order to provide greater power to 
detect whether the biological pathways involved with schizophrenia and general 
cognitive ability overlap. 
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4 The contribution of rare copy number variation to general 
cognitive ability in schizophrenia 
4.1 Summary 
Structural genetic variation in the form of copy number variants (CNVs) has 
emerged as an important contributor to many psychiatric and non-psychiatric 
diseases. This chapter investigates three aspects of rare CNVs with respect to 
general cognitive ability in schizophrenia cases.  
 
First, do those with schizophrenia who are carriers of well- supported 
‘neuropsychiatric CNVs with prior association to schizophrenia, autism and 
intellectual disability have lower general cognitive ability?   
Second, does CNV burden (as measured by size and number of genes hit) show 
association with general cognitive ability in those with schizophrenia?  
Third, does the number of genes hit by CNVs in candidate pathways (previously 
outlined in Chapter 3) show association with general cognitive ability in 
schizophrenia cases?  
 
We found schizophrenia cases carrying neuropsychiatric CNVs perform nearly 
one standard deviation lower on a measure of general cognitive ability compared 
to other schizophrenia cases. Regarding CNV burden, an increase in the numbers 
of genes hit by large (>100kb) rare CNVs was associated with lower general 
cognitive ability in schizophrenia cases. Finally, no evidence was observed for 
associations with a number of candidate pathways with links to brain structure, 
function, behaviour and cognition.  
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These results provide evidence showing rare CNVs contribute to generalised 
cognitive ability in schizophrenia cases, although larger samples are required to 
definitively assess whether disruptions in particular pathways contribute to 
these observations.  
 
4.2 Introduction 
4.2.1 Overview of CNVs associated with schizophrenia 
Schizophrenia is a severe psychiatric disorder with a complex polygenic 
architecture. Common polygenic risk contributes nearly 20% of schizophrenia 
variance, and over 100 independent loci have surpassed genome-wide 
significance for association with schizophrenia (Schizophrenia Working Group of 
the Psychiatric Genetics Consortium, 2014). Nonetheless, even the most 
significant SNPs individually have small effect sizes with odds ratios for risk 
alleles typically below 1.2 (Schizophrenia Working Group of the Psychiatric 
Genetics Consortium, 2014).  
 
Over the past decade advances in genotyping technology have allowed for the 
study of structural genetic variation, particularly CNVs. CNVs refer to changes in 
the structure of a chromosome when a section on one or both alleles are deleted, 
duplicated or rearranged. Approximately 12% of the human genome is 
comprised of chromosomal regions enriched for deletions or duplications across 
ethnically diverse populations (Redon et al., 2006). Whilst CNVs constitute 
normal genetic variation in healthy populations (Sebat et al., 2004; Redon et al., 
2006). a small number of rare CNVs are high risk factors for developing 
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schizophrenia (Kirov et al., 2009a; Rees et al., 2014b). A recent meta-analysis 
confirmed 11 rare CNVs as associated with schizophrenia and that their odds 
ratios are between ~2-50 (Rees et al., 2014b), substantially larger than for 
established common variants.  CNVs showing strong association with 
schizophrenia include deletions at 1q21.1, NRXN1, 3q29, 15q.11.2, 15q13.3 and 
22q11.2, and duplications at 1q21.2, WBS, Angelman/Prader-Willi Syndrome on 
chromosome 15, 16p13.11 and 16p11.2 (Rees et al., 2014b).  However, the 
proportion of schizophrenia cases carrying a neuropsychiatric CNV is low 
(~2%), with rates for individual neuropsychiatric CNVs typically between 0.1-
0.5% (Rees et al., 2014b). 
 
Identifying single or multiple genes within neuropsychiatric CNVs that 
contribute to pathogenesis is challenging. Neuropsychiatric CNVs are typically 
large, and may span several megabases incorporating a large number of genes. In 
comparison, a small number of CNVs associated with schizophrenia affect single 
genes, making biological inferences regarding pathogenesis somewhat easier.  
 
One example is NRXN1 (Kirov et al., 2009b; Rujescu et al., 2009), which is part of 
the neurexin family of genes. These genes, along with their binding partners 
neuroligins, organize GABAergic and glutamatergic synapses (Graf et al., 2004). 
Moreover, they have important roles in neurodevelopment, particularly in the 
expression of genes that regulate cell adhesion and neuron differentiation (Zeng 
et al., 2013).  
 
CNVs encompassing VIPR2 have also been associated with schizophrenia in 
several studies (Levinson et al., 2011b; Vacic et al., 2011). VIPR2 encodes the G-
 155 
protein-coupled receptor VPAC2, which is expressed in several brain regions 
including the suprachiasmatic nucleus, amygdala, thalamus and pyramidal cells 
in the CA1-C3 layer of the hippocampus (Sheward et al., 1995). Furthermore, 
VPAC2 receptors may have a regulatory role on hippocampal NMDA receptors 
through the AMP/PAK pathway (Yang et al., 2010b), which may be important in 
the pathogenesis of schizophrenia (Sanderson et al., 2012). However, a recent 
meta-analysis showed VIPR2 was not significantly associated with schizophrenia 
(Rees et al., 2014b), casting doubt over its role in pathogenesis.  
 
De-novo mutations (that are not transmitted from either parent) are found at a 
higher rate in schizophrenia cases compared to controls (Xu et al., 2008; Rees et 
al., 2011). This partly explains the stable prevalence of schizophrenia despite 
reduced fecundity (Rees et al., 2012). Functionally, de-novo schizophrenia CNVs 
are enriched for genes affecting the post-synaptic density (PSD), specifically ARC 
and NMDA receptors (Kirov et al., 2012).  
 
4.2.2 CNVs conferring risk across psychiatric disorders 
Some neuropsychiatric CNVs are associated with increased risk of multiple 
psychiatric and cognitive phenotypes (Sebat et al., 2009), in particular 
schizophrenia, autism and intellectual disability (Malhotra & Sebat, 2012). CNVs 
associated with both schizophrenia and autism include 1q21.1 (Brunetti-Pierri et 
al., 2008), 3q29 (Ballif et al., 2008; Levinson et al., 2011b; Levinson et al., 2011a), 
16p11.2 (Weiss et al., 2008; McCarthy et al., 2009), 17q12 (Moreno-De-Luca et 
al., 2010) and 22q11.2 (Murphy et al., 1999; Kobrynski & Sullivan, 2007).  
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Deletions at 22q11.2 are one of the most extensively studied neuropsychiatric 
CNVs, and show the most robust association with schizophrenia (Rees et al., 
2014b), and cause a wide range of phenotypes including cardiac abnormalities, 
autism and cognitive impairment, collectively known as 22q11.2 Deletion 
Syndrome (22qDS) (Kobrynski & Sullivan, 2007). Individuals with 22qDS have a 
substantial increase in risk for developing schizophrenia. Approximately 25% of 
individuals with 22qDS develop schizophrenia (Murphy et al., 1999), which is 
substantially higher than the general population risk of approximately 0.5-1%. 
Furthermore, schizophrenia cases with a 22q11.2 deletion are largely 
indistinguishable from non-22qDS patients (Bassett et al., 2003). 
 
4.2.3 The association between neuropsychiatric CNVs and general 
cognitive ability 
The overlap of neuropsychiatric CNVs across neuropsychiatric disorders with 
differing levels of cognitive impairment has led to questions over whether they 
contribute to cognitive impairment independently of or in tandem with disease 
(O'Donovan et al., 2008b). This question was addressed in a recent study 
investigating differences in cognitive ability in healthy individuals who carry a 
known neuropsychiatric CNV, compared to those who do not (Stefansson et al., 
2014). They showed neuropsychiatric CNV carriers displayed cognitive profiles 
between that of schizophrenia cases and healthy individuals who did not carry a 
neuropsychiatric CNV. These findings were consistent across a broad range of 
generalized and specific cognitive domains including verbal IQ, performance IQ, 
working memory and processing speed. However, after correction for full scale 
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IQ, associations between neuropsychiatric CNV status and individual cognitive 
tests were weaker. This finding is unsurprising given performance on individual 
cognitive domains is largely mediated through generalized cognitive ability in 
both schizophrenia cases (Dickinson et al., 2008) and healthy individuals (Deary 
et al., 2010).  
 
Neuropsychiatric CNVs affect cognition in controls, but that this has only been 
examined in small samples of those with clinical psychiatric disorders (Hanson 
et al., 2010; Citta et al., 2013; Niarchou et al., 2014). This study will be the first to 
specifically examine the effect of neuropsychiatric CNVs upon general cognitive 
ability in schizophrenia cases. 
 
4.2.4 CNV burden and general cognitive ability in schizophrenia cases 
and healthy controls 
 
Several studies have investigated rare CNV burden with respect to general 
cognitive ability in healthy populations. McRae and colleagues (2013) 
investigated CNVs greater than 20kb at a frequency of less than 5% with respect 
to IQ in 800 individuals. They found no associations between the number of 
CNVs, or their cumulative or average length, with IQ. 
 
A substantially larger study in over 6000 individuals investigated the association 
between total CNV count and length (separately for deletions and duplications 
and both combined), and number of homozygous deletions with respect to full 
scale IQ (Kirkpatrick et al., 2014). Consistent with previous findings, they found 
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no robust evidence for any single CNV measure showing association with IQ. A 
trend was present showing larger CNVs were associated with lower IQ, which 
was largely driven by duplications rather than deletions.   
 
The association of burden of large (>500kb) and rare (frequency < 1%) CNVs  
with fluid and crystallised intelligence was studied in 3133 and 3210 healthy 
controls respectively (MacLeod et al., 2012). They largely failed to identify 
associations between either fluid or crystallised intelligence and total CNV 
burden, length, or number of genes hit. Although a weak association between 
numbers of CNVs between 200-500kb and fluid intelligence was observed, this 
did not survive correction for multiple testing.  
 
Other studies have investigated the association between rare CNVs and general 
cognitive ability in patients with a psychiatric diagnosis. Yeo and colleagues 
investigated whether the length and number of large rare CNVs in 74 patients 
with alcohol dependence were associated with performance on the Wechsler 
Abbreviated Scale of Intelligence (WASI) (Yeo et al., 2011). They found a 
negative correlation between full scale IQ and total length of CNV deletions (r=-
0.3). Similar effects were also observed for the matrix reasoning task, but not for 
a verbal vocabulary task. In addition, they investigated whether carriers of 
known neuropsychiatric CNV deletions (from schizophrenia, autism and 
intellectual disability) performed significantly differently compared to all other 
carriers, but found no significant differences between them.  
 
A recent study using 386 schizophrenia cases investigated the effect of rare CNVs 
hitting brain-expressed genes upon various measures of symptom domains and 
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cognitive tests (Merikangas et al., 2014). They found no significant associations 
between the number of brain-expressed genes hit, and performance, verbal or 
full scale IQ. 
 
Overall, these studies provide evidence that the burden of rare CNVs (unselected 
for possible pathogenicity) is not associated with general cognitive ability in 
healthy individuals. However, rare CNV burden, particularly for deletions is 
associated with lower general cognitive ability in patients with schizophrenia 
and alcohol dependence. However, studies of rare CNV burden in clinical 
populations are substantially smaller compared to those in healthy individuals, 
and validation of these findings in large schizophrenia cohorts would be 
beneficial. 
 
4.2.5 Aims & Hypotheses 
The aim of this chapter was to identify associations between rare CNVs and 
general cognitive ability in a schizophrenia sample, and asks the following 
hypotheses:  
 
1. Do schizophrenia carriers with well-supported neuropsychiatric CNVs have 
lower general cognitive ability compared to non-carriers? 
 
2. Does total rare CNV burden of small (15-100kb) and large (>100kb) CNVs, 
their total length or number of genes hit show association with general cognitive 
ability? Furthermore, do different types of CNV (deletions or duplications) show 
the same, or differential associations? 
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3) Does the number of genes hit by CNVs within pathways relating to brain 
structure, function, behaviour and cognition show association with general 
cognitive ability in schizophrenia cases?   
 
4.3 Methods 
4.3.1 Schizophrenia Cognition Sample 
Schizophrenia cases were recruited from the Cardiff Cognition in Schizophrenia 
sample (Cardiff COGS). These cases were recruited from South Wales and the 
wider UK, from community, in-patient and voluntary mental health settings. 
They underwent a comprehensive psychiatric interview including the Schedule 
for Clinical Assessment in Neuropsychiatry (Wing et al., 1990) as well as 
measures of current medication, psychotic and affective symptoms and 
demographic details. Clinical ratings and best estimate lifetime diagnosis (based 
on DSM-IV criteria (American Psychiatric Association, 1994)) were made based 
upon a review of interviews and case notes.  
 
4.3.2 Cardiff COGS CNV calling / quality control 
 
CNVs in Cardiff COGS were called as part of a larger batch including CLOZUK and 
controls by Professor George Kirov and Doctor Elliott Rees as described in (Kirov 
et al., 2014). A brief description of the genotyping and CNV calling performed by 
Kirov et al (2014) follows. 
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Genotyping of schizophrenia cases in CardiffCOGS was performed at the Broad 
Institute, Cambridge, Massachusetts on the HumanOmniExpressExome-8v1 
(Combo array). These samples were analysed in tandem with other 
schizophrenia samples genotyped at the Broad Institute and controls obtained 
from the database of Genotypes and Phenotypes (dbGaP).  
 
Case and control datasets were independently analysed to overcome possible 
batch effects. Raw intensity data from each case/control batch was processed 
using the Illumina Genome Studio software (v2011.1).  This generated the log R 
ratios (LRR) and B-allele frequencies (BAF) required for CNV calling.  CNVs were 
called using the PennCNV (http://www.openbioinformatics.org/penncnv/) 
algorithm following the standard protocol adjusting for GC content.  As some of 
the cases and controls were genotyped on different Illumina arrays, CNVs were 
called using 520,766 probes common to all arrays used.  Sample level quality 
control was performed using the following QC metrics generated by PennCNV: 
BAF drift, LRR standard deviation, wave factor and total number of CNVs called 
per individual.  Samples were excluded from all subsequent analyses if for any 
one of these metrics they represented an outlier in their source dataset. 
Duplicate samples were checked using identity by descent analysis in PLINK 
(Purcell et al., 2007). Where duplicates were identified, the sample with the 
better QC was retained.  
 
All CNVs underwent the following QC filtering. Firstly, raw CNVs in the same 
sample were joined when the distance between them was less than 50% of their 
combined length. CNVs were subsequently excluded if they had low probe 
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coverage (<10), had a length of 10kb or less, overlapped with low copy repeats 
by more than 50% of their length, or had a probe density (calculated by dividing 
the size of the CNV by the number of probes covering it) greater than 20K. CNV 
loci with a frequency greater than 1% were filtered out using PLINK. In total, 
rare CNVs were identified in 430 cases in Cardiff COGS. 
 
The remaining rare CNVs underwent additional QC using an in silico median Z-
score outlier method (Kirov et al., 2012). This method standardises SNP probe 
intensities per individual across all probes, then standardises the intensity of 
each probe across all individuals. These QC stages help to reduce noise caused by 
natural fluctuations in probe intensity. The median Z-score for standardized 
probe intensities within a potential CNV region is used to identify real deletions 
and duplications, which are represented as outliers in the median Z-score 
distribution. Z-score histograms of CNVs with extreme Z-Scores (between -6 and 
-4, 2 and 4) were inspected manually using Illumina GenomeStudio v2011.1 
software. 
 
4.3.3 Cognitive Phenotype 
Patients completed the MATRICS cognitive battery (Kern et al., 2008; 
Nuechterlein et al., 2008), which measures ability on 10 separate tests 
encompassing 7 cognitive domains (attention/vigilance, reasoning/problem 
solving, speed of processing, social cognition, verbal learning/memory, visual 
learning/memory and working memory). Table 4.1 contains correlations 
between the individual MATRICS domains and the MATRICS composite score.  
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MATRICS Domain 
Correlation with 
MATRICS Composite 
Score 
 
P 
Composite 1 N/A 
Attention/Vigilance 0.77 <0.01 
Reasoning/Problem 
Solving 
0.72 <0.01 
Social Cognition 0.55 <0.01 
Speed of Processing 0.84 <0.01 
Verbal Learning 0.80 <0.01 
Visual Learning 0.80 <0.01 
Working Memory 0.84 <0.01 
Table 4-1 - Correlations between MATRICS composite score and individual domains 
 
In total, 483 individuals had complete data for the MATRICS composite score and 
CNV call information.  
 
4.3.4 Candidate pathways 
The 155 pathways used in this analysis were previously outlined in Chapter 3, 
with definitions of all gene-sets available in Appendix B. These pathways are a 
priori more likely to be enriched for genes influencing general cognitive ability. 
For each pathway, the translational start and end of genes were identified using 
hg19 (NCBI Build 37) human reference gene coordinates. All pseudo-genes were 
removed. CNVs were classed as hitting a gene if at least one base pair overlapped 
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between them. For each proband, the total number of genes hit was calculated by 
summing the number of genes hit for each CNV. 
 
4.3.5 Analyses 
4.3.5.1 Neuropsychiatric CNVs and their association with general cognitive ability 
in schizophrenia cases 
 
CNVs were denoted as neuropsychiatric if they showed prior association with 
schizophrenia, autism, intellectual disability or other congenital malformations 
(Kaminsky et al., 2011; Girirajan et al., 2012) (see Appendix F for list of 
neuropsychiatric CNVs considered pathogenic).   
 
Analyses were performed using a linear regression model. The MATRICS 
composite score was regressed against a binary variable that denoted whether a 
proband had a known neuropsychiatric CNV (n=11) or not (n=472). Individuals 
were included in the non-neuropsychiatric CNV group if they either had no CNVs 
that passed QC, or had no neuropsychiatric CNVs called. Age was included as a 
covariate within the regression model.  A permutation approach was used to 
generate an empirical p-value. The MATRICS composite score was permuted 
10,000 times, and simulated regression p-values for neuropsychiatric CNV status 
were compared against the observed p-value.  
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4.3.5.2 Effect of CNV length and number of genes hit on general cognitive ability 
To assess the contribution of small (between 15-100kb) and large (>100kb) 
CNVs upon the MATRICS composite score, a number of nested linear regression 
models were performed in R : 
 
Model 1: MATRICS composite score ~ Age   
 
Model 2: MATRICS composite score ~ Total Genes Hit (>100kb) + Age 
 
Model 3: MATRICS composite score ~ Total CNV Length (>100kb) + Total Genes 
Hit (>100kb) + Age 
 
Model 4: MATRICS composite score ~ Total Genes Hit (15-100kb) + Age 
 
Model 5: MATRICS composite score ~ Total CNV Length (15-100kb) + Total 
Genes Hit (15-100kb) + Age 
 
Model 6: MATRICS composite score ~ Total CNV Length (>100kb) + Total Genes 
Hit (>100kb) + Total CNV Length (between 15-100kb) + Total Genes Hit 
(between 15-100kb) + Age 
 
Models 2 and 4 show whether the addition of number of genes hit by large and 
small CNVs respectively are associated with the MATRICS composite score. 
Models 3 and 5 show whether total CNV length of large and small CNVs is also 
associated with the MATRICS composite score in addition to number of genes hit. 
This shows whether the addition of total CNV length explains additional variance 
of the MATRICS composite score in addition to the other variables. Model 6 uses 
CNV burden terms from both large and small CNVs. 
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4.3.5.3 Genes hit by CNVs in Candidate Pathways and their Association with the 
MATRICS composite score 
 
Two linear models were used to test the association between genes hit by CNVs 
in candidate pathways and general cognitive ability: 
 
Model 7: Composite ~ Age + Total CNV Length + Number of genes hit (not in 
pathway)   
 
Model 8: Composite ~ Total CNV Length + Age + Number of genes hit (not in 
pathway) + Number of genes hit (in pathway) 
 
An ANOVA comparison of these two models informs whether the addition of 
number of pathway genes significantly improves the model fit.  
 
A permutation approach was used to correct for the number of pathways tested. 
First, the MATRICS composite score was permuted across all individuals. ANOVA 
p-values comparing models 7 and 8 were obtained for each pathway, and the 
lowest p-value was retained. This was permuted 10,000 times. The corrected p-
value represents the number of times the original ANOVA p-value for a pathway 
was less than the lowest permuted p-value across all pathways.  
 
4.4 Results 
4.4.1 Known neuropsychiatric CNVs and their association with general 
cognitive ability 
12 schizophrenia cases in Cardiff COGS had at least one neuropsychiatric CNV 
across 10 loci (Table 4.2).   
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N 
Cases 
Loci Chromosome Start End Type CNV 
Type 
1 1q21.1 1 146501348 147820342 Duplication P 
1 NRXN1 2 50793781 50924358 Deletion P/SCZ* 
1 WBS 7 72722981 74138603 Duplication P/SCZ* 
2 15q11.2 15 22750305 23226254 Deletion P/SCZ* 
1 15q11.2 15 22678398 23226254 Deletion P/SCZ* 
1 16p11.2 
distal 
16 28825605 29028905 Duplication 
P 
1 16p11.2 16 29672982 30192561 Duplication P/SCZ* 
1 16p12.1 16 21949122 22409463 Deletion P 
1 17q12 17 34815551 36223325 Duplication P 
2 22q11.21 22 18896464 21463730 Deletion P/SCZ* 
Table -2 - Rare CNVs in Cardiff COGS with prior association to 
schizophrenia/autism/intellectual disability. P=Pathogenic (Kamisky et al,2011; Girirajan 
et al, 2012), SCZ=Schizophrenia CNV (Rees et al, 2014)  
 
One neuropsychiatric CNV carrier with a duplication at 16p11.2 was unable to 
complete the majority of the MATRICS tests, meaning a composite score could 
not be calculated in this individual. MATRICS composite scores were available 
for 11 probands with a neuropsychiatric CNV, and 472 patients with no known 
neuropsychiatric CNVs. A distribution of the composite z-scores in cases with 
and without a neuropsychiatric CNV can be found in Figure 4.1.   
 
The z-score difference between the composite score of cases in neuropsychiatric 
and non-neuropsychiatric CNV groups was 0.839 standard deviations, with the 
neuropsychiatric CNV group displaying lower cognitive performance. The 
regression model showed neuropsychiatric CNV status was a significant term 
(PEmp=0.0174), and explained 1% of the MATRICS composite score variance. 
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Figure 4.1 - Distribution of MATRICS composite z-scores in schizophrenia cases with and without a neuropsychiatric CNV
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4.4.2 Effect of CNV length and number of genes hit on general cognitive 
ability 
 
Summary information regarding the total length of rare CNVs can be found in 
table 4.2.  
 
 15-100kb > 100kb 
N Individuals 165 281 
Median Total Length (kb) 68.3 2998 
Min/Max Total Length  15.6/ 281.7 102/10222.1 
Table 4-3 - Summary information for individuals with rare CNV in Cardiff COGS 
 
Several models were used to assess the contribution of total CNV length and 
number of genes hit in respect to general cognitive ability. The first model was 
used as a baseline, simply investigating the effect of age upon general cognitive 
ability. Age was significantly associated with the MATRICS composite score 
(p=3.78E-11) and explained 10.6% of the variance.  
 
Models 2 and 3 investigated whether number of genes hit and total CNV length in 
large (>100kb) CNVs were associated with the MATRICS composite score 
separately. In model 2, an increased number of genes hit was associated with a 
lower composite score (p=0.012), explaining an additional 1.5% of the variance 
in addition to age. Model 3 added a term for total CNV length. The total number 
of genes hit remained significant (p=0.032), however total length of the CNV was 
not associated with composite performance (p=0.305). 
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Models 4 and 5 investigated whether number of genes hit and total CNV length 
for small (15-100kb) CNVs were associated with the MATRICS composite score 
separately. Model 4 showed the number of genes hit by small CNVs was not 
significantly predictive of the composite score (p=0.245). Model 5 used an 
additional term of CNV length. Neither number of genes hit (p=0.499) or total 
length of small CNVs (p=0.695) were associated with the MATRICS composite 
score.  
 
Finally, model 6 used terms for total genes hit and total CNV length for both 
small and large CNVs together. Other than age, the total number of genes hit by 
CNVs greater than 100kb was the only significant term in the model (p=0.029). 
 
Further analyses were performed separately for CNV deletions and duplications 
using the equivalent models described above. 
 
4.4.2.1 Deletions 
Summary information regarding the total length of rare CNV deletions can be 
found in table 4.3.  
 
 15-100kb > 100kb 
N Individuals 92 104 
Median Total Length (kb) 55.2 179.1 
Min/Max Total Length (kb) 15.6/237.8 102.1/6022.2 
Table 4-4 - Summary information for individuals with CNV deletions in Cardiff COGS 
 
Models 2 and 3 investigated whether number of genes hit and total CNV length in 
large (>100kb) CNV deletions were associated with the MATRICS composite 
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score. In model 2, an increased number of genes hit by deletions were associated 
with a lower composite score (p=0.037), explaining an additional 2.5% of the 
variance in addition to age. Model 3 added the additional variable CNV length. 
The total number of genes hit in model 3 became less strongly associated with 
the addition of CNV length in the model (p=0.065). Total length of large CNV 
deletions was not associated with cognition (p=0.466). 
 
Models 4 and 5 investigated whether number of genes hit by deletions and total 
length of small (15-100kb) CNV deletions were associated with the MATRICS 
composite score separately. Model 4 showed the number of genes hit by small 
CNVs was not significantly predictive of the composite score (p=0.453). Model 5 
used an additional term of CNV length. Neither number of genes hit (p=0.352) 
nor total length of small CNV deletions (p=0.579) were associated with the 
MATRICS composite score.  
 
Model 6 used terms for total genes hit and total CNV length for both small and 
large CNV deletions together. The total number of genes hit by CNV deletions 
greater than 100kb was associated at a trend level (p=0.059), but no other 
measure of CNV burden was associated with the MATRICS composite score.   
 
 
4.4.2.2 Duplications 
Summary information regarding the total length of rare CNV duplications can be 
found in table 4.4.  
 
 15-100kb > 100kb 
N Individuals 73 177 
Median Total Length (kb) 54 315.1 
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Min/Max Total Length (kb) 17/129 104.2/10222.1 
Table 4-5 - Summary information for individuals with CNV duplications in Cardiff COGS 
 
Models 2 and 3 investigated whether number of genes hit and total CNV length in 
large (>100kb) CNV duplications were associated with the MATRICS composite 
score separately. In model 2, an increased number of genes hit by duplications 
were associated at a trend level with a lower composite score (p=0.063), 
explaining an additional 1.6% of the variance in addition to age. Model 3 added 
total CNV length to the model. Neither total number of genes hit (p=0.128) nor 
total length of large CNV duplications were significantly associated with the 
MATRICS composite score (p=0.450). 
 
Models 4 and 5 investigated whether number of genes hit and total CNV length in 
small (15-100kb) CNV duplications were associated with the MATRICS 
composite score. Model 4 showed the number of genes hit by small CNVs was not 
significantly predictive of the composite score (p=0.774). Model 5 used an 
additional term of CNV length. Neither number of genes hit (p=0.184) or total 
length of small CNVs (p=0.131) were associated with the MATRICS composite 
score.  
 
4.4.3 CNV Pathway Results 
Pathway analyses were restricted to genes hit by large CNVs greater than 100kb, 
as these previously showed the greatest association with the MATRICS 
composite score. Linear regression models were used to assess whether the 
addition of total number of genes hit in each pathway significantly improved 
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model fit for association with the MATRICS composite score, compared to a 
model with age, total CNV length and total number of genes hit (not in pathway).   
  
85 pathways contained at least one hit by a rare CNV. An ANOVA was performed 
comparing models with and without the inclusion of number of pathway genes 
hit. No significant improvement over the baseline model was observed for any 
pathway, either before or after correction for multiple testing (complete results 
can be found in Appendix G). 
 
4.5 Discussion 
4.5.1 Known neuropsychiatric CNVs and their association with general 
cognitive ability in schizophrenia cases 
 
Individuals carrying rare CNVs at a small number of well-supported loci have a 
substantially increased risk of developing schizophrenia, autism and intellectual 
disability (Malhotra & Sebat, 2012; Rees et al., 2014b). In addition, these risk 
CNVs also contribute to cognitive ability in apparently healthy individuals 
(Stefansson et al., 2014).  However, no previous study has investigated whether 
schizophrenia cases carrying a neuropsychiatric CNV have greater deficits in 
general cognitive ability compared to other schizophrenia cases.  
 
The first analysis in this chapter investigated the MATRICS composite score, a 
measure of general cognitive ability, with respect to whether a patient carried a 
neuropsychiatric CNV or not. We showed that schizophrenia cases with risk 
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CNVs have a considerable decreases in general cognitive ability, approximately 
one standard deviation below other schizophrenia cases. Furthermore, one 
proband with a CNV at 16p11.2 was not included in the analysis because they 
were too cognitively impaired to complete the MATRICS assessment. Although 
this is only one individual, it nonetheless corroborates the finding that 
schizophrenia cases with well-supported risk CNVs represent a subgroup with 
significant cognitive impairment. However, we recognise the number of 
individuals with neuropsychiatric CNVs is low (n=11), and replication in an 
independent sample is required to provide greater support to these findings.  
 
There are several possible interpretations of these findings. First, biological 
pathways underlying general cognitive ability are “hit” twice in patients with 
schizophrenia, once through the effects of neuropsychiatric CNVs, and secondly 
via disease processes relating to schizophrenia. However, this is speculative as it 
is currently unknown whether genes in these CNVs contribute separately or in 
tandem regarding risk of psychiatric illness and general cognitive ability.  
 
A second interpretation is that neuropsychiatric CNVs may increase the disease 
severity of schizophrenia, which in turn is associated with lower general 
cognitive ability in patients. There is limited evidence suggesting 
neuropsychiatric CNVs are associated with early onset schizophrenia (Ahn et al., 
2014), and carriers of some neuropsychiatric CNVs such as 22q11.2 deletions 
report a higher frequency of psychotic experiences in childhood and adolescence 
(Baker & Skuse, 2005). Early onset of disease is predictive of greater disease 
severity and cognitive impairment (Haas & Sweeney, 1992; Frangou, 2010). 
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However, adding psychosis age of onset as a covariate within the model did not 
change the association between the MATRICS composite score and 
neuropsychiatric CNV status.   
 
However, not all patients with risk CNVs performed poorly. One individual with a 
duplication at 17q.12 performed approximately 1 standard deviation below 
controls, showing less impairment relative to other schizophrenia cases within 
the sample. Duplications at 17q.12 are associated with a range of phenotypes 
including autism, developmental delay, seizures and other non-psychiatric 
conditions including diabetes and problems with renal functioning (Bierhals et 
al., 2013). Conversely, a small proportion of patients with 17q.12 duplications 
have no discernable neuropsychiatric abnormalities (Faguer et al., 2011). Taken 
together with our findings this suggests that duplications at this locus may not be 
fully penetrant for cognitive impairment, although the reasons for this are 
currently unclear.  
 
Additional caution is warranted regarding the assumption that carriers of the 
same neuropsychiatric CNV have similar cognitive abilities. One example relates 
to the general cognitive ability of three probands with deletions at 15q11.2. One 
carrier was 1.3 standard deviations below the control mean, with two other 
carriers performing over 3.5 standard deviations lower. Interestingly, two cases 
shared the same CNV breakpoints at 15q11.2, with one showing substantial 
impairment, whilst the other was over two standard deviations higher. It is to be 
expected that environmental or other genetic factors contribute to differences in 
cognitive ability beyond the effects of neuropsychiatric CNVs and these factors 
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likely explain the observed variation in cognition between individuals with the 
same CNV.  
 
The distribution of composite scores in patients with and without 
neuropsychiatric also CNVs overlapped. This suggests patients with 
neuropsychiatric CNVs do not represent a distinct subgroup based upon general 
cognitive ability alone. 
 
Whilst understanding the neurobiology of CNVs and their functional relevance to 
disease is important, these findings may also be important for clinical settings. If 
patients with pathogenic CNVs can be identified through directed testing, as 
suggested by Rees et al (2014), these individuals may particularly benefit from 
intervention strategies or future pharmacological treatments that target 
cognitive symptoms. 
 
4.5.2 Rare CNV burden, candidate pathways and their associations with 
general cognitive ability in schizophrenia cases 
 
Measures of CNV burden were also investigated with respect to general cognitive 
ability in schizophrenia cases. CNVs were classified according to whether they 
were small (between 15-100kb) or large (>100kb). Using a series of nested 
linear regression models, the cumulative length and the number of genes hit 
were used as predictors of the MATRICS composite score. Lower general 
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cognitive ability was associated with a greater number of genes hit by large 
CNVs, even after covarying for total CNV length.  
 
The correlation between the length and number of genes hit in CNVs greater 
than 100kb was high (r=0.855), showing these measures of CNV burden are 
strongly related. However, the number of genes hit is a more direct measure of 
potential biological impact, and CNV length may incorporate more noise by 
including regions with little or no biological consequence.   
 
Similar, but weaker trends emerge when looking at deletions and duplications 
separately. An increase in the number of genes hit by large deletions was 
associated at a trend level after the addition of total CNV length, and was 
marginally stronger at predicting the MATRICS composite score compared to 
duplications. Conversely, neither length of large deletions or duplications was 
significant predictors of the composite score, mirroring the findings of the 
combined analysis. In addition, neither length nor number of genes hit by small 
deletions was associated with general cognitive ability.  
 
When comparing these findings with similar studies a number of differences 
emerge. Firstly, Yeo and colleagues (2011) found the cumulative length of 
deleterious CNVs were predictive of IQ in 74 patients with alcohol dependence. 
In addition, Martin and colleagues (2014) reported the cumulative length of CNV 
deletions were associated with lower full scale IQ, which is more strongly driven 
verbal, rather than performance IQ in 78 schizophrenia cases. Finally, Yeo et al 
(2013) found total number of CNV deletions was a better predictor of general 
cognitive ability compared to CNV length in 79 schizophrenia cases.  
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Although these studies differed regarding their choice of measure of CNV 
burden, the direction of effect pertaining to their association with cognitive 
ability was consistent. However, these studies are in small numbers of 
schizophrenia cases and have not been universally replicated. One study found 
no association between number of CNVs, or number of genes hit in deletions, 
duplications or combined with IQ in 350 schizophrenia cases and 322 healthy 
controls (van Scheltinga et al., 2013). Furthermore, no interaction was observed 
between disease status and IQ for any CNV burden variable. There are several 
differences between this study and previous studies. First van Scheltinga and 
colleagues assigned to a CNV if they were within a 50kb border. In addition, they 
used CNVs called from their previous study (Buizer-Voskamp et al., 2011) using 
both common and rare CNVs. van Scheltinga et al (2013) did not provide details 
of a CNV population frequency cut off. If they included common CNVs that are 
not considered to contribute substantially to disease (Conrad et al., 2010) this 
may have masked associations with cognition from rare CNVs.  
  
The functional impact of CNV burden is poorly defined, both regarding neural 
correlates, and biological mechanisms underlying cognitive ability. In part, this is 
because burden refers to the “load”, rather than specific genes. This means it will 
be difficult to extract biological meaning because the functional effects of CNV 
burden may relate to completely independent biological processes in different 
individuals.   
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However, a small number of studies have investigated CNV burden with respect 
to association with structural brain changes. One study in 79 schizophrenia cases 
and 110 controls found increases in the number of rare (frequency < 3%) 
deletions were associated with larger ventricular volume in schizophrenia cases, 
however no such effect was observed in controls (Yeo et al., 2013).  
 
A separate study has shown deletion burden is associated with numerous 
neuroanatomical changes (Martin et al., 2014). Increased grey matter in the 
striatum and superior temporal gyrus, and increased white matter in the corpus 
callosum were associated with larger cumulative length of rare CNVs (Martin et 
al., 2014). In addition, decreased functional connectivity between the prefrontal 
and dorsolateral prefrontal cortex (DLPFC), DLPFC and putamen, and DLPFC and 
the associative visual cortex was associated with increased cumulative deletion 
length. However, whilst this study did correct for multiple comparisons, it was 
nonetheless in relatively modest schizophrenia sample size (n=33). Nonetheless, 
disruption of prefrontal networks affects multiple cognitive phenotypes in 
schizophrenia including working memory (Wheeler et al., 2014), speed of 
processing (Woodward et al., 2013) and social cognition (Ursu et al., 2011). 
These findings may provide  
 
However, other studies have reported no associations between whole brain 
volume, grey or white matter volume and CNV burden measured by the number 
of genes hit by deletions, duplications or combined in patients and controls 
(Terwisscha van Scheltinga et al., 2012), and the literature remains inconclusive. 
 
 180 
There is limited evidence as to the effect of specific neuropsychiatric CNVs on 
brain structure. Steffanson and colleagues (2014) used structural magnetic 
resonance imaging to investigate differences between healthy carriers of 
15q11.2 deletions (n=15) or duplications (n=55) and non-carrier controls 
(n=201). They found changes in the grey matter volume in the perigenual 
anterior cingulate cortex and the left insula. Interestingly, individuals who carry 
the deletion have lower grey matter volume compared to controls, whilst the 
duplication is associated with a reciprocal increase in grey matter volume of the 
same order of magnitude. These reciprocal differences extend to changes for 
white matter volume of temporal lobes, whereby carriers of deletions have lower 
densities. Finally, carriers of the duplication have decreased white matter 
volume in the corpus colosum, whereas carriers of deletions have increased 
white mater volumes. Although these results are from a single study, and for one 
CNV locus, the opposite effects on brain volume metrics observed are intriguing 
and raise confidence that they may point to biological insights that are applicable 
to other CNVs.  
 
Unfortunately, the results from pathway analyses in the present, and previous 
studies have been unable to identify specific biological processes. We found no 
evidence of association between general cognitive ability and the number of 
genes hit in 85 candidate pathways. Furthermore, a previous study failed to 
identify an association between brain-enriched genes hit by CNV deletions and 
performance/verbal and full scale IQ in 386 schizophrenia cases (Merikangas et 
al., 2014). However, both our study and that of Merikangas and colleagues 
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(Merikangas et al., 2014) were conducted in relatively small samples, and likely 
to be underpowered for such pathway analyses.  
 
4.5.3 Limitations 
 
A first limitation is that of sample size. To date, studies investigating associations 
between CNV burden and cognition in schizophrenia cases have typically used 
relatively small samples. Whilst the present study was conducted in one of the 
largest schizophrenic case samples with cognitive data, it nonetheless remains a 
relatively small sample investigating rare events.  
 
A second potential limitation is that CNVs were required to hit at least one base 
pair of the gene. Given that CNVs do not need to physically hit the gene to result 
in changes to gene expression, it is possible that CNVs hitting promoter regions 
that affect transcription, but do not hit the gene directly, may also contribute to 
gene expression and affect general cognitive ability.  
 
4.5.4 Conclusion 
We investigated the association between rare CNVs and general cognitive ability 
in a schizophrenia case sample. We found cases with a known pathogenic CNV 
performed approximately 1 standard deviation below other cases on the 
MATRICS composite score, a measure of generalised cognitive ability. In 
addition, we identified that the number of genes hit by large (>100kb), rare 
(<1%) CNVs were associated with lower general cognitive ability. We failed to 
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detect specific associations with CNV deletions identified in previous studies, 
although the number of genes hit by deletions approached nominal levels of 
significance. Finally, there was no evidence of association between the number of 
genes hit in candidate pathways and general cognitive ability. These findings are 
consistent with previous research investigating associations between CNVs 
hitting brain-expressed genes and general cognitive ability. However, given the 
small samples size across both studies, the lack of association with particular 
pathways likely reflects a lack of power.  
 
Taken together, these findings suggest rare CNVs contribute to the generalised 
cognitive deficit in schizophrenia, although larger samples are required to 
identify the enrichment of gene-sets that could become targets for future 
pharmacological intervention to improve general cognitive ability in patients.  
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5 General Discussion 
5.1 Overview 
Patients with schizophrenia have substantial impairments in cognitive 
functioning (Heinrichs & Zakzanis, 1998), a substantial proportion of which is 
explained by a generalised cognitive factor (Dickinson et al., 2008). Importantly, 
current treatments do not significantly impact these cognitive impairments. 
Thus, the development of pharmacological targets that improve cognitive 
functioning in patients is seen as being a priority (Buchanan et al., 2005).  
Research examining the genetic relationships between schizophrenia and 
cognitive ability, and therefore provide insight about the underlying biology, 
offers potential to inform therapeutic development. The purpose of this thesis 
was to examine the association between both common and rare schizophrenia 
genetic variation and cognitive ability in schizophrenia cases and healthy 
controls. This chapter will present a summary of the rationale, main findings and 
interpretation of the three experimental chapters, as well as suggestions for 
further work and conclusions.  
 
5.2 Polygenic risk of schizophrenia and its association with cognitive 
ability in healthy individuals 
The studies presented in Chapter 2 were motivated by the hypothesis that there 
is common underlying biology to schizophrenia and cognition in the population, 
hence increased polygenic risk of schizophrenia would be associated with lower 
general cognitive ability in healthy individuals. During the course of the thesis 
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other groups have confirmed the polygenic overlap between schizophrenia and 
general cognitive ability (Lencz et al., 2014) but we sought to expand on these 
findings by using up to date and more powerful schizophrenia datasets, 
examining the question in relation to more specific domains of cognition and in 
more homogeneous populations. As well as pointing to shared biological 
underpinnings, within this context findings can provide evidence about whether 
specific traits, such as cognitive domains are suitable endophenotypic candidates 
for psychiatric disorders such as schizophrenia and bipolar disorder.  
 
Chapter 2 consisted of three related studies. The first investigated whether 
polygenic risk of schizophrenia predicted performance on tests of cognition in a 
well-characterised and homogeneous German sample and separately in a 
developmental study cohort of children aged 8. The cognitive tests/domains 
examined were those affected in schizophrenia including attention, processing 
speed, social cognition, reasoning/problem solving, verbal learning and working 
memory, as well as performance, verbal and full scale IQ.  
 
No study to date has investigated the association between polygenic risk of 
bipolar disorder and cognitive ability. The second study investigated whether 
polygenic risk of bipolar disorder predicted performance on the same cognitive 
domains and IQ scores described above. This approach has the potential to serve 
as a comparison for the schizophrenia/cognition polygenic analysis as well as 
further elucidate the nature of genetic overlap between bipolar disorder and 
cognition. 
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Finally, individuals with schizophrenia and bipolar disorder show differences in 
cognitive impairment. Differences in their common genetic architecture may 
therefore contribute to cognitive ability. Using GWAS summary statistics from a 
schizophrenia (case) versus bipolar disorder (control) analysis, the third study 
investigated whether polygenic risk scores (where higher scores represent 
increased polygenic risk of schizophrenia relative to bipolar disorder) were 
associated with the cognitive domains and IQ scores described above.  
 
5.2.1 Schizophrenia polygenic risk and their associations with cognitive 
ability 
Three schizophrenia discovery samples of increasing size were used; CLOZUK, 
PGC1 and PGC2 (Schizophrenia PGC, 2011; Schizophrenia Working Group of the 
Psychiatric Genetics Consortium, 2014). Two independent cognition samples 
were available. First, approximately 5500 children with cognitive data at age 8 
were used from ALSPAC a large longitudinal cohort comprised of children born 
in the 1990s in Avon (Golding et al., 2001),. A second independent sample 
comprised of 936 healthy adults of German descent was also used (Rujescu et al., 
2003).    
 
In ALSPAC, increased polygenic risk of schizophrenia was significantly 
associated with lower performance IQ when training across all schizophrenia 
discovery datasets at multiple training thresholds. The best powered analysis 
used the schizophrenia PGC2 discovery sample and ALSPAC as the target 
cognition sample. Polygenic risk of schizophrenia explained approximately 
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0.34% of the variance for performance IQ, the strongest associated cognition 
measure. Using the schizophrenia PGC1 discovery set, increased schizophrenia 
polygenic risk was associated with lower performance IQ in an independent 
adult German sample, explaining 0.56% of performance IQ variance.  
 
The relationship between schizophrenia genetic risk and performance IQ is 
supported from other analyses within our group (GCTA and polygenic analyses 
were completed by myself and Katherine Tansey and co-led by James Walters 
and Stan Zammit). We showed polygenic performance IQ scores are the 
strongest predictor of schizophrenia liability out of all the cognitive measures 
previously described (Hubbard et al, submitted). Furthermore, bivariate GCTA 
analyses show performance IQ has the strongest genetic correlation with 
schizophrenia (rg=-0.38), more than verbal (rg=-0.07) and full scale (rg=-0.20) IQ. 
These findings are in keeping with phenotypic associations between 
performance IQ and schizophrenia. A meta-analysis has shown effect sizes 
deficits are larger for performance IQ (d=1.46) compared to verbal (d=0.98) and 
full scale IQ (d=1.24) (Heinrichs & Zakzanis, 1998) and since been replicated in a 
further meta-analysis (Dickinson et al., 2013b). Overall, these results indicate 
performance IQ may be a useful endophenotype for future studies examining the 
genetic aetiology of schizophrenia. 
 
Differences in the amount of variance explained in performance IQ by 
schizophrenia polygenic risk in ALSPAC (0.34%) and German (0.56%) samples 
were observed. These differences could be attributable to differing sample 
characteristics. Cognition was measured at different ages within the two 
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samples; in ALSPAC cognition was measured at age 8, whilst individuals within 
the German samples were aged between 20-74, with a mean age of 52 years. 
Schizophrenia polygenic risk is associated with change across the lifespan in 
healthy controls (McIntosh et al., 2013), and heritability estimates show 
cognitive ability is subject to increasingly stronger genetic influence across the 
lifespan (Deary et al., 2012). The greater proportion of variance of performance 
IQ explained in the German sample may therefore be attributable to age related 
effects. However, an alternative explanation could be that a smaller 
schizophrenia discovery sample (PGC1) was used, but perhaps more importantly 
the target German sample was nearly six times smaller compared to that of 
ALSPAC. Whilst the size of the discovery sample is important for power, 
inadequately sized target samples are unlikely to affect the accuracy of the 
estimation of polygenic overlap. Thus the smaller German target sample will lead 
to a less accurate estimate of the polygenic signal and therefore the observed 
result could be a chance finding. In this respect it would be helpful to calculate 
confidence intervals for these estimates and there are emerging approaches to 
enable such calculations, which we will be pursuing in future work (Dudbridge, 
2013).    
 
Comparing the present findings with previous studies, some important 
differences are observed. We failed to fully replicate findings from previous 
studies investigating polygenic risk of schizophrenia and cognition (Lencz et al., 
2014). The proportion of variance of total IQ explained by schizophrenia 
polygenic risk in our study (r2~0.1%) is lower than that reported by Lencz and 
colleagues (~0.5% to 1%), although they measured general cognitive ability 
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through “g”, rather than full scale IQ.  Whilst “g” and full scale IQ are both 
measures of general cognitive ability, they are derived using different methods, 
which could partially explain the differences between the two studies. Lencz and 
colleagues also used a heterogeneous cognition sample comprised of multiple 
nationalities. Furthermore, they used PGC1 as a discovery dataset, which 
contains substantially less individuals compared to PGC2. Better estimates of 
SNP effect sizes in PGC2 may have resulted in a more accurate estimation of 
polygenic overlap between schizophrenia and cognition, and may indicate a 
more modest overlap than previously stated (Lencz et al., 2014)  
 
The negative findings from this analysis are also informative, with schizophrenia 
polygenic risk showing no association with problem solving, social cognition, 
verbal learning, working memory and verbal IQ even at trend levels. These 
findings are perhaps surprising given that tests measuring cognitive domains of 
attention, working memory and verbal memory are moderately heritable in 
families containing at least one schizophrenia proband (Greenwood et al., 2007). 
Other genetic factors (rare variants not tagged by polygene score or unidentified 
factors), gene-gene or gene-environmental interactions may therefore contribute 
to performance on specific cognitive domains.  
 
5.2.2 Polygenic risk of bipolar disorder and their associations with 
cognitive ability 
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The second analysis in chapter 2 investigated associations between polygenic 
risk of bipolar disorder and cognitive ability within ALSPAC. No robust 
associations were identified with any cognitive domain or IQ score, although 
increased polygenic risk of bipolar disorder was associated with better social 
cognition at the 0.0001 training threshold (p=0.039, %r2=0.08), with trends 
emerging (P<0.07) in the same direction of effect for three other training 
thresholds. A weak association was observed between bipolar polygenic risk and 
processing speed at a training threshold of 0.1 (p=0.012, %r2=0.11), however 
this likely represents a false positive association given none of the other training 
thresholds were nominally significant.  
 
This indicates polygenic risk of bipolar disorder is not associated with cognitive 
ability in healthy individuals. However, several points of consideration are 
warranted. Cognitive tests in ALSPAC were selected a-priori based upon their 
similarity with the MATRICS domains (Niarchou et al., 2013). These domains 
show the greatest impairment in schizophrenia cases (Kern et al., 2007) and may 
not accurately reflect cognitive deficits in bipolar disorder. Nevertheless, several 
studies have investigated the cognitive performance of bipolar cases using the 
MATRICS cognitive battery. Bipolar cases show impairment across the majority 
of the MATRICS domains, albeit with lower effect sizes when compared with 
schizophrenia cases (Burdick et al., 2011).  
 
Other research has indicated bipolar risk is associated with both increased and 
decreased cognitive ability (MacCabe et al., 2010).  They investigated the 
association between school performance at age 16 and risk of bipolar disorder in 
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a large population based study in Sweden. They showed superior school 
performance was associated with the great risk of developing bipolar disorder, 
although individuals with poorer performance were also at increased risk.  
 
The findings from these studies are indicative that cognitive phenotypes in 
bipolar disorder are heterogeneous, and bipolar risk is associated with both 
increases and decreases in cognitive performance. These factors add a level of 
complexity regarding bipolar genetic risk and their associations with cognitive 
ability, with implications for the present study. Specifically, if increased 
polygenic risk of bipolar disorder is associated with both higher and lower 
cognitive ability for specific cognitive domains or IQ measures, using standard 
linear regressions may be inadequate for capturing non-linear associations and 
these effects would serve to nullify any associations present when conducting 
the current analyses.   
 
5.2.3 Polygenic risk of schizophrenia versus bipolar disorder and their 
associations with cognitive ability 
 
The third analysis used summary statistics from a schizophrenia (case) / bipolar 
(control) GWAS (Ruderfer et al., 2014) to predict cognition in ALSPAC. Increased 
polygenic risk of schizophrenia relative to bipolar disorder was associated with 
lower verbal and full scale IQ, explaining approximately 0.27% of the variance 
for both tests.  
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One interpretation of these results relates to differences in premorbid cognitive 
between schizophrenia and bipolar cases. Zammit et al (2004) showed low 
premorbid IQ was associated with an increased risk of developing schizophrenia, 
whereas no association was observed in individuals who developed bipolar 
disorder. These findings are also substantiated through meta-analyses of 
premorbid impairment in schizophrenia and bipolar disorder. Schizophrenia 
cases perform approximately half a standard deviation compared to controls 
relating to premorbid IQ (Woodberry et al., 2008), whereas no differences are 
found between bipolar cases and controls (Bora et al., 2009). Given that 
cognitive deficits in schizophrenia can be detected as early as age 4 (Cannon et 
al., 2000),  these results are suggestive of a neurodevelopmental origin for 
cognitive defects in schizophrenia, but not bipolar disorder. Within the context of 
the present study, differences in common genetic variation between 
schizophrenia and bipolar disorder may be related to neurodevelopmental 
processes underlying general cognitive ability.  
 
5.2.4 Methodological considerations of polygenic analyses 
The studies in this chapter had several strengths. First, we used the largest 
schizophrenia training set available to date, providing greater power than 
previous analyses. Furthermore, ALSPAC represents the single largest  
population sample to date. All individuals completed the same cognitive tests at 
the same age within a fairly homogenous geographical area, potentially reducing 
effects of population stratification.  
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The bipolar case control,  and schizophrenia (case) bipolar (control) discovery 
datasets were both modest in size in comparison with the most recent 
schizophrenia GWAS. In the bipolar analysis, increased polygenic risk of bipolar 
disorder was weakly associated with better social cognition, and to a lesser 
extent working memory. A larger bipolar training set with a comparable size to 
schizophrenia PGC2 may provide greater clarity regarding possible associations 
between polygenic risk of bipolar disorder and social cognition.   
 
Secondly, cognitive variables within ALSPAC were measured in children aged 8.  
The availability of data restricted the current analyses to a single cross sectional 
time point, and the use of repeated measures of cognition would help minimize 
measurement error, although the fact we used cognitive data measured at 
equivalent ages can also be considered a strength.  
 
Third, the individual cognitive tests selected were based upon their relatedness 
to the MATRICS domains. They represent cognitive domains most affected in 
schizophrenia cases, and thus are a priori more likely to be influenced by 
schizophrenia genetic risk. However, it is possible the lack of association with 
any particular cognitive sub-domain is because the selected tests do not 
adequately capture aspects of cognition that are most relevant to the aetiology of 
schizophrenia. 
 
 193 
5.2.5 Polygenic summary 
Schizophrenia, bipolar and schizophrenia versus bipolar polygenic scores were 
used to predict performance on tests of cognitive domains affected in 
schizophrenia and performance, verbal and full scale IQ.  
 
Increased polygenic risk of schizophrenia was associated with decreased 
performance IQ using three schizophrenia discovery datasets, across multiple 
training thresholds and in two target samples. For the most significant 
associations, schizophrenia polygenic risk predicted 0.34% of performance IQ 
variance in ALSPAC, and 0.59% of the variance in the German sample.  
 
Bipolar polygenic risk was not robustly associated with any single cognitive 
domain or IQ measure in ALSPAC.  
 
Polygenic risk of schizophrenia versus bipolar disorder was predictive of verbal 
IQ and full scale IQ. For the most significant associations, increased polygenic 
risk predicted 0.27% of the variance of full scale IQ, and 0.27% of verbal IQ in 
ALSPAC.  
 
These results provide the most detailed investigation of schizophrenia and 
bipolar polygenic risk with respect to cognition in healthy individuals to date. 
Whilst the proportion of cognitive variance explained by polygenic risk scores 
was modest, it nonetheless provided additional insight into the common genetic 
overlap between neuropsychiatric disorders and cognitive ability. In addition, 
selecting cognitive tests with the strongest genetic association with 
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schizophrenia and bipolar disorder are required to maximise the benefit from 
future endophenotypic studies.  
 
5.3 Functional Pathways Underlying Cognitive Phenotypes in 
Schizophrenia and Control Populations 
The studies presented in Chapter 3 used two methods to investigate the 
association of 155 gene-sets with cognitive ability in schizophrenia cases and 
healthy controls. The gene-sets were members of six overarching biological 
categories relating to behaviour/cognition, cellular physiology, cellular 
morphology, development, region tract morphology and subcellular neuronal. 
The first five categories contained gene-sets that were a subset of the full MGI 
pathways. Subcellular neuronal pathways were derived from proteomic studies 
in rodents and humans. Pathways within these categories are a priori more likely 
to be enriched for SNPs influencing general cognitive ability.    
   
The first study applied a polygenic risk score approach to test whether 
schizophrenia polygenic pathway scores were associated with the MATRICS 
composite score in schizophrenia cases, and with performance IQ in healthy 
individuals. 
 
To our knowledge no previous study has investigated whether SNPs associated 
with general cognitive ability in schizophrenia cases show enrichment in the 
biological pathways described above.  
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The second study in this chapter used Brown’s method, a set-based test that uses 
information from all available SNPs within genes in the specified pathway. SNPs 
associated with the MATRICS composite score were tested for association with 
specific gene-sets. Rank tests were subsequently performed to test whether 
specific pathway categories showed greater association when compared against 
the remaining five categories.   
 
5.3.1 Schizophrenia polygenic pathway scores and their association with 
general cognitive ability in schizophrenia cases and performance IQ 
in healthy controls 
 
The results from Chapter 2 indicated increased polygenic risk of schizophrenia 
was associated with lower performance IQ in healthy controls. In Chapter 3, 
using a polygenic pathway approach, we tested whether polygenic risk scores in 
155 candidate pathways were associated with performance IQ in healthy 
controls, and also whether they were associated with the MATRICS composite 
score in schizophrenia cases.  
 
No polygenic pathway scores were associated with the MATRICS composite 
score in schizophrenia cases or performance IQ in healthy controls, after 
correction for multiple testing. In addition, there was no evidence suggesting 
gene-sets belonging to specific biological categories showed greater association 
with cognitive measures in cases or controls when compared to other biological 
gene-set categories. There are two possible explanations for these negative 
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findings. First, the size of our cognition samples was small (and thus there was 
insufficient variability in the polygenic risk scores) to detect associations with 
general cognitive ability. A second interpretation is that common genetic risk of 
schizophrenia does not strongly influence cognitive ability in specific pathways, 
instead exerting influence on cognitive ability via small effects across the 
genome.  
 
Some studies have used schizophrenia polygenic pathway scores for ZNF804A 
and cell adhesion molecular pathways to test for association with cognition in 
schizophrenia cases (Hargreaves et al., 2013; Nicodemus et al., 2014). 
Importantly, significant associations between polygenic pathway scores and 
cognition in these studies were typically modest (p uncorrected ~ 0.01-0.05), 
and the size of their schizophrenia cognition sample is similar to Cardiff COGS. 
Given current schizophrenia cognition target samples are small, and the strength 
of association between schizophrenia polygenic risk and cognition is modest for  
single pathways, this indicates the testing of multiple pathways in unfeasible 
until samples are adequately sized and powered to detect robust associations 
that can withstand multiple correction burdens.    
 
5.3.2 GWAS of MATRICS composite score and Brown’s test 
This study investigated whether SNPs associated with the MATRICS composite 
score in schizophrenia cases were enriched in individual gene-sets, or across 
broader biological categories.  
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No SNP reached genome wide-significance for association with the MATRICS 
composite score. Although rs10174400 in SCN2A recently reached genome-wide 
significance for association with general cognitive ability in a small 
schizophrenia cohort (Dickinson et al., 2014), this finding awaits independent 
replication. Associations between rs10174400 and the MATRICS composite 
score were not supported in the present study (p=0.749).   
 
Using Brown’s method, SNPs associated with general cognitive ability in 
schizophrenia cases were not enriched in any of the 155 pathways tested before 
correction for multiple testing. However, Brown’s p-values for individual brain 
region/fibre tract morphology pathways were significantly higher than those in 
other pathway categories. The MGI definitions of region tract morphology gene-
sets are based upon structural abnormalities of the mouse brain. There is 
perhaps a relatively sparse literature studying brain structure in relation to 
cognitive ability in schizophrenia. The largest study to date was performed by 
Andreasen et al (2011) using a longitudinal design in 202 schizophrenia cases 
and 125 healthy controls. They showed reductions in white matter in the frontal 
and temporal lobes were associated with lower attention, problem solving, 
fluency, verbal learning and working memory. However, these associations were 
weak, and subject to potential confounders including anti-psychotic medication, 
illicit drug use and smoking consumption. Within the context of the present 
study, evidence that brain region/fibre tract pathways are associated with 
general cognitive ability in schizophrenia cases requires replication in an 
independent sample. This would provide a basis for whether further work 
underlying their associations is warranted.  
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If the general cognitive deficit in schizophrenia is also highly polygenic, large 
schizophrenia cognition samples will be required to accurately estimate SNP 
effect sizes. Within the context of the present study, we were likely to be 
insufficiently powered to detect associations with general cognitive ability 
through GWAS, reducing the ability to detect associations from SNPs in specific 
gene sets. The lack of association between SNPs in the gene-sets tested is thus 
not reliable evidence against their involvement with general cognitive ability in 
schizophrenia cases. Larger studies with more accurately estimated effect sizes 
for SNPs associated with cognition would have greater power to detect whether 
specific gene-sets are implicated in the general cognitive deficit.    
 
5.3.3 Methodological considerations for pathway analyses 
 
To our knowledge, no previous studies have performed pathway analyses on a 
broad set of candidate pathways using SNPs associated with general cognitive 
ability in schizophrenia cases.  Given that pathway analyses using SNP data 
primarily use results generated from GWAS, small samples are unlikely to be 
sufficiently powered (Duncan et al., 2014) to reliably detect SNPs that are 
causally related to general cognitive ability in schizophrenia cases.  
 
Another potential limitation was that SNPs were assigned to genes only if they 
were within the transcriptional start and end sites of the gene boundary. There is 
inconsistency in the literature regarding the appropriate size of gene windows to 
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select for these types of analyses (Holmans, 2010). SNPs within wider gene 
windows may have regulatory effects on the gene up to 20kb away (Veyrieras et 
al., 2008), and others may be in LD with causal SNPs within the gene itself. 
However, other SNPs will have no functional role and thus no association with 
the trait under investigation (Holmans, 2010; Ramanan et al., 2012), possibly 
leading to a deflation in association with specific pathways.  
 
A final limitation regards the selection of pathways tested. We selected a subset 
of pathways within broad biological categories that a priori were more likely to 
be enriched for SNPs influencing general cognitive ability. Whilst this has 
advantages with respect to minimising the burden of multiple testing, other 
biological processes may also be influenced by schizophrenia genetic risk that 
impact upon cognitive functioning, or contribute to general cognitive ability in 
schizophrenia cases.  
 
5.3.4 Pathway analysis summary 
We were unable to provide robust evidence that polygenic risk of schizophrenia 
was associated with performance IQ in healthy individuals, or the MATRICS 
composite score in schizophrenia cases using common polymorphisms within 
155 candidate pathways.  
 
Using Brown’s method, SNPs associated with general cognitive ability in 
schizophrenia cases were not enriched in any of the candidate pathways tested. 
However, a weak association was observed showing pathways in the region tract 
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morphology pathway were ranked more highly than those in the other 5 
pathway categories. Genes in region tract morphology pathways relate to 
abnormalities in brain structure in the mouse brain. Studies investigating brain 
structure and general cognitive ability in schizophrenia have not identified 
substantial associations and are also subject to multiple confounding factors.    
 
Whilst analyses were limited to a relatively low number of pathways in 
comparison to all pathways in GO (Gene Ontology Consortium et al., 2013), or 
the MGI (Bult et al., 2013),, multiple correction burdens were still substantial. In 
addition, where studies are limited to small cognition sample sizes, they are 
unlikely to have sufficient power to detect associations. These two factors are 
important limitations of the analyses described above. Larger studies are 
required to identify whether or not common genetic risk of schizophrenia in 
biological pathways are associated with general cognitive ability in healthy 
individuals or schizophrenia cases, and whether common SNPs associated with 
general cognitive ability in schizophrenia cases are enriched for specific 
biological processes.  
 
5.4 Rare CNVs and their association with general cognitive ability 
in schizophrenia cases 
The studies presented in Chapter 4 investigated the association between rare 
CNVs and general cognitive ability in schizophrenia cases. There is robust 
evidence that a small number of rare CNVs and de novo CNVs are found at a 
higher rate in schizophrenia cases compared to controls (Rees et al., 2012; Rees 
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et al., 2014b). Furthermore, a number of rare CNVs are associated with 
neurodevelopmental disorders including autism, intellectual disability and 
attention deficit hyperactivity disorder (ADHD) (Malhotra & Sebat, 2012). These 
disorders share a common theme of cognitive impairment. During this thesis, 
work has been published showing apparently healthy carriers of 
neuropsychiatric CNVs have greater cognitive impairment when compared to 
non-carriers, although less impairment relative to schizophrenia cases 
(Stefansson et al., 2014). To date, a limited number of studies have investigated 
cognition in relatively small clinical samples of individuals carrying 
neuropsychiatric CNVs. However, no previous study has investigated whether 
schizophrenia cases with neuropsychiatric CNVs show greater cognitive 
impairment compared to cases with no known neuropsychiatric CNV. In addition 
little is known regarding the association between rare CNV burden and general 
cognitive ability in schizophrenia cases. Furthermore, it is not known whether 
genes within candidate pathways (previously described in Chapter 3) hit by rare 
CNVs  are associated with general cognitive ability in schizophrenia cases.  
 
Chapter 4 sought to address these gaps in the literature and expanded upon 
previous findings using three separate studies. The first study investigated 
whether schizophrenia cases with a known pathogenic CNV (n=11) had lower 
general cognitive ability (as measured by the MATRICS composite score) 
compared to other schizophrenia cases (n=472).  
 
The second study investigated associations between the burden of rare 
(frequency <1%) CNVs and general cognitive ability in schizophrenia cases. 
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Several measures of CNV burden were investigated; total length of large 
(>100kb) and small (between 15-100kb) CNVs as well as total number of genes 
hit by large and small CNVs. Analyses were performed for deletions and 
duplications separately, and combined.  
 
The third study investigated whether the total number of genes in candidate 
pathways (previously described in Chapter 3) hit by CNVs, was associated with 
general cognitive ability in schizophrenia cases.  
 
5.4.1 Known pathogenic CNVs and their association with general 
cognitive ability 
 
The first analysis in chapter 4 investigated differences in general cognitive ability 
between schizophrenia cases stratified by whether they carried a known 
pathogenic CNV.  
 
We showed schizophrenia cases with a known pathogenic CNV performed 
almost one standard deviation lower compared to other schizophrenia cases on 
the MATRICS composite score (p=0.017), and explained approximately 1% of the 
composite score variance. The findings of a recent study suggested 
schizophrenia cases with pathogenic CNVs have an earlier onset of disease (Ahn 
et al., 2014), which is itself associated with greater cognitive impairment, 
although the authors did not examine cognitive outcomes in this study. After 
correction for age of onset, pathogenic CNV status remained significantly 
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associated with the MATRICS composite score and so this does not seem to 
explain the association between these CNVs and cognitive impairment.  
 
This study extends the previous findings by Steffanson et al (2014) who showed 
apparently healthy carriers of neuropsychiatric CNVs had lower cognitive ability, 
between that of healthy non-carriers and schizophrenia cases. These results 
suggest that relatively subtle cognitive deficits are at the mildest end of the 
phenotypic spectrum of expression of neuropsychiatric CNVs , with additional 
genetic or environmental factors contributing towards a more severe 
neuropsychiatric phenotype. However, it is currently unknown whether 
cognitive deficits resulting from the effects of neuropsychiatric CNVs are 
independent from the cognitive symptoms observed in disorders for which the 
CNV confers risk.  The findings of the present study may indicate that pathogenic 
CNVs negatively influence cognitive ability in addition to the deficits observed as 
part of schizophrenia psychopathology and these large, rare CNVs certainly do 
not account for the sum of the cognitive deficits seen in the disorder. The fact 
that smaller CNVs were not associated with impaired cognition, as described in 
the subsequent study in Chapter 4, may indicate that rare structural variants do 
not contribute majorly to the general cognitive impairment seen in 
schizophrenia.  Studies in larger, though equally well phenotyped samples, will 
be required to answer this question definitively.   
 
Not all schizophrenia cases carrying neuropsychiatric CNVs were cognitively 
impaired beyond other schizophrenia cases. The interpretation of this finding is 
unclear. Specifically, it is unknown whether these individuals have cognitive 
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impairments attributable to the effects of the neuropsychiatric CNV, with disease 
processes relating to schizophrenia having less impact upon cognitive 
functioning. A separate interpretation is that these individuals may have other 
genetic or environmental factors that have a protective effect on cognition.  
 
These findings may have implications for future studies that identify single or 
multiple genes in pathogenic CNVs that contribute to genetic susceptibility of 
neuropsychiatric disorders and cognitive ability. A key challenge will be to 
identify which gene, or combination of genes is responsible for the phenotypic 
impact of the neuropsychiatric CNVs. If this is achieved then understanding the 
function of these genes individually, or as part of a pathway may provide insights 
into molecular targets that can form the basis for treatments designed to 
improve cognitive functioning in patients with schizophrenia.  
 
5.4.2 Rare CNV burden and their association with general cognitive 
ability in schizophrenia cases 
 
This study investigated measures of rare CNV burden with respect to association 
with general cognitive ability in schizophrenia cases. Associations were observed 
between the number of genes hit by large CNVs (>100kb) and a lower MATRICS 
composite score, both before (p=0.012) and after (p=0.032) the inclusion of total 
CNV length into the model. Neither total length nor numbers of genes hit by 
small (15-100kb) CNVs were associated with the MATRICS composite score.  
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Associations between CNV deletion and duplication burden and the MATRICS 
composite score showed similar although somewhat weaker findings . The total 
number of genes hit by large deletions (p=0.037) was a more significant 
predictor of the MATRICS composite score compared to duplications (p=0.063).  
 
The findings from previous studies of CNV burden with relation to cognition in 
schizophrenia are not entirely consistent. IQ has been associated with the total 
length of rare (frequency < 1%) CNV deletions (Martin et al., 2014), and total 
number of rare (frequency < 3%) CNV deletions (Yeo et al., 2013), although this 
has not consistently replicated (van Scheltinga et al., 2013). The total length of 
CNV deletions have also been associated with IQ in cases with alcohol 
dependence (Yeo et al., 2011), possibly indicating that rare CNV burden 
contributes to cognition in multiple psychiatric phenotypes. Our findings may 
also suggest the number of genes hit by rare CNV duplications also contribute to 
general cognitive ability in schizophrenia patients, although larger and better 
powered studies will be required to provide more definitive evidence.  
 
However, an increased number of genes hit by large and rare CNV deletions was 
associated with lower general cognitive ability, and thus consistent with the 
direction of effect of previous studies with respect to CNV deletion burden.  
 
Interestingly, rare CNV burden is not associated with general cognitive ability in 
healthy controls (Kirkpatrick et al., 2014). The associations observed in 
schizophrenia cases may indicate the effects of rare CNVs upon cognition become 
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prominent against a backdrop of other genetic vulnerabilities that increase 
schizophrenia liability (Yeo et al., 2013).  
 
5.4.3 Genes in pathways hit by large (>100kb) and rare (frequency < 1%) 
CNVs and their association with general cognitive ability in 
schizophrenia cases 
 
The previous study showed an increased number of genes hit by large (>100kb) 
and rare (frequency <1%) CNVs were associated with lower general cognitive 
ability in schizophrenia cases. We then investigated whether the number genes 
hit by these CNVs in the pathways described previously were associated with the 
MATRICS composite score.  
 
Of the 155 pathways tested, 85 pathways contained genes that were hit by at 
least one CNV.  However, the number of genes hit within any of these 85 
pathways was not significantly associated with the MATRICS composite score 
even prior to correction for multiple testing. A previous study failed to identify 
an association between brain-enriched genes hit by CNV deletions and 
performance/verbal and full scale IQ in 386 schizophrenia cases (Merikangas et 
al., 2014). However, both the present and Merikangas and colleagues study were 
performed in relatively small samples. Given that the CNVs tested have a low 
population frequency, and their effects on cognition in schizophrenia cases are 
modest, much larger samples are required to ascertain whether or not genes hit 
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by rare CNVs are enriched in specific gene-sets that influence general cognitive 
ability in schizophrenia cases.  
 
5.4.4 Methodological considerations of CNV analyses  
Only 11 schizophrenia cases in the present analysis carried known 
neuropsychiatric CNVs. Given these numbers are small, replication of the 
association between neuropsychiatric CNV status and general cognitive ability in 
an independent schizophrenia sample with cognitive data would provide greater 
support for our findings.   
 
With regards to analyses of CNV burden, only rare CNVs with a population 
frequency of less than one percent were included in the analysis. Common CNV 
burden is not associated with cognition in healthy controls (Bagshaw et al., 
2013), although their contribution to cognition in schizophrenia cases is 
unknown. 
 
Finally, CNVs were required to hit at least one base pair of the gene. However, 
CNVs can also affect gene expression when hitting regulatory or functional 
regions beyond protein coding regions (Stranger et al., 2007). CNVs hitting 
promoter regions that affect transcription, but do not hit the gene directly, may 
also contribute to gene expression and affect general cognitive ability. 
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5.5 Future work 
The findings from this thesis provide avenues for further research. First, when 
data becomes available from ALSPAC, we plan to investigate whether 
schizophrenia polygenic risk is associated with a negative change in cognitive 
ability in children between the ages of 8-15. Previous findings have indicated 
increased polygenic risk of schizophrenia is associated with a negative change 
across the lifespan (McIntosh et al., 2013). However schizophrenia genetic risk 
may exert stronger influence on change in cognitive ability during childhood and 
adolescence, a time period characterised by cognitive lag in individuals who later 
develop schizophrenia (Reichenberg et al., 2010). 
 
Second, we intend to perform polygenic pathway analyses using the 
schizophrenia PGC2 discovery dataset to predict cognition within ALSPAC. This 
would be a substantially better powered analysis in comparison to the analyses 
presented, providing a greater opportunity to detect whether or not common 
genetic risk of schizophrenia influences cognition via specific pathways.   
 
Third, we plan to investigate whether common CNV burden is associated with 
general cognitive ability in schizophrenia patients in Cardiff COGS. Although 
common CNV burden is not associated with cognition in healthy controls 
(Bagshaw et al., 2013), this has not been explicitly examined  in schizophrenia 
cases.   
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Forth, we intend to model the effects of both common polygenic risk scores and 
rare CNV burden simultaneously upon general cognitive ability in schizophrenia 
patients.   
 
Fifth, epigenetic functional genomic elements including DNA methylation, 
chromatin modification and other regulatory elements provide alternative 
mechanisms for gene expression (Encode Project Consortium, 2012), with 
relevance to the etiology of psychiatric disorders. Differences in DNA 
methylation have been identified between schizophrenia cases and controls in 
blood and frontal cortex (Wockner et al., 2014). DNA methylation has also been 
implicated in long term memory in mice (Oliveira et al., 2012), although its role 
on cognition in humans is currently unknown. Investigating the association 
between cognition in schizophrenia and epigenetic markers may provide new 
insights into schizophrenia pathophysiology.   
 
5.6 Concluding Remarks 
This thesis has investigated the impact of common and rare genetic risk factors 
for schizophrenia with respect to cognition in patients with schizophrenia and 
healthy controls. A number of novel findings have been identified. First, 
increased polygenic risk of schizophrenia is associated with lower performance 
IQ. This result was demonstrated to replicate in different training sets and in 
independent target samples. Second, no association was observed between 
bipolar polygenic risk and cognition. Third, common genetic differences between 
schizophrenia and bipolar disorder are associated with lower performance on 
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measures of verbal and full scale IQ. Fourth, schizophrenia cases carrying rare 
pathogenic CNVs have greater cognitive impairment compared to other 
schizophrenia cases. Fifth, increases in the number of genes hit by rare CNVs are 
associated with lower general cognitive ability in schizophrenia cases.  
 
Additional understanding of the genetic mechanisms underlying cognitive 
impairment in schizophrenia is a step closer toward an understanding of the 
molecular nature of these deficits, and therefore toward the development of 
better treatments. This has the potential to improve the functional capacity of 
schizophrenia patients, leading to a better quality of life and integration within 
society. 
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7 Appendices 
7.1 Appendix A – MATRICS scoring/imputation procedure 
TMT: log transform the TMT score and then reverse the sign as lower means 
better performance 
 
Z-scores: Calculate the means and standard for the controls for each test 
Minus the control mean from each raw score and divide by the control standard 
deviation for each test. For domains with more than one test, sum the z-scores 
from the tests that make up the domain using just the control data again. Get a 
new mean and standard deviation from these summed z-scores. Minus the mean 
from each of these new summed z-scores and divide by the new standard 
deviation to get the domain z-score. For the composite score repeat as above, but 
sum all the new domain z-scores. 
 
IMPUTATION  
 
FORMULA:  
Ydi = (Yd+) + (Y+i) - (Y++)  
The imputed z-score for a missing task/domain for a individual "i" (Ydi) = (the 
mean z-score of that test for all cases) plus (the mean z-score of all completed 
tests for individual "i") minus (the mean z-score of all tests for all individuals)  
 
For specific domains: 
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HVLT/BVMT: These only have summed scores in the control data. Not possible 
to impute one of the three subscores. Use imputed sum if more than two raw 
scores are missing. If first two scores present, get sum of these, and compute z-
score from this, using control sd and mean of the first two subscores. 
 
CPT - if all scores are missing, impute the mean score. However, if one or two 
subsets are missing, impute these separately and then derive the mean.  
 
LNS/WMS - if one task is present and the other missing, impute the missing task 
and create a WM domain score with this. If both are missing, impute the domain 
score itself.  
 
Speed of processing - individual missing test scores can be imputed for 
TMT/BACS and Fluency. If 2/3 tests are present, impute the missing test: this 
can be used to calculate domain score can be used towards composite.  
 
If one or no tests completed impute the SOP domain score, but should not 
contribute towards the composite score.  
 
Imputation scores should only be used when an individual has completed 5 or 
more domains. However, if hypothetically, an individual completes 
MSCEIT/BVMT/HVLT/Mazes but has a missing value for one of the SOP tasks, 
this individual task can be imputed, meaning the SOP domain can be calculated 
and thus the composite. 
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7.2 Appendix B – Candidate Pathways 
7.2.1 MGI behavioral pathways 
abnormal associative learning 
anomaly in the ability to change the frequency or form of a behavior as a result 
of the influence of the environment 
abnormal avoidance learning behavior 
anomaly in the ability to associate a previously neutral stimulus with an 
unpleasant or punishing stimuli so that the animal learns to avoid the previously 
neutral stimulus 
abnormal behavior 
any anomaly in the actions, reactions, or performance of an organism in 
response to external or internal stimuli compared to controls 
abnormal behavioral response to 
xenobiotic 
any anomaly in the behavioral response induced by a foreign compound, such as 
consumption preference, induced hyperactivity or stereotypic behavior 
abnormal chemical nociception abnormal capability to sense pain elicited by chemical stimulation 
abnormal circadian rhythm deviation from the normal 24 hour biological activity cycle 
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abnormal conditioned place preference 
behavior 
anomaly in the ability of an animal to learn and remember an association 
between a putative rewarding internal state produced by a xenobiotic or drug 
with a neutral, unchanging environment 
abnormal contextual conditioning 
behavior 
anomaly in the ability of an animal to learn and remember an association 
between an aversive experience (the unconditioned stimulus (US), usually a 
shock) and the neutral, unchanging environment (the conditioned stimulus (CS), 
or the environmental context in this case) 
abnormal cued conditioning behavior 
anomaly in the ability of an animal to learn and remember an association 
between an aversive experience (the unconditioned stimulus (US), usually a 
shock) and a neutral stimulus (the conditioned stimulus (CS), usually an auditory 
cue or light flash) 
abnormal discrimination learning 
anomaly in the ability to exhibit a differential response to different stimuli that 
is achieved by the reinforcement of the desired response for each particular 
stimulus 
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abnormal grooming behavior 
defects in the standard of behavior of cleaning and/or keeping outward 
appearance tidy (self, mate or offspring) 
abnormal involuntary movement 
anomaly in movements that occur independent of planning (e.g. reflexive 
behavior) 
abnormal mechanical nociception abnormal capability to sense pain elicited by mechanical stimulation 
abnormal motor learning 
anomaly in the ability to repeat a motor task requiring well coordinated 
movements and balance; measures cerebellar dependent learning 
abnormal nociception after inflammation changes in pain thresholds after inflammation 
abnormal object recognition memory 
anomaly in the ability to recognize objects that the animal has previously 
encountered; recognition is measured by relative amount of time exploring 
objects, which should decrease upon subsequent or multiple presentations of 
the same object when presented with novel objects at the same time 
abnormal pain threshold increased or decreased average level of perception of pain 
abnormal parental behavior altered behavior of animals that affects the ability of offspring to survive 
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abnormal reflex anomaly in an involuntary response to a peripheral stimulus 
abnormal response to new environment altered behavioral reaction associated with placing an animal in a new location 
abnormal response to novelty 
alteration in amount of exploration/investigation of a novel object, situation or 
environment 
abnormal response to tactile stimuli anomaly in the reflex action normally induced by touch or pain 
abnormal seizure response to inducing 
agent 
anomaly in the seizure activity response to an agent that normally can induce 
uncontrolled electrical activity in the brain, producing a physical convulsion 
and/or minor change in physical behavior 
abnormal sexual interaction altered initiation, failure of initiation or incomplete mating behavior 
abnormal sleep behavior 
any anomaly in the actions, reactions, or performance of an organism during a 
periodic, readily reversible state of reduced awareness and metabolic activity 
abnormal social investigation altered behavior of animals to approach and examine other animals 
abnormal spatial learning anomaly in the ability to ascertain or acquire spatial location information in 
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order to improve navigation or other behavior using such location cues 
abnormal spatial reference memory 
anomaly in the ability to recall spatial location information from previous 
encounters or training sessions in order to navigate or perform other behavior 
using such location cues 
abnormal spatial working memory 
anomaly in the ability to spontaneously process spatial location information in 
order to navigate or perform other behavior using such location cues, without 
previous encounters or training at that location 
abnormal temporal memory anomaly in the ability to recall temporal events and stimuli 
abnormal thermal nociception abnormal capability to sense pain elicited by thermal stimulation 
abnormal vocalization 
an inability, decreased ability or altered ability to produce sound from the vocal 
organs; or a general increase or decrease in the production of vocal sound 
abnormal voluntary movement 
anomaly in coordinated movements executed with a purpose and can be 
improved by learning and/or experience 
analgesia inability to sense pain 
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convulsive seizures seizures characterized by uncontrolled motor activity 
nonconvulsive seizures 
seizures without uncontrolled motor activity, but with impairment of 
consciousness 
seizures sudden and often acute manifestation of epileptic attack, sometimes convulsive 
sporadic seizures occasional seizures occurring at irregular intervals 
stereotypic behavior 
repetitive, invariant, perseverative motor patterns that do not appear to be 
purposeful 
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7.2.2 MGI cellular morphology pathways  
Cellular Morphology 
Pathways MGI Description 
Abnormal CNS glial cell 
morphology 
Any structural anomaly of non-neuronal cells of the central nervous system that form the myelin 
insulation of nervous pathways, guide neuronal migration during development, and exchange 
metabolites with neurons 
Abnormal GABAergic 
neuron morphology Any structural anomaly of the neurons that utilize gamma-aminobutyric acid as a neurotransmitter 
Abnormal Muller cell 
morphology 
Any structural anomaly of the elongated neuroglial cells that traverse all the layers of the retina 
and that act as supporting elements 
Abnormal astrocyte 
morphology 
Any structural anomaly of the large neuroglial (macroglial) cells in the central nervous system - the 
largest and most numerous neuroglial cells in the brain and spinal cord; astrocytes are irregularly 
shaped with mAny long processes, including those with 'end feet' which form the glial (limiting) 
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membrane and directly and indirectly contribute to the blood-brain barrier; astrocytes regulate the 
extracellular ionic and chemical environment, and 'reactive astrocytes' (along with microglia) 
respond to injury 
Abnormal axon 
morphology 
Any structural anomaly of the single process of a nerve cell that normally conducts impulses away 
from the cell body 
Abnormal brain 
interneuron 
morphology 
Any structural anomaly of neurons that exclusively interact with other neurons in the brain; this 
includes most brain neuronal cell types 
Abnormal cerebral 
cortex pyramidal cell 
morphology Any structural anomaly of the projection neurons in the pyramidal cell layer of the cerebral cortex 
Abnormal dendrite 
morphology 
Any structural anomaly of the highly branched tree-like process of a neuron that serves as a 
receptive field and conducts impulses toward the cell body 
Abnormal Any structural anomaly of the neurons that utilize dopamine as a neurotransmitter 
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dopaminergic neuron 
morphology 
Abnormal glial cell 
morphology 
Any structural anomaly of non-neuronal cells of the nervous system that form the myelin insulation 
of nervous pathways, guide neuronal migration during development, and exchange metabolites 
with neurons 
Abnormal microglial 
cell morphology 
Any structural anomaly of the small, migratory, phagocytic, interstitial cells derived from myeloid 
progenitor cells and found in the parenchyma of the central nervous system; microglia are 
scavengers, engulfing dead cells and other debris, and in Alzheimer's disease, microglia are found 
associated with dying nerve cells and amyloid plaques 
Abnormal neurite 
morphology 
Any structural anomaly of a neuronal process, either a dendrite or an axon in vivo, or a filamentous 
projection from a neuron such as is seen in tissue culture 
Abnormal 
neuroendocrine cell 
morphology 
Any structural anomaly of a neuron that has the specialized function to produce and secrete 
hormones, contains neurosecretory granules, and that constitutes, in whole or in part, an 
endocrine organ or system 
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Abnormal neuron 
morphology 
Any structural anomaly of the cells of the nervous system that receive, conduct, and transmit 
impulses 
Abnormal 
oligodendrocyte 
morphology 
Any structural anomaly of the neuroglia of the central nervous system that form the insulating 
myelin sheath of axons in the CNS 
Abnormal radial glial 
cell morphology 
Any structural anomaly of the supporting cells of the developing central nervous system that guide 
neuronal migration during development and exchange metabolites with developing and migrating 
neurons; these cells differentiate into astrocytes and some neuronal types in the adult 
Abnormal synapse 
morphology 
Any structural anomaly of the membrane junction site of a nerve cell to a target cell, such as 
another nerve cell, an effector cell, or a sensory receptor cell; transmission of nerve impulses may 
be mediated by chemical or by electrical means 
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7.2.3 MGI cellular physiology pathways  
Cellular Physiology 
Pathways MGI Description 
abnormal CNS synaptic 
transmission 
defect in the communication from a neuron to a target across a synapse in the central nervous 
system 
abnormal PNS synaptic 
transmission 
defect in the communication from a neuron to a target across a synapse in the peripheral nervous 
system 
abnormal excitatory 
postsynaptic currents 
defect in the size or duration of currents detected in postsynaptic cells when an excitatory impulse 
arrives at the synapse causing depolarization 
abnormal excitatory 
postsynaptic potential 
defect in the potential detected in postsynaptic cells when an excitatory impulse arrives at the 
synapse causing depolarization 
abnormal inhibitory 
postsynaptic currents 
defect in the size or duration of currents detected in postsynaptic cells when an inhibitory impulse 
arrives at the synapse causing hyperpolarization 
 252 
abnormal long term 
potentiation 
alterations in a persistent robust synaptic response induced by synchronous stimulation of pre- and 
postsynaptic cells 
abnormal miniature 
excitatory postsynaptic 
currents 
defect in the size or duration of spontaneous currents detected in postsynaptic cells that occur in 
the absence of an excitatory impulse 
abnormal miniature 
inhibitory postsynaptic 
currents 
defect in the size or duration of spontaneous currents detected in postsynaptic cells that occur in 
the absence of an inhibitory impulse 
abnormal 
neurotransmitter level 
anomaly in the amount of endogenous signaling molecules into a synaptic cleft; neurotransmitters 
are released on excitation from the axon terminal of a presynaptic neuron of the central or 
peripheral nervous system and travel across the synaptic cleft to either excite or inhibit the target 
cell 
abnormal prepulse 
inhibition 
anomaly in the ability of a relatively mild stimulus to suppress the response to a strong, startle-
eliciting stimulus 
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abnormal synaptic 
depression 
changes in the duration of the reduction of effectiveness of synaptic connections between neurons 
and target after repetitive stimulation 
abnormal synaptic 
plasticity anomaly in the ability of a synapse to change its strength as a result of successive activations 
abnormal synaptic 
transmission defect in the communication from a neuron to a target across a synapse 
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7.2.4 MGI Development Pathways  
Cellular Physiology 
Pathways MGI Description 
abnormal CNS synapse 
formation 
any anomaly in the process of generating the initial connections between an axon and effector 
tissue or neuron 
abnormal brain 
development aberrant or incomplete differentiation of the brain 
abnormal cerebellum 
development 
aberrant or incomplete differentiation of the part of the metencephalon that lies dorsal to the 
pons and medulla behind the brain stem and controls balance for walking and standing, modulates 
the force and range of movement and is involved in the learning of motor skills 
abnormal forebrain 
development 
anomaly in the formation or patterning of the anterior of the three primary divisions of the 
developing chordate brain or the corresponding part of the adult brain (in vertebrates, includes 
especially the cerebral hemispheres, the thalamus, and the hypothalamus and especially in higher 
 255 
vertebrates is the main control center for sensory and associative information processing, visceral 
functions, and voluntary motor functions) 
abnormal hindbrain 
development anomaly in the formation or pattering of the caudal region of the brain 
abnormal hippocampus 
development improper differentiation of the hippocampus 
abnormal midbrain 
development 
anomaly in the formation of or the patterning of the part of the brainstem developing from the 
middle of the three primary cerebral vesicles of the embryo 
abnormal nervous 
system development impaired or altered growth of the components of the nervous system 
abnormal neuron 
differentiation 
abnormal growth or development of the cells of the nervous system that receive, conduct, and 
transmit impulses 
abnormal 
telencephalon 
anomaly in the progression of the enlarged anteriolateral part of the brain; consists of the paired 
cerebral hemispheres and olfactory bulbs, the basal ganglia and the connecting structures, and is 
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development considered to be the seat of conscious mental processes; it develops from the anterior-most 
embryological division of the brain that develops from the prosencephalon 
 
 
 
 
 
 
 
 
 
 
 
 
 
 257 
7.2.5 Region Tract Morphology Pathways 
Region Tract 
Morphology Pathways MGI Description 
Abnormal autonomic 
nervous system 
morphology 
Any structural anomaly of the function of the sensory and motor neurons that run between the 
central nervous system (especially the hypothalamus and medulla oblongata) and various internal 
organs (heart, lungs, endocrine and exocrine glands), responsible for controlling involuntary bodily 
functions 
Abnormal basal 
ganglion morphology 
Any structural anomaly of Any of a group of nuclei associated with the ability to carry out willed 
movements, including the caudate, putamen, nucleus accumbens, globus pallidus, substantia nigra, 
and subthalamic nucleus 
Abnormal brain 
morphology 
Any structural anomaly of the brain, one of the two components of the central nervous system and 
the center of thought and emotion; controls coordination, bodily activities and the interpretation 
of information from the senses (sight, hearing, smell, etc.) 
 258 
Abnormal brain size Deviation from the average range of brain size for an organism 
Abnormal brain 
vasculature 
morphology Any structural anomaly of the blood vessel network of the brain 
Abnormal brain 
ventricle morphology 
Any structural anomaly of the system of four communicating cavities within the brain that are 
continuous with the central canal of the spinal cord 
Abnormal brain white 
matter morphology 
Any structural anomaly of the regions of the brain that are largely or entirely composed of 
myelinated nerve cell axons and contain few or no neural cell bodies or dendrites 
Abnormal brainstem 
morphology 
Any structural anomaly of the stalk-like part of the brain that comprises the midbrain (aka 
mesencephalon), the pons (aka pons Varolii), and the medulla oblongata, and connects the 
cerebral hemispheres with the cervical spinal cord 
Abnormal cerebral 
cortex morphology 
Any structural anomaly of thin layer of grey matter on the surface of the cerebral hemisphere that 
develops from the telencephalon and folds into gyri; it is responsible for intellectual faculties and 
higher mental functions 
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Abnormal cerebrum 
morphology 
Any structural anomaly of the largest part of the brain, derived from the telencephalon, and is 
composed of a right and a left hemisphere each which contains an outer cerebral cortex and a 
subcortical basal ganglia; cerebral functions include sensorimotor, emotional, and intellectual 
activities 
Abnormal corpus 
callosum morphology 
Any structural anomaly of a thick bundle of nerve fibers comprising a commissural plate connecting 
the two cerebral hemispheres; it consists of contralateral axon projections that provides 
communications between the right and left cerebral hemispheres 
Abnormal diencephalon 
morphology 
Any structural anomaly of the paired caudal parts of the prosencephalon from which the thalamus, 
hypothalamus, epithalamus and subthalamus are derived; these regions regulate autonomic, 
visceral and endocrine function, and process information directed to the cerebral cortex 
Abnormal ependyma 
morphology 
Any structural anomaly of the cellular membrane that lines the brain ventricles and the central 
canal of the spinal cord 
Abnormal forebrain 
morphology 
Any structural anomaly of the anterior of the three primary divisions of the developing chordate 
brain or the corresponding part of the adult brain (in vertebrates, includes especially the cerebral 
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hemispheres, the thalamus, and the hypothalamus and especially in higher vertebrates is the main 
control center for sensory and associative information processing, visceral functions, and voluntary 
motor functions) 
Abnormal fourth 
ventricle morphology 
Any structural anomaly of the irregularly shaped cavity in the rhombencephalon, between the 
medulla oblongata, the pons, and the isthmus in front, and the cerebellum behind; it is continuous 
with the central canal of the cord below and with the cerebral aqueduct above, and through its 
lateral and median apertures it communicates with the subarachnoid space 
Abnormal hindbrain 
morphology 
Any structural anomaly of the part of the brain developed from the posterior of the three primary 
brain vesicles of the embryonic neural tube from which the metencephalon and myelencephalon 
are derived; the metencephalon (anterior part of the embryonic hindbrain), gives rise to the 
cerebellum and pons while the myelencephalon (posterior portion of the embryonic hindbrain) 
gives rise to the medulla oblongata 
Abnormal hippocampus 
morphology 
Any structural anomaly of the deep lying structure of the cerebrum involved with memory storage 
and spatial navigation 
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Abnormal 
hypothalamus 
morphology 
Any structural anomaly of the ventral part of the diencephalon extending from the region of the 
optic chiasm to the caudal border of the mammillary bodies and forming the inferior and lateral 
walls of the third ventricle; this region regulates the autonomic nervous system via hormone 
production and release 
Abnormal innervation 
the malformation, misprojection, Abnormal fasciculation or Abnormal refinement of the 
connection, of nerve fibers to a target 
Abnormal lateral 
ventricle morphology 
Any structural anomaly of the cavity in each of the cerebral hemispheres derived from the cavity of 
the embryonic neural tube; they are separated from each other by the septum pellucidum, and 
each communicates with the third ventricle by the foramen of Monro, through which also the 
choroid plexuses of the lateral ventricles become continuous with that of the third ventricle 
Abnormal limbic system 
morphology 
Any structural anomaly of Any of a collection of structures in the brain involved in emotion, 
motivation and emotional aspects of memory; these structures act together to control the 
endocrine system and the autonomic nervous system 
Abnormal midbrain Any structural anomaly associated with the brain region derived from the middle of the three 
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morphology cerebral vesicles of the embryo; this region controls sensory and motor functions in the adult, 
including eye movement and coordination of auditory and visual reflexes 
Abnormal neocortex 
morphology 
Any structural anomaly of the larger part of the mammalian cerebral cortex, distinguished from the 
allocortex by being composed of a larger number of nerve cells arranged in six layers 
Abnormal nervous 
system morphology 
Any structural anomaly of the extensive, intricate network of electochemical structures in the body 
that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that 
receive and interpret stimuli and transmit impulses to effector organs to control body functions 
Abnormal nervous 
system tract 
morphology 
Any structural anomaly in the structure of Any bundle of myelinated nerve fibers following a 
defined path through the brain and/or spinal cord 
Abnormal parietal lobe 
morphology Any structural anomaly of the upper central part of the cerebral hemisphere 
Abnormal pituitary 
gland morphology 
Any structural anomaly of the compound gland suspended from the base of the hypothalamus, 
which secretes somatotropins, prolactin, TSH (thyroid-stimulating hormone), gonadotropins, 
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adrenal corticotropin from the anterior lobe; melanocyte stimulating hormone from the 
intermediate lobe and hormones involved in blood pressure regulation from the posterior lobe 
Abnormal postnatal 
subventricular zone 
morphology 
Any structural anomaly of the mitotically active layer of cells surrounding the brain ventricles in the 
adult that consists of migrating neuroblasts, astrocytes and transitory amplifying progenitor cells 
Abnormal somatic 
nervous system 
morphology 
Any structural anomaly of the part of the peripheral nervous system that is responsible for 
conveying voluntary motor and external sensory information, including all nerves controlling the 
skeletal muscular system and external sensory receptors (including balance, smell, sight, taste, 
touch and hearing sensory inputs) 
Abnormal 
somatosensory cortex 
morphology 
Any structural anomaly of the area of the parietal lobe that lies posterior to the central sulcus and 
is concerned with receiving and processing general sensations from the body surface 
Abnormal spinal cord 
morphology 
Any structural anomaly of the cylindrical tissue of the vertebral canal that extends from the 
medulla oblongata to the conus medullaris 
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Abnormal stratification 
in cerebral cortex Abnormal formation or pattern of the layers of the cerebral cortex 
Abnormal 
telencephalon 
morphology 
Any structural anomaly of the enlarged anteriolateral part of the brain; consists of the paired 
cerebral hemispheres and olfactory bulbs, the basal ganglia and the connecting structures, and is 
considered to be the seat of conscious mental processes; it develops from the anterior-most 
embryological division of the brain that develops from the prosencephalon 
Abnormal temporal 
lobe morphology Any structural anomaly of the lower lateral part of the cerebral hemisphere 
Abnormal thalamus 
morphology 
Any structural anomaly of the large ovoid mass of paired bodies containing mostly grey matter and 
forming part of the lateral wall of the third ventricle of the brain 
Abnormal third 
ventricle morphology 
Any structural anomaly of the narrow cleft inferior to the corpus callosum, within the 
diencephalon, between the paired thalami; its floor is formed by the hypothalamus, its anterior 
wall by the lamina terminalis, and its roof by ependyma; it communicates with the fourth ventricle 
by the cerebral aqueduct, and with the lateral ventricles by the interventricular foramina 
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Decreased brain size Smaller appearance of the brain 
Dilated lateral 
ventricles 
The luminal space of the lateral ventricles is increased in volume or area, usually with an increase 
in contained fluid, in the cavity in each of the cerebral hemispheres derived from the cavity of the 
embryonic neural tube; they are separated from each other by the septum pellucidum, and each 
communicates with the third ventricle by the foramen of Monro, through which also the choroid 
plexuses of the lateral ventricles become continuous with that of the third ventricle 
Dilated third ventricle 
The luminal space of the third ventricle is increased in volume or area, usually with an increase in 
contained fluid, in the narrow cleft inferior to the corpus callosum, within the diencephalon, 
between the paired thalami; its floor is formed by the hypothalamus, its anterior wall by the lamina 
terminalis, and its roof by ependyma; it communicates with the fourth ventricle by the cerebral 
aqueduct, and with the lateral ventricles by the interventricular foramina 
Enlarged lateral 
ventricles 
Increased size of the cavity in each of the cerebral hemispheres derived from the cavity of the 
embryonic neural tube; they are separated from each other by the septum pellucidum, and each 
communicates with the third ventricle by the foramen of Monro, through which also the choroid 
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plexuses of the lateral ventricles become continuous with that of the third ventricle 
Enlarged third ventricle 
Increased size of the narrow cleft inferior to the corpus callosum, within the diencephalon, 
between the paired thalami; its floor is formed by the hypothalamus, its anterior wall by the lamina 
terminalis, and its roof by ependyma; it communicates with the fourth ventricle by the cerebral 
aqueduct, and with the lateral ventricles by the interventricular foramina 
Increased brain size Larger than the normal physical proportions of the brain 
Thin cerebral cortex Decreased depth of the mantle covering the surface of the cerebral hemispheres 
 
7.2.6 Subcellular neuronal pathways 
5HT 2C (Becamel et al., 2002) 
ARC (Kirov et al., 2012) 
CYFIP1 all (De Rubeis et al., 2013) 
Cav2 channels (Muller et al., 2010) 
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Chrna7 (Paulo et al., 2009) 
FMRP targets (Darnell et al., 2011) 
GABA PSD (Heller et al., 2012) 
NMDAR network (Pocklington et al., 2006) 
PSD human core (Bayes et al., 2011) 
Presynaptic active zone (Morciano et al., 2009) 
Presynapse 
Pre-synaptic active zone + Synaptic vesicle 
 
Synaptic vesicle (Takamori et al., 2006) + Synaptic vesicle GABA enriched + Synaptic vesicle glutamate enriched 
Synaptic vesicle GABA enriched (Gronborg et al., 2010) 
Synaptic vesicle glutamate enriched (Gronborg et al., 2010) 
mGluR5 (Farr et al., 2004) 
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7.3 Appendix C - Full PGC schizophrenia polygenic pathway linear regression results for German cognition sample 
Pathway Pathway Category 
Training 
Threshold 
P 
P 
(Corrected) 
R2 DOE 
abnormal hypothalamus morphology 
region tract 
morphology 
0.05 0.006 0.049 0.0081 - 
abnormal neuron morphology cellular morphology 0.5 0.007 0.063 0.008 + 
abnormal basal ganglion morphology 
region tract 
morphology 
0.5 0.01 0.088 0.0073 + 
abnormal neurite morphology cellular morphology 0.5 0.011 0.099 0.0066 - 
abnormal spinal cord morphology 
region tract 
morphology 
0.05 0.013 0.118 0.0066 + 
abnormal social conspecific interaction behaviour 0.05 0.014 0.124 0.0065 + 
abnormal social investigation behaviour 0.5 0.015 0.131 0.0063 + 
abnormal neuron morphology cellular morphology 0.05 0.015 0.131 0.0066 + 
abnormal nervous system development development 0.05 0.015 0.134 0.0065 + 
abnormal long term potentiation cellular physiology 0.05 0.018 0.157 0.0061 - 
abnormal telencephalon development development 0.5 0.02 0.178 0.0058 + 
abnormal learning  memory behaviour 0.05 0.021 0.186 0.0057 + 
abnormal nervous system morphology 
region tract 
morphology 
0.05 0.021 0.19 0.0059 + 
abnormal emotion affect behavior behaviour 0.5 0.022 0.194 0.0056 - 
abnormal midbrain morphology 
region tract 
morphology 
0.5 0.023 0.207 0.0057 - 
abnormal brain morphology 
region tract 
morphology 
0.05 0.026 0.226 0.0055 + 
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abnormal nervous system morphology 
region tract 
morphology 
0.5 0.026 0.229 0.0056 + 
abnormal associative learning behaviour 0.5 0.027 0.243 0.0052 + 
abnormal glial cell morphology cellular morphology 0.5 0.03 0.262 0.0053 + 
abnormal synaptic depression cellular physiology 0.05 0.031 0.273 0.0049 + 
abnormal forebrain morphology 
region tract 
morphology 
0.5 0.031 0.274 0.0053 + 
abnormal spinal cord morphology 
region tract 
morphology 
0.5 0.036 0.317 0.0049 + 
abnormal parental behavior behaviour 0.05 0.037 0.324 0.0047 + 
abnormal eating drinking behavior behaviour 0.05 0.038 0.34 0.0047 + 
abnormal paired pulse facilitation cellular physiology 0.5 0.04 0.354 0.0046 + 
abnormal postnatal subventricular zone morphology 
region tract 
morphology 
0.05 0.041 0.364 0.0047 - 
abnormal behavioral response to xenobiotic behaviour 0.5 0.042 0.368 0.0045 + 
abnormal inhibitory postsynaptic currents cellular physiology 0.5 0.042 0.368 0.0043 + 
abnormal behavioral response to xenobiotic behaviour 0.05 0.043 0.376 0.0044 + 
abnormal social conspecific interaction behaviour 0.5 0.045 0.395 0.0044 + 
abnormal forebrain morphology 
region tract 
morphology 
0.05 0.045 0.397 0.0046 + 
abnormal brain morphology 
region tract 
morphology 
0.5 0.047 0.418 0.0045 + 
abnormal learning  memory behaviour 0.5 0.048 0.429 0.0042 + 
abnormal basal ganglion morphology 
region tract 
morphology 
0.05 0.051 0.448 0.0042 + 
abnormal eating drinking behavior behaviour 0.5 0.055 0.4708 0.0041 + 
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abnormal object recognition memory behaviour 0.5 0.056 0.4794 0.0041 - 
abnormal GABAergic neuron morphology cellular morphology 0.05 0.058 0.4965 0.0039 + 
abnormal glial cell morphology cellular morphology 0.05 0.058 0.4965 0.0041 + 
abnormal dendrite morphology cellular morphology 0.05 0.061 0.5222 0.0039 - 
abnormal limbic system morphology 
region tract 
morphology 
0.5 0.064 
0.5478 
0.0037 + 
CYFIP1 all subcellular neuronal 0.5 0.068 0.5821 0.0036 + 
dilated lateral ventricles 
region tract 
morphology 
0.5 0.07 
0.5992 
0.0036 + 
abnormal avoidance learning behavior behaviour 0.5 0.071 0.6078 0.0036 + 
abnormal paired pulse facilitation cellular physiology 0.05 0.073 0.6249 0.0034 + 
abnormal telencephalon morphology 
region tract 
morphology 
0.5 0.073 
0.6249 
0.0036 + 
abnormal hippocampus morphology 
region tract 
morphology 
0.5 0.074 
0.6334 
0.0035 + 
abnormal autonomic nervous system morphology 
region tract 
morphology 
0.05 0.077 
0.6591 
0.0034 + 
abnormal thalamus morphology 
region tract 
morphology 
0.05 0.078 
0.6677 
0.0032 + 
nonconvulsive seizures behaviour 0.05 0.084 0.7190 0.0033 - 
abnormal axon morphology cellular morphology 0.05 0.084 0.7190 0.0033 - 
abnormal microglial cell morphology cellular morphology 0.05 0.084 0.7190 0.0033 - 
analgesia behaviour 0.5 0.086 0.7362 0.0033 + 
abnormal parental behavior behaviour 0.5 0.087 0.7447 0.0032 + 
sporadic seizures behaviour 0.5 0.088 0.7533 0.0032 - 
abnormal nervous system development development 0.5 0.088 0.7533 0.0033 + 
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abnormal neurite morphology cellular morphology 0.05 0.09 0.7704 0.0031 - 
abnormal CNS glial cell morphology cellular morphology 0.5 0.091 0.7790 0.0033 + 
NMDAR network subcellular neuronal 0.05 0.091 0.7790 0.0032 - 
abnormal somatic nervous system morphology 
region tract 
morphology 
0.5 0.094 
0.8046 
0.0032 + 
abnormal dendrite morphology cellular morphology 0.5 0.099 0.8474 0.0029 - 
abnormal thalamus morphology 
region tract 
morphology 
0.5 0.099 
0.8474 
0.0028 - 
abnormal brain size 
region tract 
morphology 
0.5 0.101 
0.8646 
0.003 + 
abnormal pain threshold behaviour 0.5 0.102 0.8731 0.0029 + 
abnormal temporal lobe morphology 
region tract 
morphology 
0.5 0.103 
0.8817 
0.0029 + 
abnormal diencephalon morphology 
region tract 
morphology 
0.05 0.105 
0.8988 
0.0028 + 
increased brain size 
region tract 
morphology 
0.5 0.106 
0.9074 
0.0028 - 
Synaptic vesicle subcellular neuronal 0.5 0.107 0.9159 0.003 + 
abnormal cerebrum morphology 
region tract 
morphology 
0.5 0.111 
0.9502 
0.0029 + 
abnormal brain ventricle morphology 
region tract 
morphology 
0.5 0.115 
0.9844 
0.0028 - 
abnormal brainstem morphology 
region tract 
morphology 
0.05 0.125 
1 
0.0026 - 
Presynapse subcellular neuronal 0.5 0.127 1 0.0027 + 
abnormal excitatory postsynaptic currents cellular physiology 0.5 0.129 1 0.0024 - 
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Pre synaptic active zone subcellular neuronal 0.5 0.133 1 0.0021 - 
abnormal synaptic depression cellular physiology 0.5 0.134 1 0.0023 + 
abnormal cerebrum morphology 
region tract 
morphology 
0.05 0.134 
1 
0.0025 + 
abnormal CNS synaptic transmission cellular physiology 0.05 0.136 1 0.0023 + 
abnormal CNS glial cell morphology cellular morphology 0.05 0.14 1 0.0025 + 
abnormal fourth ventricle morphology 
region tract 
morphology 
0.5 0.145 
1 
0.0023 + 
Chrna7 subcellular neuronal 0.05 0.145 1 0.0022 + 
abnormal glutamate mediated receptor currents cellular physiology 0.5 0.148 1 0.0024 + 
abnormal radial glial cell morphology cellular morphology 0.05 0.156 1 0.0023 + 
abnormal seizure response to inducing agent behaviour 0.5 0.16 1 0.0022 + 
abnormal long term potentiation cellular physiology 0.5 0.164 1 0.0022 + 
Cav2 channels subcellular neuronal 0.5 0.165 1 0.0021 + 
Pre synaptic active zone subcellular neuronal 0.05 0.166 1 0.0018 - 
abnormal involuntary movement behaviour 0.05 0.17 1 0.002 - 
abnormal synaptic transmission cellular physiology 0.05 0.171 1 0.002 + 
abnormal somatic nervous system morphology 
region tract 
morphology 
0.05 0.172 
1 
0.0022 + 
abnormal sleep behavior behaviour 0.5 0.176 1 0.002 + 
abnormal miniature excitatory postsynaptic currents cellular physiology 0.5 0.179 1 0.002 + 
seizures behaviour 0.5 0.182 1 0.002 + 
abnormal diencephalon morphology 
region tract 
morphology 
0.5 0.182 
1 
0.0017 - 
abnormal hindbrain morphology 
region tract 
morphology 
0.05 0.184 
1 
0.0019 + 
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abnormal involuntary movement behaviour 0.5 0.188 1 0.0018 - 
5HT 2C subcellular neuronal 0.05 0.189 1 0.0017 + 
abnormal nervous system tract morphology 
region tract 
morphology 
0.05 0.191 
1 
0.002 + 
abnormal GABAergic neuron morphology cellular morphology 0.5 0.207 1 0.0017 + 
thin cerebral cortex 
region tract 
morphology 
0.5 0.208 
1 
0.0017 + 
PSD 95 core SN subcellular neuronal 0.5 0.208 1 0.0017 + 
abnormal aggression related behavior behaviour 0.5 0.215 1 0.0018 + 
abnormal contextual conditioning behavior behaviour 0.05 0.218 1 0.0017 + 
GABA PSD subcellular neuronal 0.05 0.219 1 0.0016 - 
abnormal response to tactile stimuli behaviour 0.05 0.223 1 0.0017 - 
abnormal motor capabilities coordination 
movement 
behaviour 0.5 0.23 
1 
0.0017 + 
abnormal forebrain development development 0.5 0.236 1 0.0015 + 
abnormal contextual conditioning behavior behaviour 0.5 0.24 1 0.0015 + 
CYFIP1 all subcellular neuronal 0.05 0.24 1 0.0016 + 
abnormal associative learning behaviour 0.05 0.241 1 0.0015 + 
abnormal behavior behaviour 0.5 0.241 1 0.0017 + 
abnormal synaptic transmission cellular physiology 0.5 0.242 1 0.0015 + 
abnormal telencephalon development development 0.05 0.249 1 0.0015 + 
abnormal PNS synaptic transmission cellular physiology 0.05 0.25 1 0.0015 - 
abnormal brain ventricle choroid plexus morphology 
region tract 
morphology 
0.5 0.25 
1 
0.0014 + 
abnormal stratification in cerebral cortex 
region tract 
morphology 
0.05 0.251 
1 
0.0013 - 
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abnormal third ventricle morphology 
region tract 
morphology 
0.5 0.251 
1 
0.0015 - 
abnormal CNS synaptic transmission cellular physiology 0.5 0.254 1 0.0014 + 
enlarged third ventricle 
region tract 
morphology 
0.05 0.256 
1 
0.0014 - 
abnormal midbrain hindbrain boundary 
development 
development 0.5 0.263 
1 
0.0014 + 
abnormal prepulse inhibition cellular physiology 0.05 0.264 1 0.0013 - 
abnormal excitatory postsynaptic potential cellular physiology 0.05 0.265 1 0.0013 + 
abnormal synaptic plasticity cellular physiology 0.5 0.28 1 0.0012 + 
abnormal conditioned place preference behavior behaviour 0.5 0.292 1 0.0012 + 
abnormal voluntary movement behaviour 0.5 0.294 1 0.0013 + 
convulsive seizures behaviour 0.05 0.294 1 0.0013 - 
abnormal post tetanic potentiation cellular physiology 0.05 0.295 1 0.0012 + 
abnormal brain ventricle morphology 
region tract 
morphology 
0.05 0.295 
1 
0.0012 - 
mGluR5 subcellular neuronal 0.5 0.302 1 0.0012 - 
abnormal temporal memory behaviour 0.5 0.303 1 0.0012 + 
abnormal cerebellum development development 0.05 0.305 1 0.0012 + 
abnormal brain size 
region tract 
morphology 
0.05 0.308 
1 
0.0011 + 
abnormal stratification in cerebral cortex 
region tract 
morphology 
0.5 0.308 
1 
0.0011 + 
dilated lateral ventricles 
region tract 
morphology 
0.05 0.309 
1 
0.0011 + 
abnormal midbrain development development 0.5 0.312 1 0.0011 - 
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abnormal brain white matter morphology 
region tract 
morphology 
0.05 0.312 
1 
0.0012 + 
abnormal axon morphology cellular morphology 0.5 0.315 1 0.0012 - 
abnormal neuron differentiation development 0.05 0.322 1 0.0011 + 
abnormal sensory capabilities reflexes nociception behaviour 0.05 0.325 1 0.0011 + 
abnormal excitatory postsynaptic potential cellular physiology 0.5 0.337 1 0.0009 + 
abnormal miniature inhibitory postsynaptic currents cellular physiology 0.5 0.347 1 0.0009 - 
abnormal postnatal subventricular zone morphology 
region tract 
morphology 
0.5 0.355 
1 
0.0008 + 
abnormal brain white matter morphology 
region tract 
morphology 
0.5 0.356 
1 
0.001 + 
abnormal lateral ventricle morphology 
region tract 
morphology 
0.05 0.356 
1 
0.001 + 
abnormal motor coordination  balance behaviour 0.5 0.357 1 0.001 + 
abnormal Muller cell morphology cellular morphology 0.05 0.357 1 0.0009 - 
abnormal hypothalamus morphology 
region tract 
morphology 
0.5 0.358 
1 
0.0008 - 
Presynapse subcellular neuronal 0.05 0.365 1 0.0009 + 
abnormal thermal nociception behaviour 0.5 0.369 1 0.0008 + 
abnormal depression related behavior behaviour 0.5 0.37 1 0.0008 + 
abnormal hippocampus morphology 
region tract 
morphology 
0.05 0.37 
1 
0.0009 + 
abnormal midbrain morphology 
region tract 
morphology 
0.05 0.378 
1 
0.0008 - 
5HT 2C subcellular neuronal 0.5 0.378 1 0.0008 + 
abnormal cerebral cortex pyramidal cell morphology cellular morphology 0.05 0.379 1 0.0008 - 
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convulsive seizures behaviour 0.5 0.384 1 0.0008 + 
abnormal synaptic plasticity cellular physiology 0.05 0.391 1 0.0008 + 
abnormal mechanical nociception behaviour 0.05 0.393 1 0.0008 + 
abnormal grooming behavior behaviour 0.5 0.396 1 0.0008 + 
abnormal cued conditioning behavior behaviour 0.05 0.397 1 0.0008 + 
abnormal circadian rhythm behaviour 0.5 0.398 1 0.0007 + 
abnormal conditioned place preference behavior behaviour 0.05 0.4 1 0.0008 - 
abnormal inhibitory postsynaptic currents cellular physiology 0.05 0.401 1 0.0006 + 
abnormal brain interneuron morphology cellular morphology 0.05 0.415 1 0.0008 + 
abnormal synapse morphology cellular morphology 0.05 0.415 1 0.0007 + 
abnormal touch  nociception behaviour 0.5 0.431 1 0.0006 + 
abnormal cerebral cortex morphology 
region tract 
morphology 
0.5 0.439 
1 
0.0007 + 
abnormal hippocampus development development 0.5 0.44 1 0.0006 + 
abnormal innervation 
region tract 
morphology 
0.5 0.44 
1 
0.0006 - 
abnormal ependyma morphology 
region tract 
morphology 
0.5 0.444 
1 
0.0007 - 
abnormal hippocampus development development 0.05 0.456 1 0.0006 + 
abnormal forebrain development development 0.05 0.463 1 0.0006 + 
mGluR5 subcellular neuronal 0.05 0.469 1 0.0005 + 
abnormal chemical nociception behaviour 0.5 0.47 1 0.0006 + 
abnormal Muller cell morphology cellular morphology 0.5 0.473 1 0.0005 - 
abnormal discrimination learning behaviour 0.05 0.478 1 0.0005 - 
abnormal brain development development 0.5 0.479 1 0.0006 - 
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abnormal motor capabilities coordination 
movement 
behaviour 0.05 0.492 
1 
0.0006 + 
abnormal response to novelty behaviour 0.05 0.5 1 0.0005 + 
nonconvulsive seizures behaviour 0.5 0.502 1 0.0005 - 
enlarged lateral ventricles 
region tract 
morphology 
0.05 0.509 
1 
0.0004 + 
abnormal nociception after inflammation behaviour 0.05 0.515 1 0.0004 + 
abnormal voluntary movement behaviour 0.05 0.516 1 0.0005 + 
abnormal seizure response to inducing agent behaviour 0.05 0.519 1 0.0005 - 
abnormal behavior behaviour 0.05 0.52 1 0.0005 + 
thin cerebral cortex 
region tract 
morphology 
0.05 0.523 
1 
0.0005 + 
stereotypic behavior behaviour 0.5 0.528 1 0.0004 - 
abnormal brain vasculature morphology 
region tract 
morphology 
0.05 0.528 
1 
0.0004 + 
analgesia behaviour 0.05 0.536 1 0.0005 + 
abnormal autonomic nervous system morphology 
region tract 
morphology 
0.5 0.541 
1 
0.0005 - 
abnormal midbrain development development 0.05 0.545 1 0.0004 - 
abnormal vocalization behaviour 0.5 0.55 1 0.0005 + 
abnormal motor learning behaviour 0.5 0.551 1 0.0004 - 
abnormal sleep behavior behaviour 0.05 0.554 1 0.0004 - 
Synaptic vesicle GABA enriched subcellular neuronal 0.05 0.56 1 0.0003 + 
abnormal brainstem morphology 
region tract 
morphology 
0.5 0.567 
1 
0.0004 - 
PSD human core SN subcellular neuronal 0.05 0.567 1 0.0004 - 
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abnormal motor learning behaviour 0.05 0.569 1 0.0003 + 
abnormal limbic system morphology 
region tract 
morphology 
0.05 0.572 
1 
0.0004 + 
ARC pathway SN subcellular neuronal 0.5 0.576 1 0.0004 + 
abnormal hindbrain morphology 
region tract 
morphology 
0.5 0.577 
1 
0.0004 - 
Synaptic vesicle Glu enriched subcellular neuronal 0.05 0.578 1 0.0003 + 
abnormal glutamate mediated receptor currents cellular physiology 0.05 0.583 1 0.0004 + 
abnormal depression related behavior behaviour 0.05 0.586 1 0.0004 - 
abnormal telencephalon morphology 
region tract 
morphology 
0.05 0.588 
1 
0.0003 + 
abnormal circadian rhythm behaviour 0.05 0.59 1 0.0004 - 
abnormal temporal memory behaviour 0.05 0.596 1 0.0003 + 
abnormal temporal lobe morphology 
region tract 
morphology 
0.05 0.596 
1 
0.0003 + 
abnormal innervation 
region tract 
morphology 
0.05 0.609 
1 
0.0003 - 
abnormal fourth ventricle morphology 
region tract 
morphology 
0.05 0.614 
1 
0.0003 - 
enlarged lateral ventricles 
region tract 
morphology 
0.5 0.619 
1 
0.0003 + 
abnormal aggression related behavior behaviour 0.05 0.624 1 0.0003 + 
abnormal pain threshold behaviour 0.05 0.628 1 0.0002 + 
abnormal spatial learning behaviour 0.5 0.628 1 0.0002 - 
abnormal hindbrain development development 0.05 0.635 1 0.0003 + 
abnormal post tetanic potentiation cellular physiology 0.5 0.638 1 0.0002 + 
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abnormal somatosensory cortex morphology 
region tract 
morphology 
0.05 0.638 
1 
0.0003 - 
abnormal nervous system tract morphology 
region tract 
morphology 
0.5 0.641 
1 
0.0003 + 
abnormal discrimination learning behaviour 0.5 0.642 1 0.0002 - 
Synaptic vesicle Glu enriched subcellular neuronal 0.5 0.656 1 0.0002 + 
Synaptic vesicle subcellular neuronal 0.05 0.661 1 0.0002 + 
dilated third ventricle 
region tract 
morphology 
0.5 0.664 
1 
0.0002 + 
stereotypic behavior behaviour 0.05 0.665 1 0.0002 - 
abnormal pituitary gland morphology 
region tract 
morphology 
0.05 0.668 
1 
0.0002 + 
abnormal vocalization behaviour 0.05 0.669 1 0.0002 - 
abnormal microglial cell morphology cellular morphology 0.5 0.67 1 0.0002 + 
abnormal miniature excitatory postsynaptic currents cellular physiology 0.05 0.67 1 0.0002 + 
abnormal spatial reference memory behaviour 0.05 0.671 1 0.0002 - 
abnormal neocortex morphology 
region tract 
morphology 
0.5 0.675 
1 
0.0002 + 
abnormal brain ventricle choroid plexus morphology 
region tract 
morphology 
0.05 0.676 
1 
0.0002 - 
abnormal cerebral cortex morphology 
region tract 
morphology 
0.05 0.677 
1 
0.0002 - 
ARC pathway SN subcellular neuronal 0.05 0.686 1 0.0002 + 
abnormal spatial learning behaviour 0.05 0.692 1 0.0001 - 
Chrna7 subcellular neuronal 0.5 0.695 1 0.0002 + 
abnormal motor coordination  balance behaviour 0.05 0.698 1 0.0002 + 
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decreased brain size 
region tract 
morphology 
0.5 0.699 
1 
0.0002 + 
abnormal neurotransmitter level cellular physiology 0.5 0.709 1 0.0001 + 
abnormal neuroendocrine cell morphology cellular morphology 0.5 0.712 1 0.0002 + 
abnormal astrocyte morphology cellular morphology 0.05 0.715 1 0.0001 - 
abnormal corpus callosum morphology 
region tract 
morphology 
0.05 0.716 
1 
0.0002 + 
abnormal cerebral cortex pyramidal cell morphology cellular morphology 0.5 0.717 1 0.0001 + 
abnormal dopaminergic neuron morphology cellular morphology 0.05 0.717 1 0.0001 + 
Cav2 channels subcellular neuronal 0.05 0.722 1 0.0001 + 
abnormal spatial reference memory behaviour 0.5 0.729 1 0.0001 + 
abnormal hindbrain development development 0.5 0.736 1 0.0001 - 
abnormal sexual interaction behaviour 0.5 0.754 1 0.0001 + 
abnormal somatosensory cortex morphology 
region tract 
morphology 
0.5 0.768 
1 
0.0001 + 
dilated third ventricle 
region tract 
morphology 
0.05 0.776 
1 
0.0001 + 
abnormal fear anxiety related behavior behaviour 0.05 0.778 1 0.0001 + 
abnormal parietal lobe morphology 
region tract 
morphology 
0.5 0.781 
1 
0.0001 + 
abnormal neurotransmitter level cellular physiology 0.05 0.784 1 0.0001 + 
abnormal corpus callosum morphology 
region tract 
morphology 
0.5 0.792 
1 
0.0001 + 
abnormal third ventricle morphology 
region tract 
morphology 
0.05 0.797 
1 
0.0001 - 
abnormal cued conditioning behavior behaviour 0.5 0.802 1 0.0001 + 
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abnormal cerebellum development development 0.5 0.806 1 0.0001 + 
abnormal miniature inhibitory postsynaptic currents cellular physiology 0.05 0.809 1 0.0001 + 
abnormal reflex behaviour 0.5 0.814 1 0.0001 - 
abnormal neocortex morphology 
region tract 
morphology 
0.05 0.814 
1 
0.0001 + 
NMDAR network subcellular neuronal 0.5 0.814 1 0.0001 - 
abnormal sensory capabilities reflexes nociception behaviour 0.5 0.816 1 0.0001 + 
abnormal response to new environment behaviour 0.05 0.822 1 0.0001 + 
abnormal touch  nociception behaviour 0.05 0.825 1 <0.0001 + 
abnormal CNS synapse formation development 0.05 0.828 1 0.0001 + 
abnormal brain interneuron morphology cellular morphology 0.5 0.837 1 0.0001 - 
abnormal excitatory postsynaptic currents cellular physiology 0.05 0.838 1 0.0001 + 
PSD human core SN subcellular neuronal 0.5 0.84 1 <0.0001 + 
GABA PSD subcellular neuronal 0.5 0.841 1 <0.0001 - 
abnormal lateral ventricle morphology 
region tract 
morphology 
0.5 0.847 
1 
<0.0001 - 
abnormal avoidance learning behavior behaviour 0.05 0.848 1 <0.0001 + 
abnormal social investigation behaviour 0.05 0.852 1 0.0001 + 
abnormal spatial working memory behaviour 0.5 0.864 1 <0.0001 + 
abnormal emotion affect behavior behaviour 0.05 0.865 1 <0.0001 - 
abnormal response to new environment behaviour 0.5 0.865 1 <0.0001 - 
abnormal brain vasculature morphology 
region tract 
morphology 
0.5 0.866 
1 
<0.0001 + 
abnormal CNS synapse formation development 0.5 0.87 1 <0.0001 - 
decreased brain size region tract 0.05 0.87 1 <0.0001 + 
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morphology 
abnormal PNS synaptic transmission cellular physiology 0.5 0.873 1 <0.0001 + 
Synaptic vesicle GABA enriched subcellular neuronal 0.5 0.878 1 <0.0001 + 
abnormal sexual interaction behaviour 0.05 0.889 1 <0.0001 + 
sporadic seizures behaviour 0.05 0.891 1 <0.0001 + 
abnormal oligodendrocyte morphology cellular morphology 0.05 0.891 1 <0.0001 - 
abnormal ependyma morphology 
region tract 
morphology 
0.05 0.897 
1 
<0.0001 + 
FMRP targets subcellular neuronal 0.5 0.898 1 <0.0001 + 
abnormal pituitary gland morphology 
region tract 
morphology 
0.5 0.9 
1 
<0.0001 - 
abnormal GABA mediated receptor currents cellular physiology 0.05 0.912 1 <0.0001 - 
abnormal reflex behaviour 0.05 0.915 1 <0.0001 + 
abnormal parietal lobe morphology 
region tract 
morphology 
0.05 0.918 
1 
<0.0001 + 
abnormal thermal nociception behaviour 0.05 0.925 1 <0.0001 + 
abnormal radial glial cell morphology cellular morphology 0.5 0.93 1 <0.0001 + 
abnormal mechanical nociception behaviour 0.5 0.943 1 <0.0001 + 
abnormal prepulse inhibition cellular physiology 0.5 0.945 1 <0.0001 - 
enlarged third ventricle 
region tract 
morphology 
0.5 0.945 
1 
<0.0001 + 
abnormal grooming behavior behaviour 0.05 0.948 1 <0.0001 - 
FMRP targets subcellular neuronal 0.05 0.953 1 <0.0001 - 
abnormal spatial working memory behaviour 0.05 0.955 1 <0.0001 - 
abnormal midbrain hindbrain boundary 
development 
development 0.05 0.956 
1 
<0.0001 + 
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abnormal nociception after inflammation behaviour 0.5 0.957 1 <0.0001 - 
PSD 95 core SN subcellular neuronal 0.05 0.964 1 <0.0001 - 
abnormal response to tactile stimuli behaviour 0.5 0.966 1 <0.0001 - 
seizures behaviour 0.05 0.967 1 <0.0001 - 
abnormal synapse morphology cellular morphology 0.5 0.967 1 <0.0001 - 
abnormal fear anxiety related behavior behaviour 0.5 0.969 1 <0.0001 - 
abnormal chemical nociception behaviour 0.05 0.971 1 <0.0001 - 
abnormal object recognition memory behaviour 0.05 0.971 1 <0.0001 - 
abnormal dopaminergic neuron morphology cellular morphology 0.5 0.972 1 <0.0001 - 
abnormal brain development development 0.05 0.972 1 <0.0001 - 
increased brain size 
region tract 
morphology 
0.05 0.972 
1 
<0.0001 - 
abnormal oligodendrocyte morphology cellular morphology 0.5 0.975 1 <0.0001 - 
abnormal astrocyte morphology cellular morphology 0.5 0.976 1 <0.0001 - 
abnormal response to novelty behaviour 0.5 0.981 1 <0.0001 - 
abnormal GABA mediated receptor currents cellular physiology 0.5 0.981 1 <0.0001 - 
abnormal neuron differentiation development 0.5 0.988 1 <0.0001 - 
abnormal neuroendocrine cell morphology cellular morphology 0.05 0.994 1 <0.0001 + 
 
Direction of effect refers to the sign of the regression coefficient. “+” means increased schizophrenia polygenic risk of that pathway was 
associated with a better performance IQ score. “–“ means increased polygenic risk of that pathway was associated with a worse 
performance IQ score. 
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7.4 Appendix D – Full PGC2 Minus CLOZUK schizophrenia polygenic pathway linear regression results for 
Cardiff COGS  
Pathway Category Thres P 
P 
(Corrected) %R2 DOE 
abnormal cerebellum development development 0.5 0.0105 0.0854 1.3312 + 
abnormal depression related behavior behaviour 0.05 0.0119 0.0967 1.2864 - 
abnormal hippocampus development development 0.05 0.0194 0.1576 1.1126 + 
abnormal oligodendrocyte morphology cellular morphology 0.05 0.0217 0.1762 1.0731 + 
abnormal depression related behavior behaviour 0.5 0.0246 0.1996 1.0293 - 
dilated third ventricle region tract morphology 0.5 0.0252 0.2044 1.0100 - 
abnormal temporal memory behaviour 0.5 0.0277 0.2254 0.9866 - 
abnormal hippocampus development development 0.5 0.0307 0.2496 0.9511 + 
abnormal glial cell morphology cellular morphology 0.05 0.0366 0.2976 0.8900 + 
abnormal fear anxiety related behavior behaviour 0.5 0.0395 0.3207 0.8643 - 
abnormal seizure response to inducing 
agent behaviour 0.5 0.0451 0.3660 0.8189 - 
abnormal contextual conditioning behavior behaviour 0.5 0.0456 0.3703 0.8149 - 
abnormal temporal memory behaviour 0.05 0.0501 0.4068 0.7726 - 
abnormal fear anxiety related behavior behaviour 0.05 0.0516 0.4192 0.7668 - 
abnormal behavioral response to xenobiotic behaviour 0.5 0.0525 0.4263 0.7560 - 
5HT 2C subcellular neuronal 0.05 0.0542 0.4401 0.7433 - 
abnormal CNS glial cell morphology cellular morphology 0.05 0.0563 0.4569 0.7300 + 
abnormal brain vasculature morphology region tract morphology 0.5 0.0588 0.4778 0.7235 + 
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5HT 2C subcellular neuronal 0.5 0.0596 0.4845 0.7163 - 
abnormal grooming behavior behaviour 0.5 0.0609 0.4950 0.7159 + 
abnormal glutamate mediated receptor 
currents cellular physiology 0.05 0.0610 0.4956 0.6997 - 
abnormal chemical nociception behaviour 0.05 0.0640 0.5200 0.6943 - 
abnormal contextual conditioning behavior behaviour 0.05 0.0651 0.5285 0.6885 - 
abnormal seizure response to inducing 
agent behaviour 0.05 0.0662 0.5378 0.6878 - 
abnormal glutamate mediated receptor 
currents cellular physiology 0.5 0.0663 0.5389 0.6636 - 
abnormal conditioned place preference 
behavior behaviour 0.5 0.0713 0.5793 0.6500 - 
abnormal autonomic nervous system 
morphology region tract morphology 0.5 0.0757 0.6151 0.6413 + 
abnormal synaptic transmission cellular physiology 0.05 0.0763 0.6194 0.6176 - 
abnormal CNS glial cell morphology cellular morphology 0.5 0.0819 0.6655 0.5903 + 
abnormal hindbrain development development 0.5 0.0836 0.6793 0.5703 + 
abnormal brain development development 0.5 0.0890 0.7231 0.5582 + 
abnormal associative learning behaviour 0.5 0.0946 0.7687 0.5544 - 
abnormal response to novelty behaviour 0.05 0.0950 0.7717 0.5543 + 
seizures behaviour 0.5 0.0982 0.7978 0.5500 - 
abnormal grooming behavior behaviour 0.05 0.0994 0.8071 0.5422 + 
abnormal associative learning behaviour 0.05 0.0994 0.8073 0.5400 - 
abnormal spinal cord morphology region tract morphology 0.5 0.1002 0.8143 0.5291 + 
abnormal miniature excitatory postsynaptic 
currents cellular physiology 0.5 0.1032 0.8381 0.5173 - 
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abnormal nervous system tract morphology region tract morphology 0.5 0.1054 0.8561 0.5168 + 
abnormal chemical nociception behaviour 0.5 0.1074 0.8727 0.4962 - 
Presynapse subcellular neuronal 0.05 0.1114 0.9052 0.4859 - 
abnormal mechanical nociception behaviour 0.05 0.1116 0.9067 0.4764 + 
abnormal axon morphology cellular morphology 0.5 0.1131 0.9187 0.4742 + 
abnormal cerebellum development development 0.05 0.1190 0.9669 0.4573 + 
abnormal eating drinking behavior behaviour 0.5 0.1229 0.9987 0.4549 + 
abnormal CNS synaptic transmission cellular physiology 0.05 0.1267 1 0.4356 - 
nonconvulsive seizures behaviour 0.05 0.1276 1 0.4050 - 
abnormal miniature excitatory postsynaptic 
currents cellular physiology 0.05 0.1346 1 0.3946 - 
abnormal synaptic transmission cellular physiology 0.5 0.1356 1 0.3890 - 
abnormal nervous system development development 0.5 0.1442 1 0.3838 + 
abnormal glial cell morphology cellular morphology 0.5 0.1591 1 0.3810 + 
abnormal pain threshold behaviour 0.05 0.1607 1 0.3726 - 
abnormal response to novelty behaviour 0.5 0.1646 1 0.3600 + 
Cav2 channels subcellular neuronal 0.5 0.1676 1 0.3646 - 
abnormal social conspecific interaction behaviour 0.5 0.1705 1 0.3600 + 
seizures behaviour 0.05 0.1721 1 0.3587 - 
abnormal oligodendrocyte morphology cellular morphology 0.5 0.1769 1 0.3600 + 
abnormal hindbrain morphology region tract morphology 0.5 0.1805 1 0.3500 + 
Presynapse subcellular neuronal 0.5 0.1816 1 0.3487 - 
abnormal axon morphology cellular morphology 0.05 0.1844 1 0.3487 + 
Cav2 channels subcellular neuronal 0.05 0.1852 1 0.3422 - 
Synaptic vesicle subcellular neuronal 0.05 0.1865 1 0.3422 - 
abnormal hippocampus morphology region tract morphology 0.05 0.1894 1 0.3422 + 
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abnormal somatic nervous system 
morphology region tract morphology 0.5 0.1900 1 0.3300 + 
abnormal corpus callosum morphology region tract morphology 0.5 0.1904 1 0.3300 + 
Pre synaptic active zone subcellular neuronal 0.5 0.1914 1 0.3239 - 
abnormal hippocampus morphology region tract morphology 0.5 0.1927 1 0.3065 + 
abnormal limbic system morphology region tract morphology 0.05 0.1950 1 0.3065 - 
abnormal motor coordination  balance behaviour 0.5 0.1956 1 0.2900 + 
abnormal brain size region tract morphology 0.05 0.2018 1 0.2846 - 
abnormal hindbrain morphology region tract morphology 0.05 0.2042 1 0.2600 - 
abnormal autonomic nervous system 
morphology region tract morphology 0.05 0.2052 1 0.2604 - 
abnormal CNS synaptic transmission cellular physiology 0.5 0.2081 1 0.2560 - 
abnormal discrimination learning behaviour 0.05 0.2207 1 0.2556 + 
abnormal cerebral cortex morphology region tract morphology 0.5 0.2211 1 0.2500 - 
abnormal parietal lobe morphology region tract morphology 0.5 0.2283 1 0.2493 - 
convulsive seizures behaviour 0.5 0.2381 1 0.2400 - 
abnormal midbrain morphology region tract morphology 0.5 0.2518 1 0.2321 + 
convulsive seizures behaviour 0.05 0.2591 1 0.2321 - 
abnormal long term potentiation cellular physiology 0.5 0.2632 1 0.2321 - 
abnormal behavioral response to xenobiotic behaviour 0.05 0.2635 1 0.2264 - 
decreased brain size region tract morphology 0.5 0.2660 1 0.2243 + 
abnormal reflex behaviour 0.05 0.2672 1 0.2239 - 
Pre synaptic active zone subcellular neuronal 0.05 0.2695 1 0.2234 - 
enlarged lateral ventricles region tract morphology 0.5 0.2772 1 0.2157 + 
abnormal neocortex morphology region tract morphology 0.05 0.2781 1 0.2080 + 
abnormal voluntary movement behaviour 0.05 0.2866 1 0.2075 - 
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abnormal midbrain morphology region tract morphology 0.05 0.2872 1 0.2052 + 
abnormal brainstem morphology region tract morphology 0.05 0.2895 1 0.2008 + 
abnormal neurite morphology cellular morphology 0.5 0.2927 1 0.2008 + 
abnormal inhibitory postsynaptic currents cellular physiology 0.5 0.2950 1 0.1957 + 
abnormal avoidance learning behavior behaviour 0.5 0.2953 1 0.2008 - 
abnormal inhibitory postsynaptic currents cellular physiology 0.05 0.2953 1 0.1938 + 
abnormal parental behavior behaviour 0.5 0.2959 1 0.1915 + 
sporadic seizures behaviour 0.05 0.3044 1 0.1884 - 
abnormal spinal cord morphology region tract morphology 0.05 0.3056 1 0.1862 - 
abnormal parental behavior behaviour 0.05 0.3132 1 0.1845 + 
abnormal emotion affect behavior behaviour 0.05 0.3138 1 0.1833 - 
abnormal radial glial cell morphology cellular morphology 0.05 0.3165 1 0.1799 + 
sporadic seizures behaviour 0.5 0.3218 1 0.1780 - 
abnormal hypothalamus morphology region tract morphology 0.05 0.3262 1 0.1780 - 
abnormal excitatory postsynaptic currents cellular physiology 0.05 0.3280 1 0.1776 - 
abnormal somatic nervous system 
morphology region tract morphology 0.05 0.3293 1 0.1735 - 
abnormal cued conditioning behavior behaviour 0.05 0.3304 1 0.1735 - 
abnormal reflex behaviour 0.5 0.3333 1 0.1654 - 
abnormal limbic system morphology region tract morphology 0.5 0.3362 1 0.1654 - 
abnormal post tetanic potentiation cellular physiology 0.5 0.3371 1 0.1649 + 
Synaptic vesicle GABA enriched subcellular neuronal 0.05 0.3400 1 0.1647 + 
abnormal response to new environment behaviour 0.5 0.3422 1 0.1647 + 
stereotypic behavior behaviour 0.05 0.3439 1 0.1621 - 
abnormal brain development development 0.05 0.3483 1 0.1613 + 
abnormal brain vasculature morphology region tract morphology 0.05 0.3504 1 0.1463 - 
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Synaptic vesicle subcellular neuronal 0.5 0.3508 1 0.1505 - 
abnormal paired pulse facilitation cellular physiology 0.05 0.3515 1 0.1463 + 
thin cerebral cortex region tract morphology 0.5 0.3559 1 0.1462 - 
abnormal long term potentiation cellular physiology 0.05 0.3571 1 0.1460 - 
abnormal GABAergic neuron morphology cellular morphology 0.5 0.3686 1 0.1389 - 
abnormal spatial reference memory behaviour 0.05 0.3686 1 0.1372 + 
abnormal neuroendocrine cell morphology cellular morphology 0.05 0.3692 1 0.1353 + 
mGluR5 subcellular neuronal 0.05 0.3696 1 0.1341 - 
abnormal brain morphology region tract morphology 0.05 0.3701 1 0.1281 - 
abnormal pain threshold behaviour 0.5 0.3734 1 0.1281 - 
abnormal telencephalon development development 0.5 0.3745 1 0.1281 + 
abnormal cerebral cortex morphology region tract morphology 0.05 0.3805 1 0.1253 - 
Chrna7 subcellular neuronal 0.5 0.3911 1 0.1238 + 
abnormal fourth ventricle morphology region tract morphology 0.05 0.3955 1 0.1234 + 
abnormal emotion affect behavior behaviour 0.5 0.3979 1 0.1115 - 
abnormal telencephalon development development 0.05 0.3982 1 0.1079 + 
abnormal GABAergic neuron morphology cellular morphology 0.05 0.4099 1 0.1042 - 
abnormal cued conditioning behavior behaviour 0.5 0.4128 1 0.1007 - 
abnormal social conspecific interaction behaviour 0.05 0.4160 1 0.1005 + 
abnormal sensory capabilities reflexes 
nociception behaviour 0.05 0.4181 1 0.1005 - 
abnormal basal ganglion morphology region tract morphology 0.05 0.4191 1 0.0969 + 
abnormal prepulse inhibition cellular physiology 0.05 0.4288 1 0.0951 - 
abnormal parietal lobe morphology region tract morphology 0.05 0.4310 1 0.0951 + 
abnormal response to new environment behaviour 0.05 0.4339 1 0.0947 + 
abnormal excitatory postsynaptic potential cellular physiology 0.05 0.4367 1 0.0919 + 
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abnormal sensory capabilities reflexes 
nociception behaviour 0.5 0.4373 1 0.0914 - 
abnormal thalamus morphology region tract morphology 0.5 0.4558 1 0.0907 + 
abnormal eating drinking behavior behaviour 0.05 0.4603 1 0.0947 + 
abnormal CNS synapse formation development 0.05 0.4678 1 0.0834 - 
abnormal motor learning behaviour 0.5 0.4755 1 0.0834 + 
abnormal motor learning behaviour 0.05 0.4829 1 0.0816 + 
abnormal brain ventricle choroid plexus 
morphology region tract morphology 0.5 0.4840 1 0.0810 + 
abnormal telencephalon morphology region tract morphology 0.5 0.4866 1 0.0808 + 
abnormal astrocyte morphology cellular morphology 0.5 0.4914 1 0.0791 + 
abnormal excitatory postsynaptic currents cellular physiology 0.5 0.4953 1 0.0781 - 
abnormal brain interneuron morphology cellular morphology 0.5 0.4954 1 0.0834 + 
abnormal behavior behaviour 0.05 0.4963 1 0.0756 - 
abnormal ependyma morphology region tract morphology 0.5 0.5028 1 0.0753 - 
abnormal mechanical nociception behaviour 0.5 0.5029 1 0.0750 + 
CYFIP1 all subcellular neuronal 0.5 0.5040 1 0.0741 + 
abnormal somatosensory cortex 
morphology region tract morphology 0.5 0.5051 1 0.0739 - 
abnormal touch  nociception behaviour 0.05 0.5056 1 0.0731 - 
abnormal forebrain morphology region tract morphology 0.5 0.5070 1 0.0728 - 
dilated third ventricle region tract morphology 0.05 0.5090 1 0.0731 - 
abnormal pituitary gland morphology region tract morphology 0.5 0.5165 1 0.0690 - 
abnormal brain size region tract morphology 0.5 0.5179 1 0.0629 - 
abnormal innervation region tract morphology 0.5 0.5207 1 0.0626 - 
abnormal midbrain hindbrain boundary development 0.05 0.5232 1 0.0624 - 
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development 
abnormal touch  nociception behaviour 0.5 0.5276 1 0.0607 - 
abnormal synaptic depression cellular physiology 0.05 0.5285 1 0.0602 - 
abnormal nociception after inflammation behaviour 0.5 0.5291 1 0.0594 - 
abnormal miniature inhibitory postsynaptic 
currents cellular physiology 0.5 0.5299 1 0.0578 + 
abnormal response to tactile stimuli behaviour 0.05 0.5342 1 0.0554 + 
abnormal microglial cell morphology cellular morphology 0.5 0.5366 1 0.0531 - 
abnormal third ventricle morphology region tract morphology 0.05 0.5430 1 0.0531 - 
abnormal paired pulse facilitation cellular physiology 0.5 0.5432 1 0.0523 + 
abnormal circadian rhythm behaviour 0.05 0.5442 1 0.0521 + 
abnormal involuntary movement behaviour 0.05 0.5449 1 0.0521 - 
abnormal miniature inhibitory postsynaptic 
currents cellular physiology 0.05 0.5473 1 0.0518 + 
abnormal cerebral cortex pyramidal cell 
morphology cellular morphology 0.05 0.5478 1 0.0531 - 
abnormal astrocyte morphology cellular morphology 0.05 0.5500 1 0.0531 + 
abnormal dopaminergic neuron morphology cellular morphology 0.05 0.5509 1 0.0484 + 
increased brain size region tract morphology 0.05 0.5579 1 0.0531 - 
abnormal social investigation behaviour 0.5 0.5615 1 0.0531 + 
abnormal forebrain development development 0.5 0.5792 1 0.0455 + 
abnormal learning  memory behaviour 0.05 0.5802 1 0.0440 - 
abnormal motor coordination  balance behaviour 0.05 0.5809 1 0.0440 + 
abnormal vocalization behaviour 0.5 0.5862 1 0.0376 + 
FMRP targets subcellular neuronal 0.5 0.5867 1 0.0440 - 
abnormal voluntary movement behaviour 0.5 0.5876 1 0.0359 - 
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abnormal spatial working memory behaviour 0.5 0.5900 1 0.0440 - 
analgesia behaviour 0.05 0.5950 1 0.0326 + 
abnormal nociception after inflammation behaviour 0.05 0.6007 1 0.0326 - 
abnormal neuron differentiation development 0.5 0.6030 1 0.0326 + 
abnormal dendrite morphology cellular morphology 0.05 0.6104 1 0.0303 - 
enlarged third ventricle region tract morphology 0.5 0.6120 1 0.0296 - 
abnormal neurotransmitter level cellular physiology 0.5 0.6133 1 0.0282 + 
abnormal post tetanic potentiation cellular physiology 0.05 0.6139 1 0.0271 + 
abnormal hindbrain development development 0.05 0.6140 1 0.0270 + 
abnormal sleep behavior behaviour 0.5 0.6150 1 0.0268 - 
abnormal pituitary gland morphology region tract morphology 0.05 0.6157 1 0.0265 - 
increased brain size region tract morphology 0.5 0.6235 1 0.0236 - 
abnormal synapse morphology cellular morphology 0.5 0.6266 1 0.0234 + 
abnormal third ventricle morphology region tract morphology 0.5 0.6282 1 0.0233 - 
abnormal ependyma morphology region tract morphology 0.05 0.6330 1 0.0228 - 
stereotypic behavior behaviour 0.5 0.6338 1 0.0215 - 
abnormal behavior behaviour 0.5 0.6373 1 0.0201 - 
enlarged third ventricle region tract morphology 0.05 0.6421 1 0.0197 - 
CYFIP1 all subcellular neuronal 0.05 0.6428 1 0.0175 + 
abnormal somatosensory cortex 
morphology region tract morphology 0.05 0.6604 1 0.0175 - 
PSD 95 core SN subcellular neuronal 0.5 0.6642 1 0.0167 - 
FMRP targets subcellular neuronal 0.05 0.6682 1 0.0175 - 
abnormal brainstem morphology region tract morphology 0.5 0.6713 1 0.0175 - 
abnormal forebrain development development 0.05 0.6752 1 0.0175 + 
abnormal brain white matter morphology region tract morphology 0.05 0.6772 1 0.0175 + 
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abnormal postnatal subventricular zone 
morphology region tract morphology 0.05 0.6813 1 0.0151 + 
abnormal midbrain development development 0.5 0.6899 1 0.0138 - 
abnormal motor capabilities coordination 
movement behaviour 0.05 0.6928 1 0.0137 - 
abnormal cerebrum morphology region tract morphology 0.5 0.6968 1 0.0117 + 
abnormal stratification in cerebral cortex region tract morphology 0.05 0.6985 1 0.0117 + 
nonconvulsive seizures behaviour 0.5 0.7005 1 0.0117 - 
Synaptic vesicle Glu enriched subcellular neuronal 0.5 0.7037 1 0.0112 + 
abnormal spatial reference memory behaviour 0.5 0.7107 1 0.0107 + 
abnormal involuntary movement behaviour 0.5 0.7161 1 0.0117 - 
abnormal object recognition memory behaviour 0.5 0.7166 1 0.0117 - 
abnormal synaptic plasticity cellular physiology 0.5 0.7172 1 0.0095 + 
abnormal excitatory postsynaptic potential cellular physiology 0.5 0.7190 1 0.0117 + 
GABA PSD subcellular neuronal 0.5 0.7211 1 0.0087 - 
abnormal discrimination learning behaviour 0.5 0.7344 1 0.0117 + 
abnormal brain interneuron morphology cellular morphology 0.05 0.7355 1 0.0083 + 
abnormal midbrain development development 0.05 0.7356 1 0.0079 - 
abnormal GABA mediated receptor currents cellular physiology 0.05 0.7384 1 0.0076 - 
abnormal neuron differentiation development 0.05 0.7460 1 0.0117 + 
GABA PSD subcellular neuronal 0.05 0.7539 1 0.0065 - 
abnormal circadian rhythm behaviour 0.5 0.7562 1 0.0064 + 
PSD human core SN subcellular neuronal 0.5 0.7697 1 0.0060 - 
abnormal lateral ventricle morphology region tract morphology 0.5 0.7722 1 0.0059 + 
abnormal neuron morphology cellular morphology 0.05 0.7752 1 0.0117 - 
abnormal basal ganglion morphology region tract morphology 0.5 0.7788 1 0.0052 + 
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abnormal temporal lobe morphology region tract morphology 0.05 0.7793 1 0.0052 + 
abnormal CNS synapse formation development 0.5 0.7807 1 0.0117 - 
abnormal lateral ventricle morphology region tract morphology 0.05 0.7823 1 < 0.01 + 
abnormal postnatal subventricular zone 
morphology region tract morphology 0.5 0.7826 1 < 0.01 + 
abnormal cerebrum morphology region tract morphology 0.05 0.7857 1 < 0.01 - 
abnormal radial glial cell morphology cellular morphology 0.5 0.7859 1 < 0.01 + 
abnormal nervous system development development 0.05 0.7950 1 < 0.01 + 
abnormal prepulse inhibition cellular physiology 0.5 0.7960 1 < 0.01 + 
abnormal thalamus morphology region tract morphology 0.05 0.8015 1 < 0.01 - 
abnormal stratification in cerebral cortex region tract morphology 0.5 0.8100 1 < 0.01 - 
abnormal learning  memory behaviour 0.5 0.8110 1 < 0.01 - 
abnormal neuron morphology cellular morphology 0.5 0.8149 1 < 0.01 + 
abnormal Muller cell morphology cellular morphology 0.5 0.8192 1 < 0.01 + 
abnormal microglial cell morphology cellular morphology 0.05 0.8194 1 < 0.01 - 
abnormal diencephalon morphology region tract morphology 0.5 0.8195 1 < 0.01 - 
dilated lateral ventricles region tract morphology 0.5 0.8266 1 < 0.01 - 
abnormal neurite morphology cellular morphology 0.05 0.8293 1 < 0.01 + 
abnormal forebrain morphology region tract morphology 0.05 0.8306 1 < 0.01 - 
NMDAR network subcellular neuronal 0.5 0.8366 1 < 0.01 - 
thin cerebral cortex region tract morphology 0.05 0.8389 1 < 0.01 - 
abnormal avoidance learning behavior behaviour 0.05 0.8400 1 < 0.01 + 
abnormal sexual interaction behaviour 0.5 0.8447 1 < 0.01 + 
abnormal conditioned place preference 
behavior behaviour 0.05 0.8473 1 < 0.01 - 
abnormal brain white matter morphology region tract morphology 0.5 0.8537 1 < 0.01 - 
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ARC pathway SN subcellular neuronal 0.05 0.8584 1 < 0.01 + 
abnormal response to tactile stimuli behaviour 0.5 0.8593 1 < 0.01 + 
abnormal motor capabilities coordination 
movement behaviour 0.5 0.8635 1 < 0.01 - 
abnormal synaptic depression cellular physiology 0.5 0.8642 1 < 0.01 - 
PSD human core SN subcellular neuronal 0.05 0.8657 1 < 0.01 - 
abnormal neocortex morphology region tract morphology 0.5 0.8674 1 < 0.01 - 
abnormal PNS synaptic transmission cellular physiology 0.05 0.8734 1 < 0.01 - 
abnormal neuroendocrine cell morphology cellular morphology 0.5 0.8735 1 < 0.01 + 
abnormal fourth ventricle morphology region tract morphology 0.5 0.8770 1 < 0.01 - 
abnormal nervous system tract morphology region tract morphology 0.05 0.8795 1 < 0.01 + 
abnormal thermal nociception behaviour 0.5 0.8801 1 < 0.01 + 
abnormal diencephalon morphology region tract morphology 0.05 0.8835 1 < 0.01 + 
abnormal synapse morphology cellular morphology 0.05 0.8855 1 < 0.01 + 
mGluR5 subcellular neuronal 0.5 0.8878 1 < 0.01 - 
abnormal midbrain hindbrain boundary 
development development 0.5 0.8883 1 < 0.01 - 
abnormal hypothalamus morphology region tract morphology 0.5 0.8884 1 < 0.01 + 
abnormal PNS synaptic transmission cellular physiology 0.5 0.8935 1 < 0.01 - 
abnormal aggression related behavior behaviour 0.05 0.8966 1 < 0.01 - 
abnormal Muller cell morphology cellular morphology 0.05 0.8971 1 < 0.01 - 
abnormal nervous system morphology region tract morphology 0.5 0.8974 1 < 0.01 + 
abnormal brain ventricle choroid plexus 
morphology region tract morphology 0.05 0.9002 1 < 0.01 + 
ARC pathway SN subcellular neuronal 0.5 0.9037 1 < 0.01 - 
NMDAR network subcellular neuronal 0.05 0.9109 1 < 0.01 - 
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abnormal dopaminergic neuron morphology cellular morphology 0.5 0.9152 1 < 0.01 + 
abnormal social investigation behaviour 0.05 0.9189 1 < 0.01 + 
abnormal dendrite morphology cellular morphology 0.5 0.9215 1 < 0.01 + 
PSD 95 core SN subcellular neuronal 0.05 0.9219 1 < 0.01 + 
enlarged lateral ventricles region tract morphology 0.05 0.9225 1 < 0.01 + 
decreased brain size region tract morphology 0.05 0.9226 1 < 0.01 + 
abnormal vocalization behaviour 0.05 0.9228 1 < 0.01 + 
abnormal corpus callosum morphology region tract morphology 0.05 0.9232 1 < 0.01 + 
Synaptic vesicle Glu enriched subcellular neuronal 0.05 0.9291 1 < 0.01 + 
abnormal neurotransmitter level cellular physiology 0.05 0.9295 1 < 0.01 - 
abnormal cerebral cortex pyramidal cell 
morphology cellular morphology 0.5 0.9324 1 < 0.01 - 
abnormal object recognition memory behaviour 0.05 0.9324 1 < 0.01 + 
abnormal temporal lobe morphology region tract morphology 0.5 0.9376 1 < 0.01 + 
abnormal spatial learning behaviour 0.05 0.9377 1 < 0.01 - 
analgesia behaviour 0.5 0.9393 1 < 0.01 + 
abnormal sexual interaction behaviour 0.05 0.9407 1 < 0.01 - 
abnormal GABA mediated receptor currents cellular physiology 0.5 0.9407 1 < 0.01 + 
abnormal brain morphology region tract morphology 0.5 0.9418 1 < 0.01 - 
abnormal brain ventricle morphology region tract morphology 0.05 0.9433 1 < 0.01 - 
abnormal sleep behavior behaviour 0.05 0.9447 1 < 0.01 + 
abnormal spatial working memory behaviour 0.05 0.9514 1 < 0.01 + 
abnormal aggression related behavior behaviour 0.5 0.9518 1 < 0.01 + 
abnormal spatial learning behaviour 0.5 0.9597 1 < 0.01 - 
abnormal nervous system morphology region tract morphology 0.05 0.9608 1 < 0.01 - 
abnormal telencephalon morphology region tract morphology 0.05 0.9639 1 < 0.01 - 
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abnormal brain ventricle morphology region tract morphology 0.5 0.9667 1 < 0.01 - 
abnormal synaptic plasticity cellular physiology 0.05 0.9678 1 < 0.01 + 
Synaptic vesicle GABA enriched subcellular neuronal 0.5 0.9718 1 < 0.01 + 
abnormal thermal nociception behaviour 0.05 0.9803 1 < 0.01 - 
abnormal innervation region tract morphology 0.05 0.9883 1 < 0.01 - 
dilated lateral ventricles region tract morphology 0.05 0.9935 1 < 0.01 - 
Chrna7 subcellular neuronal 0.05 0.9938 1 < 0.01 - 
 
Direction of effect refers to the sign of the regression coefficient. “+” means increased schizophrenia polygenic risk of that pathway was 
associated with a better MATRICS composite score. “–“ means increased polygenic risk of that pathway was associated with a worse 
MATRICS composite score. 
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7.5 Appendix E – Brown’s p-values for associations between SNPs in the 155 candidate pathways and general 
cognitive ability in schizophrenia cases 
Pathway Category Pathway NSNP P1 
P 
(Corrected) 
Behaviour abnormal motor learning 12793 0.056 0.095 
Behaviour abnormal discrimination learning 5607 0.073 0.124 
Development abnormal CNS synapse formation 5657 0.075 0.127 
Region Tract 
Morphology abnormal hindbrain morphology 78393 0.083 0.141 
Cellular Physiology abnormal GABA mediated receptor currents 5186 0.094 0.160 
Cellular Physiology abnormal miniature inhibitory postsynaptic currents 5658 0.119 0.202 
Region Tract 
Morphology abnormal cerebrum morphology 87344 0.121 0.206 
Region Tract 
Morphology abnormal lateral ventricle morphology 16676 0.121 0.206 
Region Tract 
Morphology abnormal telencephalon morphology 109098 0.134 0.228 
Region Tract 
Morphology abnormal forebrain morphology 132002 0.136 0.231 
Region Tract 
Morphology abnormal midbrain morphology 20284 0.147 0.277 
Region Tract 
Morphology abnormal autonomic nervous system morphology 9261 0.162 0.305 
Region Tract abnormal cerebral cortex morphology 37594 0.178 0.335 
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Morphology 
Region Tract 
Morphology abnormal brainstem morphology 37040 0.184 0.345 
Region Tract 
Morphology enlarged lateral ventricles 10680 0.189 0.355 
Region Tract 
Morphology abnormal brain morphology 215431 0.196 0.368 
Behaviour stereotypic behavior 37697 0.204 0.383 
Development abnormal cerebellum development 32712 0.204 0.384 
Behaviour abnormal response to new environment 40290 0.211 0.397 
Cellular Morphology abnormal neuroendocrine cell morphology 1150 0.222 0.416 
Development abnormal hindbrain development 37561 0.228 0.429 
Cellular Morphology abnormal cerebral cortex pyramidal cell morphology 6764 0.232 0.436 
Development abnormal hippocampus development 2849 0.233 0.437 
Cellular Physiology abnormal prepulse inhibition 25231 0.235 0.442 
Development abnormal brain development 85442 0.238 0.446 
Behaviour abnormal motor coordination  balance 142486 0.241 0.452 
Behaviour abnormal involuntary movement 115326 0.249 0.467 
Behaviour abnormal response to novelty 43621 0.249 0.468 
Behaviour abnormal reflex 95790 0.251 0.471 
Cellular Morphology abnormal radial glial cell morphology 7569 0.251 0.472 
Cellular Physiology abnormal post tetanic potentiation 3393 0.265 0.498 
Region Tract 
Morphology abnormal nervous system morphology 350376 0.270 0.506 
Region Tract 
Morphology abnormal ependyma morphology 671 0.282 0.529 
Region Tract abnormal pituitary gland morphology 16432 0.285 0.535 
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Morphology 
Subcellular Neuronal CYFIP1 all 7275 0.290 0.544 
Region Tract 
Morphology abnormal innervation 38718 0.290 0.544 
Cellular Morphology abnormal Muller cell morphology 934 0.291 0.547 
Region Tract 
Morphology abnormal limbic system morphology 53129 0.301 0.566 
Region Tract 
Morphology abnormal hippocampus morphology 47947 0.301 0.566 
Cellular Physiology abnormal neurotransmitter level 14912 0.312 0.586 
Cellular Morphology abnormal synapse morphology 29419 0.313 0.587 
Region Tract 
Morphology abnormal temporal lobe morphology 49656 0.316 0.594 
Region Tract 
Morphology abnormal brain ventricle morphology 24966 0.321 0.602 
Region Tract 
Morphology increased brain size 9253 0.321 0.603 
Region Tract 
Morphology abnormal brain ventricle choroid plexus morphology 30872 0.328 0.616 
Behaviour abnormal social investigation 21872 0.332 0.622 
Development abnormal nervous system development 150280 0.337 0.632 
Cellular Physiology abnormal paired pulse facilitation 20400 0.341 0.641 
Region Tract 
Morphology dilated lateral ventricles 5598 0.342 0.642 
Region Tract 
Morphology abnormal spinal cord morphology 47602 0.343 0.643 
Cellular Physiology abnormal synaptic plasticity 9020 0.343 0.643 
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Behaviour abnormal learning  memory 122683 0.345 0.648 
Behaviour abnormal behavioral response to xenobiotic 52232 0.361 0.677 
Region Tract 
Morphology abnormal neocortex morphology 1715 0.373 0.700 
Subcellular Neuronal Chrna7 13547 0.375 0.703 
Behaviour abnormal grooming behavior 18604 0.383 0.720 
Cellular Morphology abnormal dopaminergic neuron morphology 8503 0.387 0.727 
Region Tract 
Morphology abnormal diencephalon morphology 35091 0.389 0.731 
Development abnormal midbrain development 3652 0.390 0.732 
Cellular Morphology abnormal oligodendrocyte morphology 5615 0.396 0.744 
Behaviour nonconvulsive seizures 5223 0.399 0.749 
Cellular Physiology abnormal PNS synaptic transmission 9158 0.403 0.757 
Behaviour abnormal associative learning 54548 0.411 0.771 
Development abnormal telencephalon development 15894 0.411 0.772 
Development abnormal forebrain development 24338 0.417 0.782 
Behaviour abnormal sensory capabilities reflexes nociception 142991 0.430 0.807 
Subcellular Neuronal 5HT 2C 2371 0.430 0.808 
Cellular Morphology abnormal neuron morphology 205349 0.431 0.809 
Cellular Morphology abnormal CNS glial cell morphology 34584 0.435 0.816 
Region Tract 
Morphology abnormal brain white matter morphology 36545 0.441 0.828 
Cellular Morphology abnormal dendrite morphology 23020 0.442 0.830 
Region Tract 
Morphology abnormal somatic nervous system morphology 127652 0.443 0.832 
Region Tract 
Morphology dilated third ventricle 2547 0.443 0.832 
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Region Tract 
Morphology abnormal nervous system tract morphology 35792 0.443 0.832 
Region Tract 
Morphology abnormal brain size 32085 0.449 0.843 
Region Tract 
Morphology abnormal corpus callosum morphology 27791 0.452 0.849 
Region Tract 
Morphology abnormal thalamus morphology 6191 0.465 0.873 
Behaviour abnormal mechanical nociception 1420 0.470 0.881 
Behaviour abnormal chemical nociception 9115 0.487 0.915 
Cellular Morphology abnormal neurite morphology 50230 0.491 0.923 
Cellular Physiology abnormal CNS synaptic transmission 129079 0.492 0.923 
Region Tract 
Morphology abnormal hypothalamus morphology 3532 0.493 0.926 
Region Tract 
Morphology abnormal stratification in cerebral cortex 7829 0.496 0.931 
Behaviour abnormal sexual interaction 15301 0.500 0.938 
Region Tract 
Morphology abnormal somatosensory cortex morphology 6905 0.504 0.946 
Development abnormal midbrain hindbrain boundary development 1061 0.504 0.947 
Region Tract 
Morphology abnormal third ventricle morphology 8614 0.507 0.952 
Behaviour abnormal conditioned place preference behavior 3789 0.514 0.966 
Cellular Physiology abnormal synaptic transmission 147864 0.515 0.968 
Behaviour abnormal spatial working memory 11029 0.518 0.973 
Behaviour abnormal object recognition memory 3660 0.519 0.975 
Cellular Physiology abnormal excitatory postsynaptic currents 36747 0.523 0.981 
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Behaviour abnormal spatial learning 55636 0.524 0.984 
Region Tract 
Morphology abnormal parietal lobe morphology 7344 0.524 0.985 
Cellular Physiology abnormal synaptic depression 28224 0.526 0.987 
Cellular Physiology abnormal excitatory postsynaptic potential 19984 0.531 0.997 
Cellular Morphology abnormal glial cell morphology 46229 0.542 1 
Behaviour abnormal cued conditioning behavior 23001 0.546 1 
Behaviour abnormal seizure response to inducing agent 46789 0.552 1 
Behaviour analgesia 13655 0.554 1 
Behaviour abnormal voluntary movement 202622 0.555 1 
Behaviour abnormal avoidance learning behavior 14004 0.557 1 
Region Tract 
Morphology abnormal fourth ventricle morphology 5094 0.566 1 
Region Tract 
Morphology abnormal brain vasculature morphology 3490 0.566 1 
Region Tract 
Morphology thin cerebral cortex 7160 0.571 1 
Region Tract 
Morphology abnormal basal ganglion morphology 10079 0.579 1 
Cellular Physiology abnormal inhibitory postsynaptic currents 16184 0.581 1 
Cellular Morphology abnormal brain interneuron morphology 14836 0.584 1 
Behaviour abnormal pain threshold 40551 0.592 1 
Behaviour abnormal response to tactile stimuli 23471 0.593 1 
Behaviour abnormal social conspecific interaction 65380 0.594 1 
Behaviour abnormal touch  nociception 55421 0.595 1 
Region Tract 
Morphology decreased brain size 20799 0.600 1 
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Subcellular Neuronal Cav2 channels 74186 0.601 1 
Behaviour abnormal nociception after inflammation 8630 0.602 1 
Behaviour abnormal contextual conditioning behavior 28093 0.618 1 
Development abnormal neuron differentiation 49642 0.619 1 
Subcellular Neuronal NMDAR network 21183 0.622 1 
Region Tract 
Morphology abnormal postnatal subventricular zone morphology 7084 0.623 1 
Behaviour abnormal thermal nociception 26987 0.628 1 
Behaviour abnormal temporal memory 29640 0.632 1 
Behaviour seizures 68289 0.638 1 
Region Tract 
Morphology enlarged third ventricle 3802 0.658 1 
Subcellular Neuronal PSD 95 core SN 21212 0.664 1 
Subcellular Neuronal mGluR5 18032 0.666 1 
Cellular Morphology abnormal axon morphology 19012 0.674 1 
Behaviour abnormal vocalization 12894 0.683 1 
Behaviour convulsive seizures 31270 0.691 1 
Behaviour abnormal emotion affect behavior 79890 0.704 1 
Cellular Morphology abnormal astrocyte morphology 16670 0.704 1 
Behaviour abnormal parental behavior 29994 0.705 1 
Behaviour abnormal eating drinking behavior 79612 0.709 1 
Behaviour abnormal spatial reference memory 9398 0.724 1 
Subcellular Neuronal Synaptic vesicle GABA enriched 4661 0.730 1 
Cellular Physiology abnormal long term potentiation 49049 0.734 1 
Behaviour abnormal sleep behavior 7749 0.740 1 
Behaviour abnormal depression related behavior 10651 0.744 1 
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Subcellular Neuronal Synaptic vesicle Glu enriched 4110 0.745 1 
Subcellular Neuronal GABA PSD 9818 0.752 1 
Behaviour abnormal motor capabilities coordination movement 264692 0.756 1 
Subcellular Neuronal FMRP targets 267391 0.766 1 
Cellular Physiology abnormal glutamate mediated receptor currents 12340 0.766 1 
Behaviour abnormal circadian rhythm 8549 0.771 1 
Behaviour abnormal fear anxiety related behavior 48120 0.775 1 
Subcellular Neuronal ARC pathway SN 11767 0.784 1 
Cellular Morphology abnormal GABAergic neuron morphology 1763 0.792 1 
Behaviour abnormal behavior 372178 0.797 1 
Cellular Morphology abnormal microglial cell morphology 2574 0.806 1 
Cellular Physiology abnormal miniature excitatory postsynaptic currents 14889 0.825 1 
Subcellular Neuronal Pre synaptic active zone 31001 0.829 1 
Behaviour sporadic seizures 2368 0.834 1 
Subcellular Neuronal PSD human core SN 158492 0.856 1 
Behaviour abnormal aggression related behavior 13856 0.863 1 
Subcellular Neuronal Synaptic vesicle 71108 0.863 1 
Subcellular Neuronal Presynapse 88965 0.911 1 
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7.6 Appendix F – List of neuropsychiatric CNVs from (Kaminsky et al., 2011; Girirajan et al., 2012) 
10q23 
15q11.2 
15q13.3 
16p11.2 
16p12.1 
16p13.11 
17p11.2 
17q12 
1p36 
1q21.1 
22q11.2 
22q13 
3q29 
5q35 
7q11.23 
8p23.1 
9q34 
Potocki–Lupski 
Prader Willi Syndrome/Angelman Syndrome 
Williams-Beuren 
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7.7 Appendix G – Linear regression results for 85 pathways hit by genes in large (>100kb) CNVs and their 
association with the MATRICS composite score   
Category Pathway P Corrected P %R2 Increase Direction of Effect 
behaviour abnormal reflex 0.081 0.0996 0.329 Negative 
behaviour abnormal circadian rhythm 0.107 0.1316 0.318 Positive 
behaviour abnormal involuntary movement 0.125 0.1538 0.312 Negative 
subcellular neuronal Presynapse 0.142 0.1747 0.307 Negative 
behaviour stereotypic behavior 0.178 0.2189 0.299 Negative 
development abnormal hindbrain development 0.213 0.2620 0.292 Positive 
development abnormal midbrain development 0.213 0.2620 0.292 Positive 
cellular physiology abnormal excitatory postsynaptic potential 0.247 0.3038 0.287 Negative 
cellular physiology abnormal synaptic plasticity 0.247 0.3038 0.287 Negative 
region tract morphology abnormal hippocampus morphology 0.247 0.3038 0.287 Negative 
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region tract morphology abnormal temporal lobe morphology 0.247 0.3038 0.287 Negative 
behaviour abnormal social investigation 0.250 0.3075 0.286 Negative 
behaviour abnormal avoidance learning behavior 0.275 0.3383 0.283 Positive 
cellular physiology 
abnormal miniature excitatory postsynaptic 
currents 0.275 0.3383 0.283 Positive 
region tract morphology abnormal basal ganglion morphology 0.275 0.3383 0.283 Positive 
region tract morphology abnormal brain size 0.275 0.3383 0.283 Positive 
region tract morphology abnormal lateral ventricle morphology 0.275 0.3383 0.283 Positive 
region tract morphology abnormal third ventricle morphology 0.275 0.3383 0.283 Positive 
region tract morphology dilated lateral ventricles 0.275 0.3383 0.283 Positive 
region tract morphology dilated third ventricle 0.275 0.3383 0.283 Positive 
region tract morphology increased brain size 0.275 0.3383 0.283 Positive 
region tract morphology abnormal diencephalon morphology 0.281 0.3456 0.282 Positive 
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behaviour abnormal parental behavior 0.323 0.3973 0.277 Negative 
subcellular neuronal Chrna7 0.339 0.4170 0.276 Negative 
development abnormal forebrain development 0.345 0.4244 0.275 Positive 
behaviour abnormal behavioral response to xenobiotic 0.402 0.4945 0.271 Negative 
development abnormal brain development 0.403 0.4957 0.270 Positive 
region tract morphology abnormal limbic system morphology 0.408 0.5018 0.270 Negative 
behaviour abnormal associative learning 0.451 0.5547 0.267 Negative 
cellular physiology abnormal long term potentiation 0.451 0.5547 0.267 Negative 
development abnormal nervous system development 0.478 0.5879 0.266 Positive 
cellular morphology abnormal neurite morphology 0.524 0.6445 0.263 Positive 
development abnormal neuron differentiation 0.536 0.6593 0.263 Positive 
behaviour abnormal cued conditioning behavior 0.544 0.6691 0.262 Negative 
behaviour abnormal spatial learning 0.544 0.6691 0.262 Positive 
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region tract morphology abnormal forebrain morphology 0.576 0.7085 0.261 Positive 
behaviour abnormal spatial working memory 0.578 0.7109 0.261 Positive 
cellular morphology abnormal dendrite morphology 0.578 0.7109 0.261 Positive 
subcellular neuronal mGluR5 0.578 0.7109 0.261 Positive 
cellular morphology abnormal glial cell morphology 0.588 0.7232 0.260 Negative 
behaviour abnormal object recognition memory 0.609 0.7491 0.260 Positive 
region tract morphology abnormal brain morphology 0.613 0.7540 0.259 Positive 
region tract morphology abnormal pituitary gland morphology 0.618 0.7601 0.259 Positive 
region tract morphology abnormal cerebral cortex morphology 0.634 0.7798 0.259 Positive 
region tract morphology abnormal hypothalamus morphology 0.640 0.7872 0.258 Positive 
region tract morphology abnormal cerebrum morphology 0.645 0.7934 0.258 Negative 
region tract morphology abnormal parietal lobe morphology 0.668 0.8216 0.258 Positive 
region tract morphology abnormal somatosensory cortex morphology 0.668 0.8216 0.258 Positive 
 311 
behaviour abnormal behavior 0.670 0.8241 0.258 Negative 
behaviour abnormal chemical nociception 0.680 0.8364 0.257 Negative 
behaviour abnormal response to tactile stimuli 0.680 0.8364 0.257 Negative 
cellular morphology abnormal synapse morphology 0.685 0.8426 0.257 Negative 
cellular physiology abnormal PNS synaptic transmission 0.685 0.8426 0.257 Negative 
cellular physiology abnormal neurotransmitter level 0.685 0.8426 0.257 Negative 
behaviour abnormal sexual interaction 0.699 0.8598 0.257 Positive 
region tract morphology abnormal brain white matter morphology 0.704 0.8659 0.257 Negative 
region tract morphology abnormal corpus callosum morphology 0.704 0.8659 0.257 Negative 
region tract morphology abnormal nervous system tract morphology 0.704 0.8659 0.257 Negative 
development abnormal telencephalon development 0.708 0.8708 0.256 Positive 
cellular physiology abnormal prepulse inhibition 0.721 0.8868 0.256 Positive 
region tract morphology abnormal nervous system morphology 0.727 0.8942 0.256 Positive 
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behaviour abnormal contextual conditioning behavior 0.739 0.9090 0.256 Negative 
behaviour abnormal temporal memory 0.739 0.9090 0.256 Negative 
behaviour abnormal voluntary movement 0.743 0.9139 0.256 Positive 
cellular morphology abnormal neuron morphology 0.758 0.9323 0.255 Positive 
region tract morphology abnormal somatic nervous system morphology 0.765 0.9410 0.255 Negative 
behaviour abnormal pain threshold 0.774 1 0.255 Negative 
cellular morphology abnormal CNS glial cell morphology 0.783 1 0.255 Negative 
cellular morphology abnormal astrocyte morphology 0.783 1 0.255 Negative 
cellular morphology abnormal axon morphology 0.796 1 0.255 Positive 
region tract morphology abnormal brain ventricle morphology 0.816 1 0.254 Positive 
behaviour abnormal mechanical nociception 0.819 1 0.254 Negative 
cellular physiology abnormal synaptic transmission 0.826 1 0.254 Positive 
region tract morphology abnormal innervation 0.828 1 0.254 Negative 
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behaviour abnormal grooming behavior 0.829 1 0.254 Negative 
behaviour abnormal seizure response to inducing agent 0.829 1 0.254 Negative 
behaviour seizures 0.829 1 0.254 Negative 
behaviour abnormal response to new environment 0.831 1 0.254 Positive 
region tract morphology abnormal telencephalon morphology 0.831 1 0.254 Negative 
region tract morphology abnormal neocortex morphology 0.833 1 0.254 Positive 
cellular physiology abnormal CNS synaptic transmission 0.837 1 0.254 Positive 
behaviour abnormal thermal nociception 0.911 1 0.253 Negative 
region tract morphology abnormal spinal cord morphology 0.929 1 0.253 Positive 
region tract morphology abnormal hindbrain morphology 0.937 1 0.253 Negative 
behaviour abnormal response to novelty 0.987 1 0.253 Positive 
 
Category represents the broader biological function of the individual pathway. P represents whether the addition of the ‘number of 
pathway genes hit’ term in model 2 significantly improved fit to the data compared to model 1 using an ANOVA comparison. %R2 
 314 
represents additional variance explained of the MATRICS composite score for addition of total number of pathway genes. Direction of 
effect refers to higher (positive) or lower (negative) MATRICS scores for the number of pathway genes hit. 
 
 
